<allTrials totalCount="166" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2007-09-27T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-09-27T00:00:00.000Z">52466525</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Phase III trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Cisplatin concurrent with radiation therapy has been used in stage IV head and neck cancer. One previous study has reported that the combination of low-doses of gemcitabine with radiotherapy has a similar response in terms of overall survival and progression-free survival to that of cisplatin concurrent with radiation in patients with III, IVa, IVb stage disease. Based on these facts we decided to perform a randomised phase III trial to compare cisplatin concurrent with radiation versus low-dose gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. The hypothesis being a similar response in both conditions, but better control of adverse effects with low-dose gemcitabine/radiotherapy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Data of interest (haematologic toxicity, presence of mucositis, skin rash, nausea/vomiting, dysphagia, odynophagia, etc) is assessed and collected at the time of each visit. The first timepoint at which the outcomes will be measured will be at 6 months after inclusion in the study. Toxicity is evaluated according to the National Cancer  Institute - Common Toxicity Criteria version 3 (NCI-CTC v.3.0).</primaryOutcome>
      <secondaryOutcome>Efficacy in terms of overall and progression free-survival, will be determined with clinical examination, Computed Tomography (CT)-scans, medical lab tests (metabolic profile, Complete Blood Count [CBC], blood chemistry), endoscopy and biopsy studies.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the National Cancer Institute of Mexico Ethics and Scientific Committee (Comite de Etica y Científico del Instituto Nacional de Cancerologia) on the 5th March 2007 (ref: CB/341/06).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52466525</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>007/022/OMI</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Mexico</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d1b610ec-b094-448c-9bef-944e0676f3e6">
	  <name>St. Fernando Avenue No. 22</name>
	  <address/>
	  <city>Mexico City</city>
	  <state/>
	  <country>Mexico</country>
	  <zip>14080</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. International Union Against Cancer (UICC) classification stage IVb
2. Histologically proven and measurable squamous cell carcinoma of the head and neck (oral cavity, oropharynx, larynx, hypopharynx)
3. Previously untreated
4. Unresectable disease (when surgical resection was considered technically not feasible or surgical resection with clear margins was estimated to produce significant organ and/or function loss) or refused surgery
5. Aged 18 to 70 years
6. Squamous cell carcinoma of the head and neck without distant metastases
7. Karnofsky performance status score greater than or equal to 70%
8. Normal renal, hepatic and haematological function
9. Negative pregnancy 
10. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>216</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>216</totalTarget>
      <exclusion>1. Surgery and chemotherapy previously
2. Previous malignancy except non-melanoma skin cancer and cervical carcinoma in situ
3. Any clinical manifestation of distant metastases
4. Therapy concurrent 30 days previous with other experimental anti-neoplastic treatment
5. Systemic and/or uncontrolled disease that precludes the use of chemotherapy
6. Hypersensibility to gemcitabine or cisplatin</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Advanced squamous cell carcinoma of the head and neck</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Squamous cell carcinoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients with squamous cell carcinoma of the head and neck staged IVb will be randomised to either:

Arm 1: cisplatin at 50 mg/m^2, administered intravenously over 60 minutes with 125 ml mannitol once weekly, 3 hours before radiation. The total dose of radiation will be administered to the macroscopic tumour and to potential sites of microscopic spread was 70 Gy, over 7 weeks.

Arm 2: gemcitabine at 100 mg/dl, administered intravenously over 30 minutes once weekly, 3 hours before radiation. The total dose of radiation will be administered to the macroscopic tumour and to potential sites of microscopic spread was 70 Gy, over 7 weeks.

The maximal dose to the spinal cord was restricted to 45 and 54 Gy to the brain stem and optic nerves, respectively. Total treatment time is seven weeks; overall time of this trial is three years.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Gemcitabine, cisplatin, mannitol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16786-0</funderId>
      <contactId>Contact54744_16786</contactId>
      <sponsorId>Sponsor53300</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54744_16786">
    <title>Dr</title>
    <forename>Jose Luis</forename>
    <surname>Aguilar Ponce</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>St. Fernando Avenue No. 22
Sec. XVI</address>
      <city>Mexico City</city>
      <country>Mexico</country>
      <zip>14080</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53300">
    <organisation>National Cancer Institute of Mexico (Instituto Nacional de Cancerologia [INCAN]) (Mexico) </organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o Dr Jose Luis Aguilar Ponce
St. Fernando Avenue No. 22
Sec. XVI  
Mexico, D.F.</address>
      <city>Mexico City</city>
      <country>Mexico</country>
      <zip>14080</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.419167.c</gridId>
    <rorId>https://ror.org/04z3afh10</rorId>
  </sponsor>
  <funder id="Funder16786-0">
    <name>National Cancer Institute of Mexico (Instituto Nacional de Cancerologia [INCAN]) (Mexico)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-24T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2007-09-24T00:00:00.000Z">88124420</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pharmacological modulation of heterosynaptic LOng-TErm POtentiation in humans by LOrazepam and METHylphenidat</title>
      <scientificTitle/>
      <acronym>LOTEPOLOMETH</acronym>
      <studyHypothesis>Long-Term Potentiation (LTP) within the nociceptive system is one of the mechanisms underlying central sensitisation, which accounts for some hyperalgesic pain states in chronic pain patients. In the study we will use a human surrogate model of nociceptive LTP to study the involvement of the GABAergic and the catecholaminergic system in the induction of hyperalgesia following high-frequency electrical stimulation of nociceptive afferents in the skin. 

We will study the contribution of GABAA-receptors (by lorazepam, a GABAA-receptor agonist) and receptors of catecholamines (by methylphenidat, a dopamine/noradrenaline re-uptake inhibitor) in plastic changes within the nociceptive system, which occur typically after a tissue injury, but in contrast to a real lesion we mimic an injury by high-frequency electrical stimulation of nociceptive afferents in the skin. This conditioning stimulation will lead to pain to light tactile stimuli (dynamic mechanical allodynia) and to an increase of pain to punctuate mechanical pain stimuli (static mechanical hyperalgesia). Both phenomena can typically been found in a subset of neuropathic pain patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following outcomes will be assessed based on the sensory changes determined by QST during the intervention: 
1. Spread of the area of dynamic allodynia and static hyperalgesia 
2. Combined analgesic and anti-hyperalgesic effect to mechanical and electrical stimuli on the site of conditioning stimulation</primaryOutcome>
      <secondaryOutcome>The following outcomes will be assessed based on the sensory changes determined by QST during the intervention:
1. Anti-hyperalgesic effect to electrical and mechanical test stimuli 
2. Analgesic effect to electrical and mechanical test stimuli 
3. Anti-wind up pain, tested by mechanical pinprick stimuli</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Local Ethics Committee (Ethikkommission der Landesärztekammer Rheinland-Pfalz) on 15 March 2003 (ref: 837.002.03[3664]) and was conducted in accordance with the declaration of Helsinki, the German Medicines Act (AMG), and the guidelines of the International Conference on Harmonisation (ICH) for Good Clinical Practice (GCP).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88124420</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Tr 236/16-2/LTP-Methyl-Lora</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A double-blind, randomized, placebo-controlled, three-way cross-over study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="92923fa3-82b3-4864-84ba-020b07ae0247">
	  <name>Institute of Physiology and Pathophysiology</name>
	  <address/>
	  <city>Mainz</city>
	  <state/>
	  <country>Germany</country>
	  <zip>55128</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Healthy volunteer</participantType>
      </participantTypes>
      <inclusion>1. Healthy volunteers of full age
2. Subject familiarized with the experimental procedure prior to experimentation and had given written informed consent
3. At least a 50% increase of pain to pinprick stimuli and a 25% increase of pain to electrical stimuli following high-frequency electrical stimulation in a screening visit</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>18</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>18</totalTarget>
      <exclusion>1. Skin lesions at the test and/or control site
2. Use of any medication within one day prior to study onset except contraceptives
3. Known hypersensitivity to histamine or methylphenidate and lorazepam and their derivates
4. Any history of allergy or drug hypersensitivity
5. Chronic use of analgesics or Central Nervous System (CNS) active drugs
6. Pregnancy or nursing
7. Any acute or chronic disease</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hyperalgesic pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Hyperalgesic pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The effect of 40 mg methylphenidate and 2.5 mg lorazepam orally (p.o.) will be compared to placebo in a three-way cross-over design (placebo-methylphenidate-lorazepam). Sensory changes will be determined by Quantitative Sensory Testing (QST) using non-nociceptive and low-intensity painful mechanical and electrical stimuli. 

The QST-protocol consists of mildly painful and non-painful mechanical and electrical stimuli, which were applied in runs alternating between two skin sites on the forearms (a test site and a control site). In addition, we will apply a moderate painful high-frequency electrical stimulation protocol to induce nociceptive LTP (only at the test site). All test stimuli will last between 0.5 - 2 seconds depending on the modality tested. 

The QST will be carried out over 30 min before the application of the conditioning stimulus and over 90 min at the beginning and immediately after the stimulus.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Methylphenidate, Lorazepam</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16831-0</funderId>
      <contactId>Contact54789_16831</contactId>
      <sponsorId>Sponsor53345</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54789_16831">
    <title>Prof</title>
    <forename>Rolf-Detlef</forename>
    <surname>Treede</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute of Physiology and Pathophysiology
The Johannes Gutenberg University of Mainz
Duesbergweg 6</address>
      <city>Mainz</city>
      <country>Germany</country>
      <zip>55128</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">treede@uni-mainz.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53345">
    <organisation>Individual sponsor (Germany)</organisation>
    <website>http://www.uni-mainz.de/eng/index.php</website>
    <sponsorType>Other</sponsorType>
    <contactDetails>
      <address>c/o Prof Rolf-Detlef Treede
Institute of Physiology and Pathophysiology
The Johannes Gutenberg University of Mainz
Duesbergweg 6</address>
      <city>Mainz</city>
      <country>Germany</country>
      <zip>55128</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)61313925715</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">treede@uni-mainz.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder16831-0">
    <name>German Research Foundation (Deutsche Forschungsgemeinschaft) (Grant ref: Tr236/16-2)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-09-19T00:00:00.000Z">72183044</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised double-blind parallel-group study evaluating effcacy and safety on MEGA tablets compared to Kalcipos® tablets in adult subjects</title>
      <scientificTitle/>
      <acronym>MEGA</acronym>
      <studyHypothesis>The treatment to be tried will result in recommended levels of serum 25-hydroxy-vitamin D.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Serum levels of 25-hydroxyvitamin D, measured at baseline, 3, 6, 9 and 12 months.</primaryOutcome>
      <secondaryOutcome>1. Serum levels of parathyroid hormone and biochemical bone markers, measured at baseline, 6 and 12 months
2. Safety, measured at baseline, 3, 6, 9 and 12 months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from Regionala Etikprovningsnamnden i Linkoping, Sweden (one of six regional ethical boards in Sweden) on the 11th October 2006 (ref: Dnr M150-06 [EudraCT-nr: 2006-002595-17]).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72183044</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CT06-MEGA-001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective randomised double-blind parallel group study evaluating efficacy and safety of a one year treatment.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bd016961-2691-40c3-b628-919994cb5984">
	  <name>Department of Endocrinology</name>
	  <address/>
	  <city>Linköping</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>S-58185</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men and women 55 to 85 years of age 
2. Mild or moderate vitamin D insufficiency (serum 25-hydroxy-vitamin D 10-70 nmol/L)</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>56</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>56</totalTarget>
      <exclusion>1. Subjects with severe vitamin D deficiency (serum 25-hydroxy-vitamin D below 10 nmol/L)
2. Suspected osteomalacia
3. Serious diseases or drug treatments that may interfere with study results</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mild or moderate vitamin D deficiency</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Vitamin D deficiency</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Supplementation with either calcium and vitamin D or calcium alone. The subjects will be treated with two tablets per day for twelve months. The allocation of subjects to treatment, study product (vitamin D and calcium) or reference product (calcium), will be done by randomisation at start of the study.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Kalcipos®, vitamin D</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16584-0</funderId>
      <contactId>Contact54542_16584</contactId>
      <sponsorId>Sponsor53097</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54542_16584">
    <title>Dr</title>
    <forename>Goran</forename>
    <surname>Toss</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Endocrinology
EM-kliniken
University Hospital</address>
      <city>Linköping</city>
      <country>Sweden</country>
      <zip>S-58185</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)13 222 000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Goran.Toss@lio.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53097">
    <organisation>Recip AB (Sweden)</organisation>
    <website>http://www.recip.se/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Lagervagen 7</address>
      <city>Haninge</city>
      <country>Sweden</country>
      <zip>S-13650</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.496608.5</gridId>
    <rorId>https://ror.org/01apnjb23</rorId>
  </sponsor>
  <funder id="Funder16584-0">
    <name>Recip AB (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-11T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-09-11T00:00:00.000Z">58825135</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Early diagnosis of colorectal cancer by faecal occult blood detection - the Goteborg trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>By detection of early stages of colorectal tumours in the "healthy population", mortality from colorectal cancer is reduced. 

Underlying this hypothesis is a further hypothesis that colorectal tumours develop over a time sequence, probably several years, from benign adenomas through localised cancer to cancer with spread growth, and that tumours in this sequence of development can be detected before they give symptoms observed by the individual.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mortality in colorectal cancer.

Time points were: after invitation, after screening participation, after work-up of positive screen test and after treatment for patients with positive work-up.</primaryOutcome>
      <secondaryOutcome>1. Overall mortality
2. Quality of life
3. Sensitivity and specificity of screening procedure
4. Sensitivity and specificity of work up procedure
5. Stage distribution of adenomas and cancers

The questionnaires used were specifically designed for this trial, with face validation and tested in pilot populations before use. Time points were: after invitation, after screening participation, after work-up of positive screen test and after treatment for patients with positive work-up.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the ethical committee of Goteborg University, Goteborg (Sweden) in 1982 (ref: 21-82).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN58825135</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, single centre, population based, interventional trial; control group not invited for screening.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1982-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="466114cf-e1c7-4a7e-9e6b-e4ce9a52020c">
	  <name>Bruna Straket 11B</name>
	  <address/>
	  <city>Goteborg</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE 413 45</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>The entire population was born between 1918 and 1931, men and women, in Goteborg, Sweden. Only those randomised to "intervention, i.e., screening for occult faecal blood" were invited to participate, the control group was not contacted. Initial invitation to the trial was when each individual was between the ages of 60 to 64 years, thus inclusion from 1982 to 1995 in cohorts of five years.</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>68000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>68,000</totalTarget>
      <exclusion>Does not meet the above criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1982-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Colorectal cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Colorectal cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: detection of faecal blood by Haemoccult analyses of samples from three consecutive stools, in the group randomised to "screening"
Control: no contact/information

If blood was detected, there was a continued intervention involving consultation with colorectal surgeon, sigmoidoscopy (60 cm) and barium enema. If found at sigmoidoscopy, adenomas were removed. If cancer/suspected cancer found at either investigation, surgery was followed at earliest possible date. 

Total duration of follow-up was 11 - 19 years, mean of 15 years.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1986 Other publications in https://pubmed.ncbi.nlm.nih.gov/3790958
1987 Other publications in https://pubmed.ncbi.nlm.nih.gov/3792765
1988 Other publications in https://pubmed.ncbi.nlm.nih.gov/3292038
1989 Other publications in https://pubmed.ncbi.nlm.nih.gov/2720326
1990 Other publications in https://pubmed.ncbi.nlm.nih.gov/2322788
1990 Other publications in https://pubmed.ncbi.nlm.nih.gov/2276015 .
1991 Other publications in https://pubmed.ncbi.nlm.nih.gov/2056836 .
1992 Other publications in https://pubmed.ncbi.nlm.nih.gov/1439536 .
1994 Other publications in https://pubmed.ncbi.nlm.nih.gov/8306829
1994 Other publications in https://pubmed.ncbi.nlm.nih.gov/8036464
1995 Other publications in https://pubmed.ncbi.nlm.nih.gov/7601048 .
1995 Other publications in https://pubmed.ncbi.nlm.nih.gov/7732341 .
1996 Other publications in https://pubmed.ncbi.nlm.nih.gov/8646956
1997 Other publications in https://pubmed.ncbi.nlm.nih.gov/9085461</publicationDetails>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="50f732e7-699f-445f-9f82-1be69dbb5784" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1986-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/3790958"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="07f98f83-4da9-40a3-be2e-b15b372af63a" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1987-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/3792765"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="7a51b317-acab-47e4-b09f-ded689d13610" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1988-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/3292038"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="fa0fec52-f7c6-4fca-92e8-9b5b75a3b909" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1989-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/2720326"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="f41adbfb-bf1e-47f7-969a-898965ead581" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1990-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/2322788"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="4e583c69-14d4-46e3-a18f-e4b0daee6006" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1990-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/2276015"/>
	<description>.</description>
	<productionNotes/>
      </output>
      <output id="e4e4cfcd-458a-470b-b3ed-7eb8d5fe3a47" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1991-06-12T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/2056836"/>
	<description>.</description>
	<productionNotes/>
      </output>
      <output id="e4810e71-f78f-44d7-a6f9-011796194a44" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1992-10-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/1439536"/>
	<description>.</description>
	<productionNotes/>
      </output>
      <output id="8688b5ee-09ad-45e7-87e5-c56e7482b6c0" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1994-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/8306829"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="11df0a51-ae90-4e02-9996-3a7f229ca201" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1994-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/8036464"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="305f87cd-836d-457d-ac55-7fd39da17e99" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1995-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/7601048"/>
	<description>.</description>
	<productionNotes/>
      </output>
      <output id="788afdb3-10ee-464f-9dcb-4dfdd5ff051e" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1995-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/7732341"/>
	<description>.</description>
	<productionNotes/>
      </output>
      <output id="037863a1-84f5-4273-b55d-5f842eabc2e9" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1996-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/8646956"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="60716711-ad13-4012-85e6-3af9c69c992a" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1997-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/9085461"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16819-0</funderId>
      <funderId>Funder16819-1</funderId>
      <funderId>Funder16819-2</funderId>
      <funderId>Funder16819-3</funderId>
      <funderId>Funder16819-4</funderId>
      <funderId>Funder16819-5</funderId>
      <funderId>Funder16819-6</funderId>
      <contactId>Contact54777_16819</contactId>
      <sponsorId>Sponsor53333</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54777_16819">
    <title>Prof</title>
    <forename>Eva</forename>
    <surname>Haglind</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Bruna Straket 11B
Sahlgrenska University Hospital</address>
      <city>Goteborg</city>
      <country>Sweden</country>
      <zip>SE 413 45</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)31 3426096</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">eva.haglind@vgregion.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53333">
    <organisation>Swedish Cancer Society (Sweden)</organisation>
    <website>http://www.cancerfonden.se</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>David Bagares Gata 5</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE 101 55</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)8 6771000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@cancerfonden.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453026.6</gridId>
    <rorId>https://ror.org/0527jb766</rorId>
  </sponsor>
  <funder id="Funder16819-0">
    <name>Swedish Cancer Society (Sweden)</name>
    <fundRef>http://dx.doi.org/10.13039/501100002794</fundRef>
  </funder>
  <funder id="Funder16819-1">
    <name>Assar Gabrielsson Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16819-2">
    <name>Goteborgs Lakarsallskap, Inga-Britt and Arne Lundberg Research Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16819-3">
    <name>Magnus Bergvall Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16819-4">
    <name>Gunnar and Elisabeth Nilsson Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16819-5">
    <name>Jubileumsklinikens Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16819-6">
    <name>Sahlgrenska University Hospital Foundation (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-09-10T00:00:00.000Z">55976458</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Workplace AIDS prevention - a randomised controlled trial of community engagement by employees of motor dealers</title>
      <scientificTitle/>
      <acronym>CIET-BM1</acronym>
      <studyHypothesis>Engaging motor dealership employees community outreach education increases their Human Immunodeficiency Virus (HIV)-protective attitudes and practices.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>HIV-related protective attitudes and practices among dealership employees, measured after one year.</primaryOutcome>
      <secondaryOutcome>1. Work absenteeism
2. Work performance
3. HIV related knowledge
4. Attitudes
5. Positive deviation from subjective norms
6. Intention to change
7. Sense of agency to implement prevention measures
8. Discussion of HIV prevention

All secondary outcomes measured after one year.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from CIET Africa Ethics Board on the 30th April 2007 (ref: BM2-2007).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN55976458</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CIET-BM1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Pragmatic randomised controlled cluster trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Botswana</country>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f5fee87b-2061-4bb7-8967-9255cf043bd9">
	  <name>CIET Trust Botswana</name>
	  <address/>
	  <city>Gaborone</city>
	  <state/>
	  <country>Botswana</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All employees of participating dealerships</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>3000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>3000 employees</totalTarget>
      <exclusion>Dealerships declining to participate prior to randomisation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>HIV/Acquired Immune Deficiency Virus (AIDS) prevention</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>HIV/AIDS</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The unit of randomisation is the dealership, each dealership employing a staff of 40 - 100 people and an adjacent community where a large number of the staff live. Some 20 participating dealerships nationally will be allocated randomly to first wave or second wave of intervention. Although the dealerships are typically in well-to-do or commercial areas, the linked communities tend to be much more modest.

Workplaces are randomised after baseline survey, to early and late initiation of intervention.

Intervention:
1. AIDS prevention education
2. Sexual violence education
3. Participant involvement in community outreach education

The intervention lasts 4 - 6 months in each dealership, although aspects of this will continue well beyond the investment. For example, employees will be trained to implement the sexual violence prevention education, which they will continue to implement on an ongoing basis, once a week.

Control:
Usual education

The impact of the first wave of dealerships will be assessed after one year, while the second wave (controls for the first wave) will be assessed a year later.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16524-0</funderId>
      <contactId>Contact54482_16524</contactId>
      <sponsorId>Sponsor53037</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54482_16524">
    <title>Dr</title>
    <forename>Neil</forename>
    <surname>Andersson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>CIET Trust Botswana
PO Box 1240</address>
      <city>Gaborone</city>
      <country>Botswana</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53037">
    <organisation>Community Information, Empowerment and Transparency (CIET) Trust (South Africa)</organisation>
    <website>http://www.ciet.org/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>c/o Neil Andersson
CIET Trust Botswana
PO Box 1240</address>
      <city>Gaborone</city>
      <country>Botswana</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487352.f</gridId>
    <rorId>https://ror.org/02cfx3y90</rorId>
  </sponsor>
  <funder id="Funder16524-0">
    <name>BMW (South Africa)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-09-10T00:00:00.000Z">79325454</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Grannies do AIDS-speak: a randomised controlled trial of empowerment of female elders in rural South Africa</title>
      <scientificTitle/>
      <acronym>Grannies</acronym>
      <studyHypothesis>Empowering female elders through discussion of results for a national youth survey can increase their engagement in and support of young people in their communities.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>HIV-related protective attitudes and practices among youth, measured 12 months after intervention, in a school-based study in communities where the granny groups took place.</primaryOutcome>
      <secondaryOutcome>1. Conscious knowledge of HIV risk and related attitudes
2. Positive deviations from subjective norms
3. Intention to change
4. Sense of agency
5. Discussion of HIV risks

All measured 12 months after intervention, in a school-based study in communities where the granny groups took place.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from Community Information, Empowerment and Transparency (CIET) Africa. Separate ethics approvals were also obtained for Limpopo (ref: LIM2-2006) dated 21st February 2006 and Eastern Cape (ref: CAG1-2006) dated 26th October 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN79325454</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CIET-LPEC</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Cluster pragmatic randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Botswana</country>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b80c0d26-f79f-4640-af8a-7ae20da728a4">
	  <name>CIET Trust Botswana</name>
	  <address/>
	  <city>Gaborone</city>
	  <state/>
	  <country>Botswana</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Female elders in target community</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>1000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1000 female elders</totalTarget>
      <exclusion>Men</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) prevention</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After the baseline surveys, communities were randomised to intervention and control sites (unit of randomisation is the school with its attendant community). In Limpopo, there were 15 such intervention communities, 9 Xitsonga and 6 Sepedi speaking. There were 15 control communities, also 9 of them Xitsonga and 6 Sepedi speaking. In Amathole district in the Eastern Cape, also after the baseline survey, there were 13 intervention and 15 control communities.

Communities were randomised after youth baseline survey to early and late initiation of intervention.

Intervention:
1. AIDS prevention education
2. Sexual violence education 
Based on national youth survey

Control:
Usual education

The intervention lasts 3 - 5 months with follow-up study 12 months after intervention.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16523-0</funderId>
      <funderId>Funder16523-1</funderId>
      <contactId>Contact54481_16523</contactId>
      <sponsorId>Sponsor53036</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54481_16523">
    <title>Dr</title>
    <forename>Neil</forename>
    <surname>Andersson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>CIET Trust Botswana
PO Box 1240</address>
      <city>Gaborone</city>
      <country>Botswana</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53036">
    <organisation>Community Information, Empowerment and Transparency (CIET) Trust (South Africa)</organisation>
    <website>http://www.ciet.org/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>c/o Neil Andersson
CIET Trust Botswana 
PO Box 1240 </address>
      <city>Gaborone</city>
      <country>Botswana</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487352.f</gridId>
    <rorId>https://ror.org/02cfx3y90</rorId>
  </sponsor>
  <funder id="Funder16523-0">
    <name>Australia's Overseas Aid Program (AusAID) (Australia) - Addressing Domestic Violence in Limpopo</name>
    <fundRef/>
  </funder>
  <funder id="Funder16523-1">
    <name>The Conflict and Governance Facility (CAGE) (South Africa) - funded by the South African Government and The European Commission</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-09-05T00:00:00.000Z">19709160</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Analyses of PAThogen and HOSt determinants in hospitalised patients with a laboratory confirmed infection caused by Staphylococcus aureus: the PATHOS study</title>
      <scientificTitle/>
      <acronym>PATHOS study</acronym>
      <studyHypothesis>To identify candidate antigens for the development of a prophylactic Staphylococcus aureus vaccine by studying expression profiles of host and pathogen determinants during natural infection.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Putative antigen targets for the development of a Staphylococcus aureus vaccine.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19709160</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, non-randomised, non-controlled, single armed clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4efae4cd-8d58-4209-ac05-dea2340bb5fe">
	  <name>Vrije University Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1007 MB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult patients (greater than 18 years) with S. aureus bacteraemia or wound infection
2. Diagnosis of S. aureus infection within 48 hours after initial cultures
3. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50</totalTarget>
      <exclusion>1. Incapacitated patients (Glasgow Coma Scale [GSC] less than 15)
2. Patients with neutropenia (less than 500x 10^6 neutrophils/L)
3. Patients with haematological malignancy
4. Transplantation patients
5. Patients who are treated with immunosuppressive drugs</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Staphylococcus aureus infection and vaccination</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Blood will be drawn at days 2, 7 and 14 after the moment that the initial blood and wound cultures were obtained. This will be done simultaneously to drawing blood for routine haematology and chemistry investigations according good clinical practice, so no extra venapuncture is required for participation in the study. At day 2 two nasal swabs will be obtained for assessment of Staphylococcus aureus nasal carriage.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16901-0</funderId>
      <contactId>Contact54860_16901</contactId>
      <sponsorId>Sponsor53418</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54860_16901">
    <title>Prof</title>
    <forename>J.A.J.W. </forename>
    <surname>Kluytmans</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Vrije University Medical Centre
Department of Medical Microbiology and Infection Control
P.O. Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 0552</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jan.kluytmans@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53418">
    <organisation>Wyeth Pharmaceuticals B.V. (The Netherlands)</organisation>
    <website>http://www.wyeth.nl/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 255</address>
      <city>Hoofddorp</city>
      <country>Netherlands</country>
      <zip>2130 AG  </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)23 567 2567</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info-nl@wyeth.com </email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487416.8</gridId>
    <rorId>https://ror.org/02bzf1224</rorId>
  </sponsor>
  <funder id="Funder16901-0">
    <name>Wyeth Pharmaceuticals B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-09-05T00:00:00.000Z">45091963</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Preventing early language delay: a pilot study</title>
      <scientificTitle/>
      <acronym>LLL (Let's Learn Language)</acronym>
      <studyHypothesis>To determine the feasibility of conducting a randomised controlled trial investigating a preventative approach to improve children's language development and behaviour problems at two years of age. Aims of this pilot were to:
1. Examine whether families whose children score at or below the 20th percentile on a standardised vocabulary measure agree to be randomised to a six-week Parent Language Program and to a non-intervention group
2. Compare the usefulness of two standardised vocabulary measures for post-test assessment: the SureStart 100 word Vocabulary Checklist (adapted from the MacArthur Bates Communicative Development Inventories [MBCDI] by Roy, Kersley and Law [2005]) or the Vocabulary Checklist from the complete MBCDI (approx 680 words divided into semantic categories)
3. Trial the videotaping of post-test assessment at 21 - 24 months
4. Solicit parents' evaluations of the program's content and format to provide information about program changes that may increase the feasibility of the Parent Language Program for families in Victoria

This is the pilot study to the randomised trial assigned to ISRCTN20953675.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcomes are to pilot and refine: 
1. Parent interest in, and attendance at, a six-week parent language promotion program 
2. Organisation and format of the Parent Language Program sessions, adapted from You Make The Difference™ program
3. The sensitivity of the assessment tools used during the follow-up</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite>http://www.rch.org.au/emplibrary/ccch/TheLetsLearnLanguage.pdf</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Received ethics approval from The Royal Children's Hospital Ethics in Humans Research Committee (EHRC) on the 7th June 2007 (ref: 26073A).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45091963</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Pilot randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-06-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b375517e-4400-4ab2-9456-99848c2decb8">
	  <name>Royal Children's Hospital</name>
	  <address/>
	  <city>Melbourne</city>
	  <state/>
	  <country>Australia</country>
	  <zip>3052</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Parents of 18 - 21 month-old toddlers 
2. Attending any of eight well-child clinics within one Melbourne local government area
3. Identified by a brief, parent-reported vocabulary questionnaire as having minimal or no expressive vocabulary (e.g., scoring at or below the 20th percentile relative to age and sex norms)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Target sample size was 100 to identify 20 eligible children. Recruitment status achieved was 103, which identified 30 eligible children.</totalTarget>
      <exclusion>1. Children with already-diagnosed (or a referral for) cognitive delay or major medical conditions
2. Children with symptoms of Autism Spectrum Disorder
3. Parents with insufficient English to attend a parent language program and complete brief written questionnaires</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-06-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Early delay in acquiring expressive vocabulary</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Vocabulary disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>For each pair of eligible families recruited, one was randomly allocated to the Parent Language Program Group and one to the Usual Care Group. Masking occurred at randomisation, with group allocation concealed from the principal researcher and participants until allocation was complete. Group allocation was concealed from the researcher conducting follow-up direct assessments with intervention (Parent Language Program) families until data collection was complete.  

Arm A - Parent Language Program Group: 
A six-week parent language promotion program (six two-hour group sessions) adapted from the Hanen You Make The Difference™ program, offered to parents when children were 19 - 22 months old. The Parent Language Program teaches child-centred, interaction-promoting and language-modelling responsive interaction strategies targeting the development of vocabulary and multi-word phrases. The Parent Language Program was conducted within the family's local community, facilitated by an early childhood professional.

Arm B - Usual Care Group:
Usual care from the Maternal and Child Health (MCH) nurses who provide a universal and free surveillance service to Melbourne families in the first five years of life (active control).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16684-0</funderId>
      <contactId>Contact54642_16684</contactId>
      <sponsorId>Sponsor53197</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54642_16684">
    <title>Dr</title>
    <forename>Melissa </forename>
    <surname>Wake</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Royal Children's Hospital
Flemington Road
Parkville</address>
      <city>Melbourne</city>
      <country>Australia</country>
      <zip>3052</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)3 9345 5761</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">melissa.wake@rch.org.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53197">
    <organisation>Murdoch Childrens Research Institute, Parkville (Australia)</organisation>
    <website>http://www.rch.org.au/rch/index.cfm?doc_id=1495</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o Associate Professor Melissa Wake
Royal Children's Hospital
Flemington Road
Parkville</address>
      <city>Melbourne</city>
      <country>Australia</country>
      <zip>3052</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)3 9345 5761</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">melissa.wake@rch.org.au</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.1058.c</gridId>
    <rorId>https://ror.org/048fyec77</rorId>
  </sponsor>
  <funder id="Funder16684-0">
    <name>Murdoch Childrens Research Institute, Parkville (Australia)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-03T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-09-03T00:00:00.000Z">07857866</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The  Effectiveness of Acupuncture for Insomnia</title>
      <scientificTitle/>
      <acronym>EAI</acronym>
      <studyHypothesis>Traditional Chinese Medicine (TCM) Meridian Theory.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pittsburgh Sleep Quality Index (PSQI) records (PSQI assessment will be carried out on a weekly basis).</primaryOutcome>
      <secondaryOutcome>Serious adverse events.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Institutional Review Board at Taipei City Hospital (IRB/TCH) (ref: 960302)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07857866</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>096XDAA00028</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-03T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Taiwan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="995a6e0b-892b-4f97-a103-2ba3934d61e9">
	  <name>145 Zhengzhou Road</name>
	  <address/>
	  <city>Taipei City</city>
	  <state/>
	  <country>Taiwan</country>
	  <zip>10341</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Participants suffering from insomnia who have not taken any sleep medications associated with psychiatric disorders within 30 days.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>90</totalTarget>
      <exclusion>1. Pregnancy 
2&#129;. Central nervous system disease such as seizure disorder, cerebrovascular disease, dementia etc.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-03T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Insomnia</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Insomnia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Acupuncture 
2. Stilnox® (non-benzodiazepines) 5 mg/day at bedtime (hs) for 4 weeks</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16826-0</funderId>
      <contactId>Contact54784_16826</contactId>
      <sponsorId>Sponsor53340</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54784_16826">
    <title>Dr</title>
    <forename>Yu-Yang </forename>
    <surname>Chiang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>145 Zhengzhou Road
Datong District</address>
      <city>Taipei City</city>
      <country>Taiwan</country>
      <zip>10341</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+886 2 25523234 ext 5207</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">chiang3940@yahoo.com.tw</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53340">
    <organisation>Taipei City Hospital (Taiwan)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>145 Zhengzhou Road
Datong District</address>
      <city>Taipei City</city>
      <country>Taiwan</country>
      <zip>10341</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+886 2 25523234</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">chiang3940@yahoo.com.tw</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.410769.d</gridId>
    <rorId>https://ror.org/02gzfb532</rorId>
  </sponsor>
  <funder id="Funder16826-0">
    <name>Taipei City Government (Taiwan)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-03T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-09-03T00:00:00.000Z">82127342</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Metabolic control of hospitalized diabetes mellitus patients: Application of standardised insulin protocols to hospitalized diabetes mellitus patients</title>
      <scientificTitle/>
      <acronym>COMETADIH</acronym>
      <studyHypothesis>Type 2 Diabetes Mellitus (DM2) is the leading cause of death and the most common diagnosis in hospitalized patients in Mexico. The economic burden that DM2 imposes to the public health system is onerous. Strategies focused on improving medical care and optimising resources are of paramount importance.

In-patient hyperglycemia negatively affects related comorbidities and has been linked to negative outcomes when compared to strategies that attain good glycemic control. Traditional insulin sliding scales are still widely used to treat in-patient hyperglycemia, even though this approach has been questioned and at present time is not considered good clinical practice. Novel strategies must be explored and compared to traditional insulin sliding scales.

Hypothesis of this study: Glycemic control of in-patients can be improved by the implementation of standardised insulin protocols. Glycemic control achieved by standardised insulin protocols will be better compared to traditional insulin sliding scales.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Mean CBG during study period 
2. Mean VBG during study period
3. Hypoglycemic episodes</primaryOutcome>
      <secondaryOutcome>1. Clinical condition at the end of study period
2. Health team acceptance and adherence to the protocol guidelines
3. In-hospital morbidity and mortality registered during hospitalization</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Human Biomedical Research Institutional Committee (an internal regulatory organisation for clinical research and ethics) approved this trial on June 10th, 2005 (ref: 1434).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82127342</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CIBH-1434</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, interventional, randomized, unblinded trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Mexico</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="32721684-a377-4b88-bd42-da9d01d01924">
	  <name>Direccion Medica</name>
	  <address/>
	  <city>Mexico City</city>
	  <state/>
	  <country>Mexico</country>
	  <zip>14000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult hospitalized patients of any age or gender 
2. Diabetes mellitus (World Health Organization criteria) and uncontrolled hyperglycemia on admission (capillary blood glucose &gt;200 mg/dL or HbA1c &gt;7.0)
3. Signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Forty five patients on each protocol. Al teast ninety patients overall.</totalTarget>
      <exclusion>1. Good glycemic control on oral medication
2. Refusal to participate</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Type 2 Diabetes Mellitus</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Type 2 Diabetes Mellitus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two general wards of a tertiary care hospital were randomly assigned to one of two standardised insulin protocols. 

The two protocols consist of different proportions of intermediate and regular unmodified human insulin. One of the protocols was delivered in 4 daily injections and the other in 3. At initiation total daily insulin dose was calculated with the same guidelines for both protocols, further dose titration was provided according to pre-stablished glycemic goals and individual requirements. 

Training was provieded to the nursing and medical staff and adherence to the protocol guidelines was supervised by the research team.

After inclusion to this study the patient was treated with the protocol assigned to the ward. Capillary Blood Glucose (CBG) was measured 4 times a day. Fasting Venous Blood Glucose (VBG) was measured according to the attending physician decision. All hypoglycemic episodes were registered in one of two categories: 

1. Laboratory hypoglycemia (CBG &lt;60 mg/dL) 
2. Clinical hypoglycemia (Presence of adrenergic or neuroglycopenic symptoms with CBG &gt;60 mg/dL that reverted after the ingestion of food)

Cause of the hypoglycemic episode was tracked and registered.

The patient was followed until discharge or until transfered to other areas such as the intensive care unit.

Glycemic control was compared in both protocols and, in a secondary analysis, the best protocol was compared with historical controls.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>insulin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16820-0</funderId>
      <contactId>Contact54778_16820</contactId>
      <sponsorId>Sponsor53334</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54778_16820">
    <title>Dr</title>
    <forename>Armando</forename>
    <surname>Villegas-Jimenez</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Direccion Medica
Vasco de Quiroga 15
Seccion XVI
Tlalpan</address>
      <city>Mexico City</city>
      <country>Mexico</country>
      <zip>14000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+52 55 56 55 90 68</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">armandov@quetzal.innsz.mx</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53334">
    <organisation>The National Institute of Medical Sciences and Nutrition (Mexico)</organisation>
    <website>http://www.innsz.mx</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Vasco de Quiroga 15
Seccion XVI
Tlalpan</address>
      <city>Mexico City</city>
      <country>Mexico</country>
      <zip>14000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+52 55 54 87 09 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">acabral@quetzal.innsz.mx</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416850.e</gridId>
    <rorId>https://ror.org/00xgvev73</rorId>
  </sponsor>
  <funder id="Funder16820-0">
    <name>This trial was funded by an unrestricted grant from institutional research budget of the National Institute of Medical Sciences and Nutrition (Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran). The National Institute of Medical Sciences and Nutrition is a non-profit organization, and its parental organizations are the Mexican Health Ministry (Secretaria de Salud de Mexico) and the Mexican National Autonomous University (Universidad Nacional Autonoma de Mexico). The National Institute of Medical Sciences and Nutrition is a tertiary care academic hospital.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-30T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-08-30T00:00:00.000Z">16469166</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Nutrition and wasting in tuberculosis (TB): Can nutritional supplementation in TB patients improve body weight gain, body composition and treatment outcome?</title>
      <scientificTitle/>
      <acronym>TBGIZI ("GIZI" means "nutrition" in Indonesian)</acronym>
      <studyHypothesis>Th hypothesis is that supplementation of TB patients with macro- and micronutrients patients during the first 2 months of treatment increases body weight gain, as compared to TB patients on standard TB treatment. Secondary hypothses include that above supplementation will increase the production of pro-inflammatory cytokines as measured by ex-vivo whole blood stimulation assay and that lean body mass increases more in patients receiving micro- and macronutrient supplementation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Body weight gain and body composition between start of TB treatment and end of the active phase of treatment (2 months later)</primaryOutcome>
      <secondaryOutcome>The following will be assessed at baseline and 2 months: 
1. Micronutrient status
2. Production of inflammatory cytokines</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>1. The Ethical Review Board of Hasan Sadikin University, University of Padjajaran, Bandung, Indonesia, approved in August 2006 
2. The Ethical Advisory Board, Radboud University Nijmegen, The Netherlands, approved on 16 Feb 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN16469166</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WV93-411</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Indonesia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8f561fe7-ba16-41e6-9fd4-30eb1951ecfa">
	  <name>Dept. of Internal Medicine</name>
	  <address/>
	  <city>Bandung</city>
	  <state/>
	  <country>Indonesia</country>
	  <zip>40161</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Subjects must meet all of the following inclusion criteria to be eligible for participation in this study:
1. Patients with Ziehl-Neelsen (ZN) staining - positive pulmonary TB 
2. Patients starting, or started &lt;2 weeks ago, with the intensive phase of TB treatment 
3. Subject is &gt;18 years of age
4. Willing to participate in the study, and signing the informed consent form</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>No informed consent.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tuberculosis / nutritional status and wasting / nutrition and public health</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Tuberculosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Newly diagnosed TB patients who fullfil the eligiblity criteria will be randomly allocated according to a previously made random list (randomization in blocks of 4) to either standard treatment + nutritional supplementation (75 patients) or standard treatment only (75 patients). Patients allocated to the nutritional supplementation group will receive 3 biscuits per day for 2 months, containg macro- and micronutriets in addition to their standard TB treatment. These 3 biscuits will provide approximately 450 KCal of energy (or approximately 20% of the daily energy requirements), as well as a wide range of minerals and vitamins, in a doses of approximately half the Daily Required Intakes (DRI&#146;s), and NOT containing iron. Patients will be followed up according to standard clinical practice by the health services until the end of the intensive TB drug treatment phase (2 months).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16468-0</funderId>
      <contactId>Contact54426_16468</contactId>
      <sponsorId>Sponsor52981</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54426_16468">
    <title>Dr</title>
    <forename>Frank</forename>
    <surname>Wieringa</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept. of Internal Medicine
Hasan Sadikin Hospital
Jl. Pasir Kaliki 191</address>
      <city>Bandung</city>
      <country>Indonesia</country>
      <zip>40161</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+62 22 2038 986</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wieringa@tiscali.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52981">
    <organisation>NWO/WOTRO - Netherlands Organisation for Scientific Research (The Netherlands) </organisation>
    <website>http://www.nwo.nl/nwohome.nsf/pages/NWOA_6UB9S8</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Anna van Saksenlaan 51   </address>
      <city>The Hague</city>
      <country>Netherlands</country>
      <zip>2593 HW </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)70 3440763 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">WOTRO@nwo.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.420488.2</gridId>
    <rorId>https://ror.org/04jsz6e67</rorId>
  </sponsor>
  <funder id="Funder16468-0">
    <name>NWO/WOTRO - Netherlands Organisation for Scientific Research (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-30T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-30T00:00:00.000Z">91251359</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The use of magnetic resonance in non-invasive pancreatic beta-cell imaging: the relation between pancreatic triglyceride accumulation and beta-cell function in human (pre)diabetes</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pancreatic triglyceride accumulation, measured by magnetic resonance spectroscopy, is related to beta-cell function in subjects with Impaired Glucose Tolerance and/or Impaired Fasting Glucose.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Triglyceride content of the human pancreas in vivo assessed using non-invasive 1H-MRS
2. Relation between pancreatic triglyceride accumulation and beta-cell function
3. Relation between triglyceride accumulation in the pancreas and other fat compartments within the abdomen</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee VU University Medical Center 18-12-2006 (ref: 2006/219)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN91251359</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2006/219 sub1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational study.</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="067ddee4-402d-41ac-9e8e-78de8ba9972d">
	  <name>VU University Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 HV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male and female subjects (aged 35-70 years) 
2. Impaired Fasting Glucose (IFG; plasma glucose &gt; = 6.1 and &lt; 7.0 mmol/l) and/or 
3. IFG (plasma glucose &gt;= 5.6 and &lt; 7.0 mmol/l) and a family history of Diabetes Mellitus type two (DM2; i.e. first and second degree [i.e. grandparents] relatives) and/or 
4. Impaired Glucose Tolerance (IGT; 2-hour plasma glucose during 75 g Oral Glucose Tolerance Test  [OGTT] 7.8-11.1 mmol/l)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Known diabetes
2. History or present liver, exocrine pancreatic or renal disease
3. Drug-/alcohol abuse
4. Acute cardiovascular disease &lt;3 months prior to screening
5. Malignant disease
6. Claustrophobia and metal implants or pacemakers (MRI)
7. Lack of capacity to understand the aim of the research
8. Use of the following: 
8.1.  Glucocorticoids
8.2. Cytostatic drugs
8.3. Thiazolidinediones
8.4. Metformin
8.5. Oral contraceptives
8.6. Fibrates
8.7. Anti epileptic drugs
8.8. Centrally acting drugs for neurologic and/or psychiatric indications</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Subjects with impaired glucose tolerance and/or impaired fasting glucose</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Glucose Tolerance , Fasting Glucose</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The following will be performed in each subject: 
1. A modified euglycaemic hyperglycaemic clamp with arginine stimulation (After an euglycaemic clamp [120 minutes, 5 mmol/L], there is an hour rest period followed by a hyperglycaemic clamp [110 minutes, 15 mmol/L with 5 grams arginine stimulation])
2. Magnetic Resonance Imaging (MRI) of the abdominal fat compartments 
3. Proton Magnetic Resonance Spectroscopy (1H-MRS)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16609-0</funderId>
      <contactId>Contact54567_16609</contactId>
      <sponsorId>Sponsor53122</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54567_16609">
    <title>Dr</title>
    <forename>M</forename>
    <surname>Diamant</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>VU University Medical Center
Deparment of Endocrinology/ Diabetes Center
De Boelelaan 1117</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53122">
    <organisation>VU University Medical Center, Diabetes Center (The Netherlands)</organisation>
    <website>http://www.vumc.nl/english/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr M Diamant
VU University Medical Center 
Deparment of Endocrinology / Diabetes Center 
De Boelelaan 1117 </address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder16609-0">
    <name>Merck Sharp &amp; Dohme B.V. Protocol number: P 2129 V1 (International)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-28T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">58162568</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The surplus value of doppler in haemorrhoid artery ligation procedure</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Standard localised ligations are as feasible as doppler-guided ligations of haemorrhoid arteries.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incontinence at four months postoperatively.</primaryOutcome>
      <secondaryOutcome>1. Operative variables
2. Visual Analogue Scale (VAS)-pain scores, analgesics (seven days, month one and four)
3. Cleveland Incontinence Score, Complaints (month one and four)
4. Costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Medisch-Ethische toetsingscommissie) on the 24th of May 2007 (ref: METC number M071729).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN58162568</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0161b6f0-62d4-4799-b7f2-af99aef0b66f">
	  <name>Canisius-Wilhelmina Hospital</name>
	  <address/>
	  <city>Nijmegen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6500 GS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged greater than 18 years
2. Symptomatic grade II/III/IV haemorrhoids
3. At least one unsuccessful rubber band ligation
4. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>92</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>92</totalTarget>
      <exclusion>1. Previous anal surgery
2. Bleeding disorder</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Haemorrhoid arteries</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Artery diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Doppler-guided and standard localised haemorrhoidal artery ligation.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16861-0</funderId>
      <contactId>Contact54819_16861</contactId>
      <sponsorId>Sponsor53376</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54819_16861">
    <title>Dr</title>
    <forename>S.</forename>
    <surname>Nienhuijs</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Canisius-Wilhelmina Hospital
P.O. Box 9015</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 GS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)24 365 7657</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.nienhuijs@hccnet.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53376">
    <organisation>Catharina Hospital Eindhoven (The Netherlands)</organisation>
    <website>http://www.catharina-ziekenhuis.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Surgery
P.O. Box 1350</address>
      <city>Eindhoven</city>
      <country>Netherlands</country>
      <zip>5602 ZA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413532.2</gridId>
    <rorId>https://ror.org/01qavk531</rorId>
  </sponsor>
  <funder id="Funder16861-0">
    <name>Catharina Hospital Eindhoven (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">82467578</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Bacterial Translocation and intestinal permeability in patients undergoing open or laparoscopic total colectomy: open, right side or left side first laparoscopically</title>
      <scientificTitle/>
      <acronym>BactTrans</acronym>
      <studyHypothesis>We hypothesise that bacterial translocation is the least in open colectomy followed by laparoscopic colectomy starting the devascularisation on the left side followed by laparoscopic colectomy starting the devascularisation on the right side. 

The longer period of devascularisation results in an increased permeability and higher risk of bacterial translocation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Intestinal permeability, measured before, during and directely after surgery
2. Amount of bacterial translocation, measured before, during and directely after surgery</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Medical Ethics Committee AMC, Amsterdam on the 26th April 2006 (ref: MEC 06/045).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82467578</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7006bb6e-a835-4547-a664-3c4bb561b772">
	  <name>Academic Medical Centre (AMC)</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged greater than 18 years
2. Patients planned for laparoscopic total colectomy for inflammatory bowel diseases or familial adenomatous polyposis or patients undergoing subtotal colectomy
3. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Antibiotics within a week prior to surgery (perioperative antibiotics are allowed)
2. Use of probiotic products four weeks before or during the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bacterial translocation and intestinal permeability</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Bacterial translocation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Devascularisation beginning left or right in case of laparoscopic colectomy. In case of open colectomy mobilisation from lateral to medial.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16863-0</funderId>
      <contactId>Contact54821_16863</contactId>
      <sponsorId>Sponsor53378</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54821_16863">
    <title>Dr</title>
    <forename>W.A.</forename>
    <surname>Bemelman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Centre (AMC)
Department of Surgery
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 9111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">W.A.Bemelman@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53378">
    <organisation>Academic Medical Centre (AMC) (The Netherlands)</organisation>
    <website>http://www.amc.uva.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Surgery
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder16863-0">
    <name>Academic Medical Centre (AMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-26T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">52352361</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Implementation of a strategy of osteoporosis screening in patients over 50 years of age with a first fracture</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The nurse practitioner will actively approach all fracture patients above the age of 50 for screening and intensive treatment of osteoporosis. This will improve the number of fracture patients screened and treated for osteoporosis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Percentage of patients with a fracture of 50 years and older that is screened by a fracture nurse for osteoporosis (the goal is 70%)
2. Percentage of patients that are screened and treated and still use their medication after one year (the goal is 70%)</primaryOutcome>
      <secondaryOutcome>1. Percentage of patients that present with a fracture within a year of the initial fracture
2. Percentage screened patients and percentage compliant patients in the fracture nurse group compared to the parallel group
3. The costs and barriers to implement a fracture nurse

The final follow up will take place after one year, the patients will be contacted every three months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from VU University Medical Center Ethics Board, Amsterdam, on the 21st June 2007 (ref: 2007/132).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52352361</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, parallel group clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="80b28810-84b4-441f-91d7-9e0729cd1896">
	  <name>Vrije University Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 HV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients 50 years of age or older, who have a clinical fracture and a low Bone Mineral Density (BMD) defined as a T score greater than or equal to 2.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>1650</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1650</totalTarget>
      <exclusion>1. Patients with a fracture after a traffic accident
2. Patients with a pathological fracture
3. Patients with fractures of hand, foot or scull
4. Serious co-morbidity or dementia
5. Incapable of visiting the out patient clinic</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoporosis screening</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoporosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>In the implementation group the patients will be screened for osteoporosis by Dual energy X-ray Absorptiometry (DXA) measurement, and a spine X-ray will be performed. At baseline and after 12 months a blood sample will be taken. At baseline, after 3, 6, 9 and 12 months questionnaires will be performed. The follow up period is 1 - 1.5 years (depending on the time it takes to include enough patients). Patients will be treated with anti-osteoporosis medication according to the CBO guidelines (first choice bisphosphonates).

In the parallel group only the questionnaires will be performed.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16869-0</funderId>
      <contactId>Contact54827_16869</contactId>
      <sponsorId>Sponsor53384</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54827_16869">
    <title>Dr</title>
    <forename>D.A.</forename>
    <surname>Eekman </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Vrije University Medical Centre
Department of Rheumatology, 4a-42
Boelelaan 1117</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 3432</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">d.eekman@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53384">
    <organisation>Vrije University Medical Centre (VUMC) (The Netherlands)</organisation>
    <website>http://www.vumc.nl/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Rheumatology</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder16869-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">87502236</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of SCH 351125 on mononuclear cell trafficking to joints, synovial inflammation and expression of chemokines in subjects with rheumatoid arthritis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>SCH 351125 50 mg twice daily (BID) 2/days is an effective treatment for Rheumatoid Arthritis (RA).

Primary objectives of the study are to determine the effects of SCH 351125 on mononuclear cell migration into synovial tissue in subjects with rheumatoid arthritis, and to evaluate the safety and tolerability of multiple-dose administration of SCH 351125 50 mg BID in subjects with rheumatoid arthritis when administered for 28 days.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. To determine the effects of SCH 351125, a CCR5 receptor antagonist, on  mononuclear cell migration into synovial tissue in subjects with rheumatoid arthritis 
2. To evaluate the safety and tolerability of multiple-dose administration of SCH 351125 50 mg twice-daily in subjects with rheumatoid arthritis when administered for 28 days</primaryOutcome>
      <secondaryOutcome>1. To explore the effects of SCH 351125 on:  
1.1. Synovial inflammation via MRI 
1.2. Chemokine expression and concentrations in the plasma, synovial tissue and synovial fluid (messenger Ribonucleic Acid [mRNA] expression only)
1.3. Mononuclear cell concentrations in the peripheral blood
1.4. Clinical signs and symptoms of rheumatoid arthritis
1.5. To determine the single-dose and multiple dose pharmacokinetic profile of SCH 351125 in subjects with rheumatoid arthritis</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Medical Ethics Committee of the Academic Medical Centre (University of Amsterdam) on the 21st January 2004 (ref: 03/267).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87502236</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P03653</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="19cc24de-e7d6-46b4-bf80-38c48be918af">
	  <name>Academic Medical Centre (AMC)</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Subjects 18 to 70 years of age, of either sex, and of any race
2. Diagnosis of RA according to the American College of Rheumatology (ACR) criteria, for at least six weeks prior to entry in the study
3. Active RA defined as: 
3.1. Three or more tender joints
3.2. Three or more swollen joints, and 
3.3. At least one of the following three:  
3.3.1. Duration of morning stiffness equal to or greater than 45 minutes 
3.3.2. Erythrocyte sedimentation rate equal to or greater than 28 mm/hour
3.3.3. C-reactive protein equal to or greater than 10 mg/L
4. Functional class I, II or III
5. Subjects must be free of any clinically significant disease (other than rheumatoid arthritis) that would interfere with the study evaluations and/or safety
6. Subjects must be willing to give written informed consent and able to adhere to dose and visit schedules
7. Females must not be breast-feeding, and either be of non-childbearing potential (i.e., sterilised via hysterectomy or bilateral tubal ligation or at least one year postmenopausal) or if of child bearing potential, must be practicing effective double barrier contraceptive methods from at least two weeks prior to day 1 and until 30 days following cessation of dosing
8. Female subjects of childbearing potential must have a negative serum pregnancy test (beta human Chorionic Gonadotropin [beta-hCG]) at screening
9. Males must practice an effective barrier method of contraception from day 1 until 30 days following cessation of dosing
10. A physical examination must be without clinically significant findings with exception of those finding related to rheumatoid arthritis
11. At screening, Electrocardiogram (ECG) conduction intervals must be within the gender specific normal range (i.e., QTc for males less than 430 msec and females less than 450 msec)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Individuals with a history of any significant medical disorder which require a physician's care (excluding rheumatoid arthritis) and would interfere with the study evaluations or compromise subject safety
2. Individuals who have a history of any clinically significant local or systemic infectious disease within four weeks prior to drug administration
3. Any subject with an allergy to gadolinium
4. Any subject with a pacemaker, metal object implanted their body or any other device or condition which may interfere with a subject's safety during the Magnetic Resonance Imaging (MRI) procedure
5. Any subject who has received Disease Modifying Anti-Rheumatic Drug (DMARD) treatment within 30 days prior to enrolment (leflunomide requires a charcoal or cholestyramine washout)
6. Any subject who has received anti-Tumour Necrotising Factor (anti-TNF) therapy (except enteracept) or any biologic therapy within the previous 90 days
7. Any subject whose baseline Disease Activity Score (DAS-28) has significantly changed since screening to indicate unstable disease
8. Any individual who does not comply with the requirement that he should not have used:
8.1. Any drugs (including herbal and mineral supplements or vitamins), other than acetaminophen or an approved stable regimen of low dose prednisone (10 mg/day) and/or Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), for at least two weeks prior to study drug administration
8.2. Alcohol in amounts of greater than 50 grams a day throughout the study
9. Subjects that have been diagnosed with Juvenile RA
10. A history of systemic lupus erythematosus, or signs and symptoms suggesting systemic lupus erythematosus
11. Subjects who are positive for hepatitis B surface antigen, hepatitis C Ribonucleic Acid (RNA) or for Human Immunodeficiency Virus (HIV) antibodies
12. Individuals who have participated in a clinical trial of an investigational drug within 90 days prior to the start of study drug administration, or have received prior treatment with a CCR5 receptor antagonist
13. Individuals with a positive screen for drugs of abuse
14. Individuals who have donated blood (greater than 300 mL) within the preceding 90 days
15. Males who are unwilling to use/practice an effective method of contraception (i.e., condom in conjunction with spermicide from study start until 30 days after the last study treatment
16. Females who are unwilling to use/practice an effective method of contraception (i.e., condom in conjunction with spermicide from two weeks prior to study start until 30 days after the last study treatment
17. Individuals who have received any vaccinations within 30 days prior to screening
18. Individuals with any clinically significant history of food or drug allergy or allergy to any component of SCH 351125
19. Subjects who are not willing to follow the study restrictions or procedures</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Arthropathies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects with active Rheumatoid Arthritis (RA) were enrolled in a randomised double-blind, placebo-controlled, parallel-group study exposed  to either SCH 351125 50 mg BID or matched placebo, in a 2:1 ratio, for 28 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>SCH 351125</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16857-0</funderId>
      <contactId>Contact54815_16857</contactId>
      <sponsorId>Sponsor53372</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54815_16857">
    <title>Prof</title>
    <forename>P.P.</forename>
    <surname>Tak</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Centre (AMC)
Department of Clinical Immunology and Rheumatology
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 2171</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.p.tak@amc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53372">
    <organisation>Schering Plough Research Institute (USA)</organisation>
    <website>http://www.schering-plough.com/schering_plough/research/research_institute.jsp</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Schering-Plough Corporation Headquarters
2000 Galloping Hill Road
Kenilworth</address>
      <city>New Jersey</city>
      <country>United States of America</country>
      <zip>07033-0530</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.417993.1</gridId>
    <rorId>https://ror.org/02891sr49</rorId>
  </sponsor>
  <funder id="Funder16857-0">
    <name>Schering Plough Research Institute (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">74137878</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study to evaluate the different levels of attention and VALence direction for erotic stimuli, in relation to genital and subjective sexual arousal in healthy female subjects and healthy female subjects with female sexual dysfunction</title>
      <scientificTitle/>
      <acronym>VAL</acronym>
      <studyHypothesis>In the present placebo controlled study we will investigate the influence of valence on attention when viewing visual erotic stimuli. Especially when under the treatment condition of testosterone with sildenafil. In addition, we will investigate the effects of testosterone in combination with sildenafil on vaginal and subjective sexual arousal induced by visual erotic stimuli in females with Female Sexual Dysfunction (FSD) and control subjects, for individual motivational and emotional differences (valence). In earlier study's we've found a distinction between groups that differ in colour naming of erotic words compared to neutral words. These two groups also differed in their benefit from testosterone combined with sildenafil. 

We expect that for some women this treatment, testosterone with sildenafil will work adequately. For the other group, we expect that negative sexual experiences and personality differences and therefore the negative/defensive motivational neural circuit is responsible for the more diffuse reaction to the treatment of testosterone and sildenafil, in women with FSD.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Evaluation of the women's judgment of valence (negative or positive) for erotic stimuli under placebo condition and the condition of 0.5 mg sublingual testosterone combined with sildenafil (50 mg) and the influence of positive and/or negative valence on attention for erotic cues, in healthy female subjects with and without Female Sexual Dysfunction. 

Data for analysis:
1. Attention for erotic stimuli (strooptask: speedrate). A masked version of the Emotional Stroop Task comparing colour-naming latencies on neutral and erotic words will be used. The word is presented before and after the erotic film excerpts in the attention condition for about 24 ms and then masked by randomly cut, reassembled signs in the same colour (red, green, yellow or blue). The colour of the mask has to be assigned, and subjects are asked to verbally name the colours as quickly as possible. The stimuli are presented in the centre of the screen. An extra set of stimuli will be prepared for practice-trials. A trial consists of a fixation point, which will be shown for 750 ms, followed by the target stimulus (the coloured neutral or erotic word and mask). Vocal responses will be recorded and will terminate the trials. The order of these 2 blocks will be randomly assigned. Attention will be measured on both the experimental days in the morning (pre-dose) and in the afternoon (post-dose).
2. Vaginal Pulse Amplitude (VPA. A vaginal photoplethysmograph will be used to measure Vaginal Pulse Amplitude (VPA) (the AC component of the signal), which is a reliable index for genital vasocongestion. Changes in the amplitude of the signal reflect changes in vaginal vasocongestion. The Vaginal Photoplethysmograph (VP) is a clean tampon shaped device, which contains an infrared Light-Emitting Diode (LED) as a light source and a photosensitive light detector (photodiode). It measures the blood volume in the tissue surrounding the plethysmograph. The light emitted by the LED is reflected by the blood vessels in the tissue. This light is measured by the photodiode. The output signal of the photodiode varies with changes in the amount of blood in the vessels. VPA will be measured on both the experimental days in the morning (pre-dose) and in the afternoon (post-dose)
3. Valence for erotic stimuli. Perceived emotional valence of erotic stimuli will be measured and compared to neutral, pleasant and unpleasant stimuli. Facial expressions reveal emotions with corresponding appetitive and defensive motivational circuits. The amygdala projects to the facial motor nucleus, which reflects the chosen motivational circuit; appetitive or defensive. Therefore, Electromyographic (EMG) activity will be measured over the corrugator, zygomatic major and orbicularis oculi muscles. Activation of the zygomatic muscle reveals a smile, but co-activation of the zygomatic and orbicularis mirrors a major smile. Activation of the corrugator muscle alone is correlated with viewing unpleasant events. More specifically, co-activation of the corrugator and orbicularis oculi reflects the emotion of repulsion and aversion. While viewing International Affective Picture System (IAPS) pictures (eight pictures for each domain; pleasant, neutral, unpleasant and erotic) and an additional category of sexually explicit pictures (depicting vaginal coitus), activation of the three muscles will be measured two seconds before picture onset and for six seconds during picture presentation. The activation of the orbicularis oculi muscle is also a component of the startle reflex. When viewing the pictures, half of all pictures will be accompanied by a startle stimulus. The acoustic startle stimulus consists of a 50-ms burst of white noise, presented at 95 dB. The startle stimuli will be presented through earplugs, between 3 and 5 seconds following picture onset. Prior to the first block, six startle sounds will be presented to allow habituation of the startle reflex. After the presentation of the pictures subjects are instructed to give a subjective rating of the emotional pictures by finger pointing at a touch screen. Each emotional picture will be followed by a picture of five figures with expressions ranging from happy (smiling) to unhappy (frowning). Subjects are instructed to rate on a 9-point scale how their feeling towards the preceding picture was reflected by one of the figures. The same was done for arousal, with excited, wide-eyed figures to sleepy, relaxed figures. Valence be measured on both the experimental days in the morning (pre-dose) and in the afternoon (post-dose).</primaryOutcome>
      <secondaryOutcome>1. To evaluate the correlation between subjective ratings of sexual functioning and physiological sexual responses
2. To evaluate the changes in differences in direction of valence when viewing visual erotic stimuli under the placebo condition and the condition with testosterone combined with sildenafil
3. To evaluate the individual differences in attention in relation to positive and/or negative valence induced by visual erotic stimuli
4. To evaluate the influence of personality traits on the differences in vaginal &amp; subjective sexual arousal, EMG, valence direction and startle reflex
5. Subjective ratings of sexual functioning
6. Startle reflex
7. EMG activation
8. Personality traits
9. Negative sexual experiences will be assessed with a questionnaire and in the clinical interview, both during screening</secondaryOutcome>
      <trialWebsite>http://www.emotionalbrain.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval gained from the local ethics committee (Stichting Therapeutische Evaluatie Geneesmiddelen, Medische Etische Toetsingscommissie [STEGMETC]) on the 13th June 2007 (ref: R07-013).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74137878</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EB069 (VAL)</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo controlled, crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1978-06-21T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7746c3a3-1740-4e82-b154-de06d8b6700c">
	  <name>Emotional Brain BV</name>
	  <address/>
	  <city>Almere</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1311 RL</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>40 Subjects must meet the following criteria:
1. Subjects must have a heterosexual orientation
2. Subjects must be between 21 and 65 years of age
3. Subjects with normal sexual functioning
4. Subjects must have signed the Informed Consent Form
5. Inclusion will be following the selection criteria including, but not limited to, a physical examination, gynaecological examination, medical history, vital signs, pregnancy test and Electrocardiogram (ECG)

80 Subjects must meet the following criteria:
1. Subjects must have a heterosexual orientation
2. Subjects must be between 21 and 65 years of age
3. Subjects must have experienced low sexual arousal and/or low sexual desire for at least six months prior to study entry according to Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM IV) criteria. The diagnosis will be made by an experienced psychologist/sexologist
4. Subjects must have signed the Informed Consent Form
5. Inclusion will be following the selection criteria including, but not limited to, a physical examination, gynaecological examination, medical history, vital signs, pregnancy test and ECG, and by the scoring on the strooptask during familiarization trial</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>Subjects will not be eligible for inclusion if one of the following criteria applies: 
1. Use of oral contraception containing anti-androgens (Like Diane 35 or Minerva)
2. Use of oral contraception containing 50 µg oestrogen or more
3. Pregnancy, or intention to become pregnant during this study (note: a serum or urine pregnancy test will be performed in all women prior to the administration of study medications)
4. A pelvic inflammatory disease or an untreated vaginal infection at screening
5. Lactating or subjects who have given birth in the previous six months
6. Previous prolapse and incontinence surgery affecting the vaginal wall
7. Women with other unexplained gynaecological complaints, such as abnormal uterine bleeding patterns;
8. History of endocrinological treatment or current endocrinological treatment (with the exception of the use oral contraceptives and of  fertility-promoting treatment)
9. History of neurological treatment or current neurological treatment
10. History of  serious psychiatric treatment or current psychiatric treatment
11. Any underlying cardiovascular condition including unstable angina pectoris, that would preclude sexual activity
12. History of myocardial infarction, stroke or life-threatening arrhythmia within the prior six months
13. Uncontrolled atrial fibrillation/flutter at screening (ventricular response rate greater than 100 bpm), or other significant abnormality observed on Electrocardiogram (ECG)
14. Systolic blood pressure greater than 140 mmHg and/or diastolic blood pressure greater than 90 mmHg. For subjects with age greater than 60 years and without diabetic mellitus, familiar hypercholesterolemia or cardiovascular disease: systolic blood pressure greater than 160 mmHg and/or diastolic blood pressure greater than 90 mmHg (according to the CBO-guideline hypertension [CBO.2000a])
15. Subjects who are taking strong CYP3A4-inhibitors:  ritonavir (Human Immunodeficiency Virus [HIV] Protease inhibitor), ketoconazole and itraconazole 
16. Subjects who are taking less strong CYP3A4-inhibitors: clarithromycin, erythromycine and saquinavir
17. Subjects who are taking CYP3A4-inducers: carbamazepine, phenytoin, phenobarbital, St Johns Wort, rifampicine
18. Severe chronic or acute liver disease, history of moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment
19. Use of medicinal herb as Ginkgo Biloba and nutrition containing grapefruit
20. Subjects who are taking nitrates or nitric oxide donors
21. A substance abuse disorder that in the opinion of the investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study; mild or moderately alcohol drinking behaviour is allowed, only 12 hours before the experimental days is alcohol drinking not allowed. Three weeks before the start of the experimental day is the taking of any recreational drug not allowed. Smoking is allowed
22. Use of any treatment for FSD within the seven days before visit one or during the study, including oral medications or constrictive devices
23. Subjects who are illiterate, unwilling or unable to understand and complete the questionnaires
24. Any other clinically significant abnormality or condition which in the opinion of investigator would interfere with the participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if she took part in the trial
25. Moderate and severe hearing impairment
26. Subjects who are colour blinded
27. Subjects who are having botox® (or other equivalents of botox, like dysport) in the facial area within six months before the first experimental day</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1978-06-21T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Female sexual dysfunction</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Female sexual dysfunction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Testosterone, administered as a solution sublingually (0.5 mg) and sildenafil, type 5 phosphodiesterase (PDE5) inhibitor, administered as an encapsulated tablet orally (50 mg):

Treatment A: 0.5 mg testosterone and sildenafil 50 mg 
Treatment P: placebo testosterone and placebo sildenafil 

The two treatments (A and P) will be randomised across the 120 subjects. Two different drug combinations will be given on separate days: (day 1) placebo, (day 2) sildenafil plus testosterone. Drug administration will be divided into two parts. Testosterone will be administered first. Two hours after testosterone administration, sildenafil (Viagra) will be administered. Testosterone will have a behavioural effect, increasing sexual desire and arousal, after four hours of intake. Sildenafil will have a physical effect, increasing blood flow to the genitals, after 1 hour of intake. It's duration is about six hours.

Two separate experimental days are separated by a three to ten day period.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Testosterone, sildenafil</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16846-0</funderId>
      <contactId>Contact54804_16846</contactId>
      <sponsorId>Sponsor53361</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54804_16846">
    <title>Dr</title>
    <forename>D.</forename>
    <surname>van Ham</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Emotional Brain BV</address>
      <city>Almere</city>
      <country>Netherlands</country>
      <zip>1311 RL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)36 546 8346</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">d.vanham@emotionalbrain.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53361">
    <organisation>Emotional Brain B.V. (The Netherlands)</organisation>
    <website>http://www.emotionalbrain.nl/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Louis Armstrongweg 78</address>
      <city>Almere</city>
      <country>Netherlands</country>
      <zip>1311 RL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476322.6</gridId>
    <rorId>https://ror.org/03vy5fy74</rorId>
  </sponsor>
  <funder id="Funder16846-0">
    <name>Emotional Brain B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-17T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-17T00:00:00.000Z">83770226</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Impact of Spirulina platensis supplementation on general health status of HIV infected patients in Burkina Faso</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Daily Spirulina platensis supplementation can improve clinical, nutritional and immunobiological status of HIV infected patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The impact of active daily supplementation of Spirulina platensis on the clinical, nutritional and immunological status of HIV infected patients will be assessed by the following: 
1. Measurement of CD4, viral load, hematological and biochemical parameters at the start, 6 and 12 months of trial
2. Monthly measurement of anthropometric parameters</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Institutional Ethics Committee of Centre Muraz (Institut de Recherche en Sciences de la Santé [IRSS]), approved on 20 December 2005 (ref: 022/2005/CEI-CM)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83770226</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind randomized controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Burkina Faso</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="94467c70-9df4-49f3-a6fa-da5c49dad463">
	  <name>Institut de Recherche en Sciences de la Santé</name>
	  <address/>
	  <city>Bobo-Dioulasso</city>
	  <state/>
	  <country>Burkina Faso</country>
	  <zip>545</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. HIV infected 
2. At least 18 years old 
3. Willing to be followed up for at least 12 months 
4. Informed consent to be provided by the patient</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. Patients who do not consent to be involved in the trial
2. Under the age of 18 years
3. Patients who are pregnant 
4. Cardiopathy or cancer
5. Currently receiving Spirulina platensis spplementation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>HIV / AIDS</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>HIV / AIDS</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: 60 Patients with 200 CD4/µl of peripheric blood or lower (patients who are currently receiving antiretroviral treatment) 
Sub-group 1 (30 patients): four capsules (a capsule contains 420 mg of spiruline) three times daily per os (orally) for each patient for 12 months 
Sub-group 2 (30 patients): The same number of capsules as in sub-group 1 but placebo instead of active supplement 

Group 2: 60 Patients with 200 &lt; CD4 &lt; 400 (patients who are currently receiving antiretroviral treatment) 
Sub-group 1 (30 patients): four capsules (a capsule contains 420 mg of spiruline) three times daily per os for each patient for 12 months 
Sub-group 2 (30 patients): The same number of capsules as in sub-group 1 but placebo instead of active supplement 

Group 3: 60 Patients with CD4 &gt;400 (some of these patients are currently receiving antiretroviral treatment) 
Sub-group 1 (30 patients): four capsules (a capsule contains 420 mg of spiruline) three times daily per os for each patient for 12 months 
Sub-group 2 (30 patients): The same number of capsules as in sub-group 1 but placebo instead of active supplement 

Each included patient in the trial will be followed up monthly by a physician. 
Anthropometric parameters of the participants will be measured monthly and their CD4, viral load, hematological and biochemical parameters will be measured semestrially.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Spirulina platensis</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16577-0</funderId>
      <contactId>Contact54535_16577</contactId>
      <sponsorId>Sponsor53090</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54535_16577">
    <title>Prof</title>
    <forename>Jean Bosco</forename>
    <surname>Ouedraogo </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institut de Recherche en Sciences de la Santé
Direction Régionale de l'Ouest
399, Avenue de la Liberté
01 BP 545 Bobo-Dioulasso 01</address>
      <city>Bobo-Dioulasso</city>
      <country>Burkina Faso</country>
      <zip>545</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+226 20 98 18 80</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jbouedraogo.irss@fasonet.bf</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53090">
    <organisation>Ministry of Health of Burkina Faso, Drug Directorate (DGPML)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Projet Spiruline Nayalgue 
S/C Pr Jean-Baptiste Nikiema </address>
      <city>Ouagadougou</city>
      <country>Burkina Faso</country>
      <zip>03 BP 7009 Ouaga</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+226 50 32 46 60 / 61</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jbnikiema@yahoo.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.491199.d</gridId>
    <rorId>https://ror.org/03h83vk17</rorId>
  </sponsor>
  <funder id="Funder16577-0">
    <name>Ministry of Health of Burkina Faso, Drug Directorate (DGPML)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-11T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-08-15T00:00:00.000Z">45665690</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy and safety of artesunate and sulfadoxine-pyrimethamine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in low to moderate sentinel sites in Sudan</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To assess the efficacy of the first (artesunate and sulfadoxine-pyrimethamine) and second line treatment (artemether-lumefantrine) for the treatment of uncomplicated Plasmodium falciparum infections in different sentinel sites in Sudan.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Adequate clinical and parasitological response Polymerase Chain Reaction (PCR) corrected.</primaryOutcome>
      <secondaryOutcome>Incidence of adverse events.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. Federal Ministry of Health (Sudan) on the 3rd May 2007
2. Ethical Research Committee of the World Health Organization (WHO) on the 11th June 2007 (ref: RPC220)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45665690</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC220</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>One-arm surveillance study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-11-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sudan</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cfa40408-67db-4481-81a5-4eea739e4e09">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged over 6 months old
2. Infection with P. falciparum
3. Parasitaemia, 1000 - 100 000 asexual forms per µl
4. Axillary temperature of 37.5°C or oral/rectal temperature of 38°C
5. Ability to swallow oral medication
6. Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule
7. Informed consent from the patient or from a parent or guardian in case of children</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. Presence of general danger signs among children less than 5 years old or other signs of severe and complicated falciparum malaria according to current WHO definitions
2. Mixed or mono-infection with another Plasmodium species
3. Presence of severe malnutrition (defined as a child whose weight-for-height is below -3 standard deviation or who has symmetrical oedema involving at least the feet)
4. Presence of febrile conditions due to diseases other than malaria (measles, acute lower tract respiratory infection, severe diarrhoea with dehydration, etc.), or other known underlying chronic or severe diseases
5. History of hypersensitivity reactions to any of the drug(s) being tested or used as alternative treatment
6. Pregnancy or lactation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Each patient will receive both:
1. Artemether-lumefantrine six consecutive doses according to manufacturer recommendation over three days orally (per os)
2. Artesunate 12 mg/kg over three days per os and sulfadoxine-pyrimethamine 1/2 tablet 500 mg - 25 mg/10 kg single dose per os

Principal Investigator:
Dr Khalid A. Elmardi
National Malaria Control Programme
Federal Ministry of Health
P.O. Box 1204
Khartoum
Sudan
Tel: +249 (0)183 776809
Fax: +249 (0)183 770397
Email: khalidmrd9@hotmail.com</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Artesunate, sulfadoxine-pyrimethamine, artemether-lumefantrine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16808-0</funderId>
      <contactId>Contact54766_16808</contactId>
      <sponsorId>Sponsor53322</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54766_16808">
    <title>Dr</title>
    <forename>Pascal</forename>
    <surname>Ringwald</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 34 69</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ringwaldp@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53322">
    <organisation>World Health Organization (WHO)/HIV/AIDS, Tuberculosis and Malaria (HTM) - Global Malaria Programme</organisation>
    <website>http://www.who.int/malaria/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder16808-0">
    <name>World Health Organization (WHO) (Sudan)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-09T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-08-08T00:00:00.000Z">67123277</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Circadian intraocular pressure, blood pressure and diastolic ocular perfusion pressure with timolol-dorzolamide fixed combination compared with latanoprost in newly-diagnosed glaucoma patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the short-term effect of Timolol-Dorzolamide Fixed Combination (TDFC), and latanoprost 0.005% on the 24-hour Intraocular Pressure (IOP), ambulatory Blood Pressure (BP), and Diastolic Ocular Perfusion Pressure (DOPP), in newly-diagnosed Primary Open-Angle Glaucoma (POAG) patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were measured at baseline, and at the end of each treatment period: 
1. 24-hour IOP
2. Ambulatory BP
3. Calculated DOPP</primaryOutcome>
      <secondaryOutcome>Adverse events</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Institutional Review Board of Clinica Oculistica Università degli studi Brescia (ref: 02/2005/03)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67123277</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, observer-masked, two-treatment, two-period cross-over study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8e3b6778-ef98-4ef0-ba21-ac7cd7366c21">
	  <name>Centro per lo studio del glaucoma</name>
	  <address/>
	  <city>Brescia</city>
	  <state/>
	  <country>Italy</country>
	  <zip>25123</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>We enrolled in the present study consecutive newly diagnosed and previously untreated POAG patients who demonstrated typical optic disc excavation and visual field abnormalities. We included POAG patients older than 45 years with no previous history of ocular surgery or laser. Additional inclusion criteria were: 
1. Open-angle by gonioscopy (Grade III-IV according to Shaffer&#146;s grading system)
2. Untreated diurnal IOP between 23 and 32 mm Hg (mean of the two highest values recorded in a daytime IOP curve with measurements every 2 hours between 08:00 and 18:00 by a calibrated Goldmann applanation tonometry)
3. Visual acuity 20/40 or better
4. Mean defect &gt;6 dB using the Humphrey 24-2 program (Humphrey Visual Field Analyzer model 745 perimeter, Humphrey Instruments, Inc., USA)
5. No history of allergy to the ingredients of any of the study drugs
6. No history of cardiovascular disease (e.g. arterial hypertension, heart disease, arrhythmia)
7. No concomitant systemic treatment (e.g. beta-blockers, angiotensin-converting enzyme inhibitors) that could modify IOP, or blood pressure. 
8. Females were enrolled in the study only if they were postmenopausal or were using contraceptives</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>27</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>27</totalTarget>
      <exclusion>See inclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Primary open-angle glaucoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Primary open-angle glaucoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Following the monitoring of the baseline or washout IOP and BP all study patients were randomly assigned to receive either one drop of TDFC twice daily (08:00 and 20:00) or one drop of latanoprost once in the evening (20:00). 

Twenty-four hour IOP and ambulatory BP were measured at the beginning after the interim washout and at the end of each treatment period, thus obtaining 4 circadian curves. At the time of 24-hour IOP and BP assessments patients were hospitalized, and the drugs were administered by the dosing coordinator of the study according to the protocol. 

The IOP was measured every two hours. A calibrated Goldmann applanation tonometer (Haag-Streit, Switzerland) was employed to measure sitting IOP at the slit lamp between 08:00 and 22:00, while supine IOP was measured between 24:00 and 06:00, with the patient in bed, by means of a calibrated handheld electronic tonometer (TonoPen XL; Bio-Rad, USA). At each timepoint, the mean of 3 consecutive readings was calculated. 

Ambulatory blood pressure monitoring was recorded by means of an automated portable BP device, TM-2430 (A&amp;D Co, Saitama, Japan). Ambulatory BP monitoring units indirectly measure BP through oscillometric measurement of the vibratory signals associated with blood flow in the brachial artery. The BP device satisfies the recommendation by the British Hypertension Society and Association for Advancement of Medical Instrumentation on accuracy levels for both systolic and diastolic blood pressures. A cuff of appropriate size was placed in the subject&#146;s non-dominant arm and BP measurements were taken automatically every 15 minutes between 08:00 to 22:00, and every 30 minutes from 22:00 to 08:00. If a certain reading was not performed properly the 
device was programmed to repeat it. The recorded BP values throughout the 24-hour period were later recovered from the recording chip and stored in a personal computer. 

During the study BP and IOP readings were monitored in the hospital on two separate days, so as to not influence BP readings by the process of IOP measurements, or by waking the patient during the night for IOP evaluation. 
IOP measurements were performed by three well-trained masked observers who were unaware of the treatment assignments; their agreement was previously tested on a pilot sample of 15 patients, resulting in an intraclass correlation coefficient of 0.97 and 0.99 for Tonopen and Goldmann tonometry, respectively. 
A comprehensive ocular and systemic examination was performed at baseline and at the conclusion of each phase of the trial, and any ocular or systemic adverse events were noted.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16799034 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5694185f-4941-4d9d-a941-04122fbf9ee3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16799034"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16738-0</funderId>
      <contactId>Contact54696_16738</contactId>
      <sponsorId>Sponsor53252</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54696_16738">
    <title>Prof</title>
    <forename>Luciano</forename>
    <surname>Quaranta</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centro per lo studio del glaucoma
Piazzale Spedali Civili 1 </address>
      <city>Brescia</city>
      <country>Italy</country>
      <zip>25123</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)30 3995 847</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">quaranta@med.unibs.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53252">
    <organisation>Clinica Oculistica (Italy)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Piazzale Spedali Civili 1 </address>
      <city>brescia</city>
      <country>Italy</country>
      <zip>25123</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)30 3995 847</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">quaranta@med.unibs.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder16738-0">
    <name>Ministry of Education, University and Research  (Ministero dell&#146;Università e della Ricerca; MIUR) (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-22T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-07-16T00:00:00.000Z">38727701</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Determinants of thiazide induced hyponatraemia in pre-exposed elderly - a controlled experiment</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Thiazide-induced hyponatraemia is caused by impaired free water excretion either due to alterations in the Arginine Dihydrolase (ADH) - Arginine Vasopressin Receptor 2 (AVPR2) - Aquaporin-2 (AQP2) pathway or impaired renal sodium handling.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Effect of a single oral dose hydrochloorthiazide 50 mg intake on the serum and urine sodium, serum ADH, prostaglandin E2 and urinary aquaporin-2 excretion in elderly patients (aged 60 - 80 years) with previous thiazide-induced hyponatraemia (sodium less than 125 mmol/l) without another cause for their hyponatraemia and matched controls receiving a thiazide diuretic without hyponatraemia. 

Urinary hydrochlorothiazide concentrations are measured to analyse differences in thiazide metabolism. The response to ADH will be assessed by expression of AVPR2 in a cell-culture and determine its activity by measurement of cyclic Adenosine Monophospahte (cAMP).

Outcomes will be measured at baseline (n = 0) and after 4, 8 and 24 hours.</primaryOutcome>
      <secondaryOutcome>To identify (elderly) patients who are at risk of thiazide induced hyponatraemia.

Outcomes will be measured at baseline (n = 0) and after 4, 8 and 24 hours.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Medical Ethics Committee of the AMC on the 16th August 2007 (ref: MEC 07/059).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN38727701</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-randomised, controlled experimental study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cf52a276-32d1-4353-8f9b-dda39ffe2677">
	  <name>Academic Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1105 AZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 60 - 80 years
2. Previously admitted with thiazide-induced hyponatraemia
3. Patients must be willing and medically able to discontinue anti-hypertensive therapy six weeks before the study and for the duration of the study
4. Patients must be willing to be admitted for 24 hours and must be medically able to take the study medication
5. Patients must be willing to give informed consent</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>36</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>36</totalTarget>
      <exclusion>1. Other causes for hyponatraemia (e.g. heart failure, pulmonary disease, medication associated with hyponatraemia)
2. Renal dysfunction (estimated clearance less than 50 ml/min according to Cockroft-Gault)
3. Liver cirrhosis
4. Heart failure
5. Medication: antipressiva (Selective Serotonin Reuptake Inhibitors [SSRI&#146;s]), antiepileptica, prednisone, Non-Steroidal Anti-Inflammatory Drugs (NSAID&#146;s), opioids, other diuretics (e.g. lasix, burinex, chloorthalidon, dytac)
6. Allergy for sulphonamide derivates
7. Therapy resistant hypertension (Blood Pressure [BP] greater than 140/90 mmHg while using three or more anti-hypertensive drugs)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Thiazide induced hyponatraemia</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Metabolic disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All subjects included in this controlled experiment will receive a single dose of Hydrochloorthiazide 50 mg. After that they will be monitored for 24 hours.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Hydrochloorthiazide</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16729-0</funderId>
      <contactId>Contact54687_16729</contactId>
      <sponsorId>Sponsor53243</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54687_16729">
    <title>Dr</title>
    <forename>Nanne </forename>
    <surname>Frenkel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Centre
Department of Vascular Medicine</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">w.j.frenkel@amc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53243">
    <organisation>Academic Medical Centre (AMC) (The Netherlands)</organisation>
    <website>http://www.amc.uva.nl#http://www.amc.uva.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Vascular Medicine
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder16729-0">
    <name>Dutch Kidney Foundation (Nierstichting Nederland) (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100002997</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-07-02T00:00:00.000Z">20060588</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Palliative pylorus-preserving pancreatic head resection and postoperative chemotherapy versus primary chemotherapy alone for patients with advanced carcinoma of the pancreatic head</title>
      <scientificTitle/>
      <acronym>Palliative Pylorus-Preserving Pancreatododenectomy (Palliative PPPD)</acronym>
      <studyHypothesis>Survival and quality of life after palliative pylorus-preserving pancreatoduodenectomy and postoperative chemotherapy with Gemzar® is increased when compared to Gemzar® chemotherapy alone.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Survival, measured after 3, 6 and 12 months</primaryOutcome>
      <secondaryOutcome>1. Quality of life, measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) and the EORTC Quality of Life Questionnaire for Pancreatic cancer (QLQ PAN26). This will be measured after 3, 6 and 12 months
2. Surgical complications, measured after 3, 6 and 12 months
3. Toxicity of chemotherapy, measured after 3, 6 and 12 months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from local Institutional Review Board (IRB) (Ethics Board of the Charité, Medical Faculty, Humboldt University, now known as the Ethics Committee State Berlin) on the 30th August 2002.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN20060588</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2002</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open prospective randomised study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="99fce4ac-6c8c-4e8b-84b8-4b2064cad717">
	  <name>Department of Surgery</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>13589</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Medical centres experienced in surgical and medical care of patients with pancreatic head carcinoma.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>15 to 20 patients</totalTarget>
      <exclusion>No exclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pancreatic head carcinoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Pancreatic head carcinoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: standard pylorus-preserving pancreatic head resection with regional lymphadenectomy (this is an internationally well accepted surgical procedure) and after completion of wound healing (up to four weeks postoperative) standard chemotherapy with gemcitabine is started (see below). The chemotherapy is the same as in group 2.
Group 2: standard gemcitabine chemotherapy alone: 1000 mg/m^2 body surface once per week for four weeks with a one-week break, i.e., three weeks treatment and one week free. This is an internationally accepted standard for gemcitabine in advanced pancreatic carcinoma treatment. 

Drugs will be administered on an out patient basis intravenously (i.v.) through a port system. Follow up period is one year.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Gemcitabine (Gemzar®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16540-0</funderId>
      <contactId>Contact54498_16540</contactId>
      <sponsorId>Sponsor53053</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54498_16540">
    <title>Prof</title>
    <forename>Jan</forename>
    <surname>Langrehr</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Surgery
Evangelisches Waldkrankenhaus Spandau
Stadtrandstrasse 555</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>13589</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)30 3702 1101</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.langrehr@waldkrankenhaus.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53053">
    <organisation>Humboldt University Berlin (Germany)</organisation>
    <website>http://www.charite.de/start/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of General-, Viszeral- and Transplantational-Surgery
Charite Universitaetsmedizin Berlin
Campus Virchow-Klinikum
Augustenburger Platz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>13353</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)30 450 552001</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jan.langrehr@charite.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7468.d</gridId>
    <rorId>https://ror.org/01hcx6992</rorId>
  </sponsor>
  <funder id="Funder16540-0">
    <name>Humboldt University Berlin (Germany) - Department of Surgery at Charité Campus Virchow Clinic</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-06-27T00:00:00.000Z">20350801</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Early Endoscopic Ultrasonography (EUS)-guided coeliac plexus neurolysis versus opioids for the treatment of pain in pancreatic carcinoma</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We want to investigate which treatment modality is better, the fentanyl patches or the Endoscopic Ultrasonography (EUS)-guided Coeliac Plexus Neurolysis (CPN). This has never been investigated before. We think that the latter treatment might be less effective than one would expect according to earlier studies.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Quality of Adjusted Life Years (QALYs) will be the primary outcome parameter. This is a composite endpoint linking survival and quality of life, i.e. the number of quality adjusted life years. These are based on biweekly assessments of health status with the EuroQoL questionnaire (EQ-5D). The utility of each observed health score profile on the EQ-5D will be derived from previous research in which the time trade off based elicitation technique during interviews with adults from the general population has been applied.</primaryOutcome>
      <secondaryOutcome>1. Health-related quality of life (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ-C30])
2. Survival
3. Opioid requirement
4. Health status (EQ-5D)
5. Adverse effects
6. Costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN20350801</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, crossover multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="32fbdf85-3dcc-44ee-a0c3-c7e85b72c12e">
	  <name>Academic Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Cytological or histological proven irresectable pancreatic carcinoma
2. Chronic pain unresponsive to non-opioid analgesic drugs and low dose fentanyl (Durogesic®) transdermal patches (Visual Analogue Scale [VAS] score greater than three while using fentanyl transdermal patches maximum 50 ug/h, one patch per three days)
3. Age above 18 years
4. Karnovsky score greater than 30%</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>1. Previous coeliac plexus blockade
2. Use of opioids
3. Refusal to sign informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pancreatic carcinoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Pancreatic carcinoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be randomised according to two treatment algorithms. The first &#147;conventional&#148; type treatment algorithms consists of increasing dosages of transdermal fentanyl patches. In this algorithm, EUS-guided CPN (rescue) will only be performed in case of failure of opioid treatment because of insufficient pain relief (VAS score greater than or equal to 4) or unmanageable side effects. The second treatment algorithm consists of early (repeated) EUS-guided CPN. In case of insufficient pain relief after the second CPN, opioid treatment with transdermal fentanyl patches may be started. Adequate response to therapy (either after EUS-guided CPN or opioids) is defined as a pain score less than or equal to 3 on a scale from 0 - 10 (VAS score) and the absence of unmanageable opioid-related side effects.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Transdermal fentanyl patches</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16652-0</funderId>
      <contactId>Contact54610_16652</contactId>
      <sponsorId>Sponsor53165</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54610_16652">
    <title>Dr</title>
    <forename>A.M.C.J.</forename>
    <surname>Voorburg </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Centre</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 8712</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.m.voorburg@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53165">
    <organisation>Academic Medical Centre (AMC) (The Netherlands)</organisation>
    <website>http://www.amc.uva.nl#http://www.amc.uva.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Gastroenterology
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder16652-0">
    <name>Academic Medical Centre (AMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-06-27T00:00:00.000Z">48083859</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>VErtebroplasty versus Radiotherapy As palliative treatment of vertebral metastases of Multiple Myeloma (M. Kahler)</title>
      <scientificTitle/>
      <acronym>VERAMM</acronym>
      <studyHypothesis>Vertebroplasty improves the quality of life of the individual patient by increased pain reduction and restoration of mobility. Vertebroplasty also reduces costs, as it decreases the number of inpatient days, the number of outpatient visits and follow-up treatments, and the need for home care.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Degree of pain (VAS-pain score, scale: 0 - 10), measured at day 0 (pre-treatment), day 0 (post-treatment), day 7, week 4, week 12, month 6 and year 1
2. Use of pain medication, measured at day 0 (pre-treatment), day 0 (post-treatment), day 7, week 4, week 12, month 6 and year 1</primaryOutcome>
      <secondaryOutcome>1. Initial technical success and complications, measured at day 0 (post-treatment) and week 4 respectively
2. Mobility (Oswestry-daily activity scale), measured at day 0 (pre-treatment), day 7, week 4, week 12, month 6 and year 1
3. Quality of life (questionnaires: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire on Myeloma [EORTC QLQ-MY24], 36-item Short Form health survey [SF-36]), measured at day 0 (pre-treatment), day 7, week 4, week 12, month 6 and year 1
4. Collapse of treated vertebrae (lateral X-WK), measured at day 0 (pre-treatment), week 4, week 12, month 6 and year 1
5. Mortality, measured at year 1
6. Direct medical costs (e.g. procedure costs, hospitalisation days, pain medication, secondary interventions, revalidation or nursing home costs, follow-up), measured at year 1</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The VERAMM trial was approved by the Medical Ethics Committee Erasmus MC (METC) on the 15th March 2007 (ref: MEC-2007-033).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48083859</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CCMO NL14746.078.07; Erasmus MC METC 2007-033</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-06-04T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b58ac38b-070a-4386-b181-26934a462779">
	  <name>Department of Radiology Hs-220</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3015 CE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Persistent pain caused by vertebral metastases from myeloma (including plasmacytoma) with Visual Analogue Scale (VAS) score greater than 4 (scale: 1-10)
2. Informed consent
3. Older than 18 years</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>104</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>104</totalTarget>
      <exclusion>1. Greater than four affected vertebrae
2. Vertebral fracture through back wall with retropulsion that consumes more than 33% of the spinal channel
3. Myelum compression with neurological degeneration: Frankel A/B
4. Epiduritis
5. Incorrigible coagulopathy
6. Karnofsky score less than 30 (moribund)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-06-04T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Spinal metastases, vertebroplasty, multiple myeloma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Myeloma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Arm I (control): radiotherapy (20 Gy) of affected vertebrae
Arm II: vertebroplasty of affected vertebrae</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16662-0</funderId>
      <contactId>Contact54620_16662</contactId>
      <sponsorId>Sponsor53175</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54620_16662">
    <title>Dr</title>
    <forename>Edwin</forename>
    <surname>van der Linden</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Radiology Hs-220
Erasmus MC - University Medical Center Rotterdam
's Gravendijkwal 230</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015 CE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 463 2886</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">e.vanderlinden@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53175">
    <organisation>Erasmus Medical Centre (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/content/englishindex.htm </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Radiology
&#146;s-Gravendijkwal 230</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015 CE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder16662-0">
    <name>Erasmus Medical Centre (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-06-01T00:00:00.000Z">88423868</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of the diagnostic quality of manganese chloride tetrahydrate (CMC-001©) in liver magnetic resonance imaging in patients with liver metastases in comparison to gadolinium benzyloxypropionictetraacetate (BOPTA): a randomised cross-over phase III trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The primary objective is to assess the feasibility of manganese chloride tetrahydrate (CMC-001©) as a contrast medium in liver Magnetic Resonance Imaging (MRI) scanning in patients with liver metastases in comparison with gadolinium Benzyloxypropionictetraacetate (BOPTA) (MultiHance©) MRI.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary objective is to assess the feasibility of CMC-001© as a contrast medium in liver MRI scanning in patients with liver metastases in comparison with gadolinium BOPTA (MultiHance©) MRI.</primaryOutcome>
      <secondaryOutcome>The secondary objectives are to further evaluate the safety and tolerability of CMC-001© in patients:
1. ECG, vital signs, blood for laboratory analyses and urine is drawn at screening and after MRI
2. AEs are asked for during the whole trial as well as at the phone calls 24 and 48 hours after contrast</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Regional Ethics Board in Stockholm on the 30th March 2005 (ref: 2005/305-31/1).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88423868</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CMC-P 004</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>The study will be of a single centre, randomised and open cross-over design.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7c90e809-f1de-4c19-8067-a31ad84b95f3">
	  <name>Lars Vedin AB</name>
	  <address/>
	  <city>Stockholm</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-114 75</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Signed written informed consent after oral and written information about the study has been given by the investigator
2. Patients with one to six liver metastases from colorectal cancer verified with other methods
3. Men or women over 18 years old
4. The patient is conscious and co-operative</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Clinically relevant medical history or abnormal physical findings which could interfere with the safety or objectives of the study as judged by the investigator
2. Clinically relevant Electrocardiogram (ECG), haematology, clinical chemistry, serology and urine chemistry abnormalities. This is based on the judgement of the treatment physicians
3. Allergy to any of the study product compounds
4. Drug or alcohol abuse by asking the patient at screening
5. Patients who are deemed to be unsuitable for any other reason in the opinion of the investigator
6. Participation in another clinical study concerning another contrast preparation within the last three months or seven days after this study
7. Previous inclusion in this study
8. Pregnancy after randomisation at the day of MRI before contrast
9. The patient is scheduled to receive intravascular iodinated contrast medium within 24 hours after this study
10. The patient is being investigated on an emergency basis
11. The patient has newly discovered unstable diabetes or undergoes haemodialysis or peritoneal dialysis
12. The patient has a known or suspected clinically severe concurrent illness that may influence the renal function or has undergone kidney, liver or bone marrow transplantation
13. The patient has a concurrent severe illness in the Gastrointestinal (GI) tract like paralysis or malabsorption or clinically manifest icterus
14. Known Human Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS)
15. Known hepatitis
16. Known cirrhosis
17. The patient has uncompensated cardiac failure (cardiac failure New York Heart Association [NYHA] grade IV)
18. A patient may be excluded during the trial based on the clinical judgement of the clinician or the radiologist</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Colorectal cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Colorectal cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Each patient will have two MRI sessions, one with each product. This means that each patient will be his/her own control. The evaluation of MR images will be performed by two independent observers. The final evaluation will however be made in consensus.

When a suitable patient arrives at the clinic he/she will be informed about the trial both orally and in writing and is offered a to take part in the trial with two different MRI sessions, one with Gadolinium BOPTA and a second MRI with CMC-001© as contrast. After that he/she will sign the informed consent form.

The patients will visit the clinic three times:
1. For screening and eligibility test
2. For MR imaging of the first contrast
3. For MR imaging of the second contrast

After this, they will be called by phone 24 and 48 hours and asked about Adverse Events (AEs).

The order of administration of the two contrast agents is randomised. MRI after CMC-001© is performed three hours after contrast and MRI after MultiHance©, the comparator, is performed two hours after contrast.

Electrocardiogram (ECG), vital signs, blood for laboratory analyses and urine is drawn at screening and after MRI.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Manganese chloride tetrahydrate (CMC-001©) and gadolinium BOPTA (MultiHance©).</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16453-0</funderId>
      <contactId>Contact54411_16453</contactId>
      <sponsorId>Sponsor52966</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54411_16453">
    <title>Dr</title>
    <forename>Lars</forename>
    <surname>Vedin</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Lars Vedin AB
Floragatan 13</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE-114 75</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)8 5064 5751</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lv@cmc-contrast.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52966">
    <organisation>Copenhagen Malmö Contrast AB (CMC Contrast AB) (Sweden)</organisation>
    <website>http://www.cmc-contrast.se</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Lars Vedin AB
Floragatan 13</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE-11475</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)8 5064 5751</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lv@cmc-contrast.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476186.a</gridId>
    <rorId>https://ror.org/015x46y72</rorId>
  </sponsor>
  <funder id="Funder16453-0">
    <name>Copenhagen Malmö Contrast AB (CMC Contrast AB) (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-22T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-05-30T00:00:00.000Z">08206786</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>My story as informal care-giver: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The new preventive intervention will lead to a significant decrease in psychological problems and perceived stress, an improvement in the quality of life of the informal care-givers as compared with a waiting list control group.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Depressive symptoms
2. Perceived stress
3. Quality of life

Outcomes will be measured at:
T0: one week before start of intervention
T1: after three months (directly after intervention)
T2: after six month (three months after intervention)</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local ethics committee (METIGG kamer Noord) on the 23rd January 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08206786</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, multicentre, placebo controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b5190312-eef5-4cc5-9fc7-32e717c8ff57">
	  <name>Trimbos-Instituut</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3500 AS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adults above the age of eighteen who provide informal care for a parent and feel they are under stress as a result.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. The parent of the informal care-provider is no longer able to take part in the life review, e.g. because of having severe dementia
2. The health situation of the parent or informal caregiver requires acute assistance</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Informal care-givers, prevention, depression, burnout, stress</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Psychological problems</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The Informal care-givers in Balance course consists of eight two-hour sessions and is designed for adult children who provide structural care for a parent in need of care and are under high perceived stress as a result. At the first three sessions, the participants learn to interview their own parent according to the life review method. Starting at the fourth session of the course, the perspective shifts to the informal care-givers&#146; own life. The informal care-givers focus on the meaning and effects, especially undesirable ones, of the informal care on their lives and on the balance they would like to establish in their lives in accordance with the life review method. The possibilities are addressed for introducing a better balance.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16554-0</funderId>
      <contactId>Contact54512_16554</contactId>
      <sponsorId>Sponsor53067</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54512_16554">
    <title>Dr</title>
    <forename>Ernst</forename>
    <surname>Bohlmeijer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Trimbos-Instituut
P.O. Box 725</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3500 AS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2971100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ebohlmeijer@trimbos.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53067">
    <organisation>Trimbos-Institute - Netherlands Institute of Mental Health and Addiction (The Netherlands)</organisation>
    <website>http://www.trimbos.nl/default37.html</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>P.O. Box 725</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3500 AS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2971100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@trimbos.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416017.5</gridId>
    <rorId>https://ror.org/02amggm23</rorId>
  </sponsor>
  <funder id="Funder16554-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-04T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-05-30T00:00:00.000Z">81465865</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of electrical neurostimulation on collateral perfusion during acute coronary occlusion</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Neurostimulation can improve collateral perfusion measured as a coronary wedge pressure (Pw)/aortic pressure (Pa) ratio, during acute coronary occlusion.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary endpoint was collateral perfusion, the Pw/Pa ratio. This was measured during a one-minute balloon inflation during PCI. The Pw/Pa ratio was measured in each patient during two ischaemic episodes. To compare the Pw/Pa ratio with and without electrical neurostimulation, the Pw/Pa ratio is measured intracoronary, using a pressure wire.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN81465865</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="37603721-b3d4-43a5-8a65-17a38c12c6b8">
	  <name>Thorax Centre</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9713 GZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with stable angina
2. Evidence of myocardial ischaemia
3. Planned for elective Percutaneous Coronary Intervention (PCI)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Recent myocardial infarction
2. Prior coronary artery bypass grafting
3. Undtable angina
4. Conduction disturbances
5. Pacemaker
6. Internal cardio-defibrillator</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Angina pectoris, electrical neurostimulation, coronary collaterals, angioplasty</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Ischaemic heart diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention was electrical neurostimulation, during five minutes before and during the one-minute ischaemic episode. Within a patient we measured during the one-minute ischaemic episode the collateral perfusion, with and without electrical neurostimulation. The ischaemic episode was established by balloon inflation during elective PCI.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17597524 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4909579f-7266-424f-9850-f719318cfec2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17597524"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16565-0</funderId>
      <contactId>Contact54523_16565</contactId>
      <sponsorId>Sponsor53078</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54523_16565">
    <title>Dr</title>
    <forename>J.</forename>
    <surname>de Vries</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Thorax Centre 
University Medical Centre Groningen
Hanzeplein 1</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9713 GZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.de.vries@thorax.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53078">
    <organisation>University Medical Centre Groningen (UMCG) (The Netherlands)</organisation>
    <website>http://www.umcg.nl/azg/nl/english/azg/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Thorax Centre
Department of Cardiology</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4494.d</gridId>
    <rorId>https://ror.org/03cv38k47</rorId>
  </sponsor>
  <funder id="Funder16565-0">
    <name>University Medical Centre Groningen (UMCG) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-05-30T00:00:00.000Z">77521636</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Transjugular Intrahepatic Porto-systemic Shunt (TIPS) with Gore-tex® covered stent-graft versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Transjugular Intrahepatic Porto-systemic Shunt (TIPS) using covered stents will be equally or more effective, cost-effective and safe as/safer than endoscopic treatment in the secondary prevention of gastro-oesophageal variceal bleeding.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Recurrence of variceal bleeding</primaryOutcome>
      <secondaryOutcome>1. Occurrence of treatment failure (either switch to other therapy -&#147;cross-over&#148;- or death)
2. Incidence of encephalopathy, defined as occurrence of grade II, III or IV encephalopathy
3. Liver function (according to Child-Pugh class)
4. Mortality
5. Quality of life
6. Costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN77521636</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, multicentre, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4a48d23c-9302-4d1b-be7d-d576d91977d9">
	  <name>Erasmus Medical Centre</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3015 CE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients presenting with a first or second episode of oesophageal or gastric variceal bleeding, as documented by endoscopy and meeting accepted diagnostic criteria
2. Initial stabilisation (absence of evidence of continued bleeding)
3. Informed consent
4. Aged more than 18 and less than 76 years</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>124</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>124</totalTarget>
      <exclusion>1. History of serious or refractory encephalopathy, unrelated to gastrointestinal bleeding
2. History of significant heart failure (New York Heart Association [NYHA] class III &amp; IV)
3. Portal hypertension due to other causes than liver disease (e.g. portal vein or splenic vein thrombosis)
4. Previous TIPS placement
5. Advanced hepatocellular carcinoma
6. Severely compromised liver function (Child-Pugh score greater than 13)
7. Sepsis and/or multiorgan failure</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Gastro-oesophageal variceal bleeding</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Gastro-oesophageal variceal bleeding</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Transjugular Intrahepatic Porto-systemic Shunt (TIPS)(intervention group): 
A shunt is made between the portal vein and the systemic veins, which decreases blood pressure in the portal vein to normal. This decreases the risk of re-bleeding. The procedure takes approximately two hours.

Endoscopic treatment (control group): 
The bleeding varices are ligated or sclerosed. The pressure in the portal vein remains too high. This procedure has to be repeated several times until the varices are completely obliterated.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16555-0</funderId>
      <contactId>Contact54513_16555</contactId>
      <sponsorId>Sponsor53068</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54513_16555">
    <title>Dr</title>
    <forename>F.H.D. </forename>
    <surname>Sebus </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Centre
Department of Radiology
&#146;s-Gravendijkwal 230</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015 CE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4632277</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">f.sebus@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53068">
    <organisation>Erasmus Medical Centre (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/content/englishindex.htm#http://www.erasmusmc.nl/content/englishindex.htm</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Radiology
Dr. Molewaterplein 50</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015 GE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder16555-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-05-30T00:00:00.000Z">53810679</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Bortezomib (Velcade®) therapy combined with Donor Lymphocyte Infusion in patients with relapsed multiple myeloma following allogeneic stem cell transplantation</title>
      <scientificTitle/>
      <acronym>DLI-Velcade® study</acronym>
      <studyHypothesis>The combination of DLI with bortezomib given before and after the DLI improves the Graft versus Myeloma effect without effect on the Graft versus host disease</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome is response rate. The included patients will be analysed with analysis of the m-protein at entry, after bortezomib cycle 2, 4, 6, 8 and before administration of DLI or before cycle 4,6,8 if no more DLI is given. After each DLI before administration of bortezomib
cycle 3, 5, 7 and in follow up every 2 months. Bone marrow examination
will be done on indication, for example confirmation of CR.</primaryOutcome>
      <secondaryOutcome>Secondary outcomes are evaluated at the same time points as the primary outcome. Blood samples for experimental immunology are taken before:
1. First administration of bortezomib in cycle one
2. First DLI
3. First administration of bortezomib in cycle three
4. Second DLI
5. First administration of bortezomib in cycle five
6. Third DLI
7. First administration of bortezomib in cycle seven 
8. Stopped treatment and/or occurring GvHD</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN53810679</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>interventional, non-randomised, non-controlled, multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5812c995-666e-4a06-b303-b695fccf0a82">
	  <name>University Medical Centre Utrecht</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male or female and at least 18 years-of-age; 
2. MM patients with any type of relapse or progressive disease following (non) myeloablative allo-SCT for which DLI is considered a treatment option (including patients previously participating in Hovon 54 or Hovon 65 studies);
3. Informed consent; 
4. Haematological parameters; Hb &gt; 4.0 mmol/L, leucocytes &gt; 1.0¡Á109/L , thrombocytes &gt; 25 ¡Á109/L, with or without transfusion</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Use of the immunosuppressive drugs cyclosporin, MMF, or corticosteroids;
2. Existing GvHD &gt; grade A;
3. Any non-hematological toxicity CTC grade ¡Ý 3;
4. Neuropathy and/or neuropathic pain CTC grade ¡Ý 2; 
5. Pregnancy;
6. History of allergic reaction to compounds containing boron or mannitol;
7. Uncontrolled or severe cardiovascular disease, including myocardial infarctiin within 6 months, NYHA class III of IV heart failure (appendix E), uncontrolled angina, clinically significant pericardial disease or cardiac amyloidosis;
8. Previous use of bortezomib is not an exclusion criterion, however patients refractory to bortezomib during previous treatments are excluded from this study.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Multiple myeloma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Multiple myeloma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention consists of a sequential approach over bortezomib cycli (2) with DLI. The bortezemib cycli are given before and 2 weeks after the DLI infusion. If the patient reaches a CR the treatment is
stopped. If a PR is reached the patient continues with bortezomib, maximum 8 cycli. In case of a minimal reaction the patient can receive a second and third DLI, combined with bortezemib. During the study blood and bone marrow sampling will determine the response rate. This is no
control group, comparison with historical data will be performed.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Bortezomib (Velcade®), Donor Lymphocyte Infusion</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16558-0</funderId>
      <contactId>Contact54516_16558</contactId>
      <sponsorId>Sponsor53071</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54516_16558">
    <title>Dr</title>
    <forename>M.C.</forename>
    <surname>Minnema</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Centre Utrecht
Department of Haematology, B02.226
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2507230</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.c.minnema@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53071">
    <organisation>University Medical Centre Utrecht (UMCU) (The Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/ </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Haematology
P.O. Box 85500</address>
      <city>Alkmaar</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5477.1</gridId>
    <rorId>https://ror.org/04pp8hn57</rorId>
  </sponsor>
  <funder id="Funder16558-0">
    <name>University Medical Centre Utrecht (UMCU) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-10T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-05-25T00:00:00.000Z">09602471</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Role of rapid diagnostic testing in the context of home management of childhood fever with Coartem®: an open randomised controlled trial in a rural and seasonal malaria transmission area of Burkina Faso</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Community level treatment of malaria and/or acute respiratory infections guided by malaria Rapid Diagnostic Testing (RDT) and respiratory rate counting improves clinical recovery rate of children with febrile disease.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Clinical recovery rate at 72 hours after treatment (defined as apyrexia and axillary temperature less than 37.5°C).</primaryOutcome>
      <secondaryOutcome>1. Evaluate influence of the seasonal variation of malaria transmission on the impact, measured at eight days post onset of the treatment
2. Assess the cost-effectiveness of RDT in the context of the HMM strategy with Coartem®, measured at the end of the study  
3. Describe the operational feasibility and acceptability of RDT in the context of the HMM strategy with Coartem®, measured at the end of the study</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Comité d&#146;ethique pour la Recherche en Santé du Burkina (CERS-B) on the 15th February 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN09602471</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A60486</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open randomised, controlled, clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Burkina Faso</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1d5ee311-cc87-4d3b-9663-6c320f611fba">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Written informed consent from parent/guardian
2. Aged 6 to 59 months
3. Weight equals 5 kg
4. Willing to comply with the study procedures
5. History of fever within the last 24 hours or documented fever (axillary temperature equals 37.5°C)</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Months" value="59.0"/>
      <gender>Both</gender>
      <targetEnrolment>1200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1200</totalTarget>
      <exclusion>1. Severe malaria 
2. Danger signs (unable to drink or eat, incoercible vomiting, convulsions, prostration)
3. History of allergic reaction to the study drugs
4. History of treatment with artemisinin derivatives in the past seven days
5. Previous participation in this study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria, acute respiratory infection</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised between:
1. Treatment with Coartem® and/or cotrimoxazole based on rapid diagnosis test results and respiratory rate count
2. Presumptive treatment with Coartem®, on day three after the onset of the treatment

Principal Investigator:
Tiono Alfred
Centre National de Recherche et de Formation sur le Paludisme
01 BP 2208 
Ouagadougou 01
Burkina Faso
Tel: +226 70 28 57 26
Email: t.alfred@fasonet.bf</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Coartem®, cotrimoxazole</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16430-0</funderId>
      <funderId>Funder16430-1</funderId>
      <contactId>Contact54388_16430</contactId>
      <sponsorId>Sponsor52942</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54388_16430">
    <title>Dr</title>
    <forename>Franco</forename>
    <surname>Pagnoni</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization 
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52942">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int/tdr/topics/mim/default.htm</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder16430-0">
    <name>Multilateral Initiative on Malaria (MIM)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16430-1">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-05-01T00:00:00.000Z">59798735</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease</title>
      <scientificTitle/>
      <acronym>COXPKPD (COX-2 inhibition monitored by PK11195 in Parkinson's Disease)</acronym>
      <studyHypothesis>Celecoxib inhibits cerebral activated microglia in Parkinson's disease</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>One baseline and one follow-up Positron Emission Tomography (PET) scan (PK11195) and one Magnetic Resonance Imaging (MRI) scan will be performed to assess the reduction of specific cerebral radiotracer uptake (volume of distribution according to Logan graphical method) after celecoxib.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Medical Ethics Review Committee of the University Medical Center Groningen. Approval pending as of 28 February 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN59798735</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>16901</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open, non-randomised, non-placebo controlled, pilot phase trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cee260f2-c435-4e29-84b5-ee4a168c5a35">
	  <name>University Medical Center Groningen (UMCG)</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9700 RB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Early Parkinson's disease patients
2. Hoehn and Yahr Parkinson's Disease Rating Scale (HY) 1 - 2</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Gastrointestinal diseases</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Parkinson's disease</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Parkinson's disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Interventions amended as of 05/09/2007: 
All participants will receive celecoxib oral medication of 100 mg daily for 1 month. 

Interventions provided at time of registration: 
Celecoxib oral medication of 100 mg daily for 1 month.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Celecoxib</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16254-0</funderId>
      <funderId>Funder16254-1</funderId>
      <contactId>Contact54209_16254</contactId>
      <sponsorId>Sponsor52763</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54209_16254">
    <title>Prof</title>
    <forename>Klaus</forename>
    <surname>Leenders</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Groningen (UMCG) 
Hanzeplein 1</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52763">
    <organisation>University Medical Center Groningen (UMCG) (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Hanzeplein 1</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">k.l.leenders@neuro.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4494.d</gridId>
    <rorId>https://ror.org/03cv38k47</rorId>
  </sponsor>
  <funder id="Funder16254-0">
    <name>University Medical Center Groningen (UMCG) Neurology department deparmental funding (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16254-1">
    <name>Stichting International Parkinson Fonds (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="16">
    <isrctn dateAssigned="2007-04-30T00:00:00.000Z">41474531</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised, controlled, double-blind clinical study on the effect of a functional milk-product on metabolism of men with diagnosed metabolic syndrome</title>
      <scientificTitle/>
      <acronym>EFOMS (Effect of Functional milk product On the Metabolic Syndrome)</acronym>
      <studyHypothesis>The goal of the investigation is the question, to what extent the risk of the metabolic syndrome may be reduced by substances naturally occurring in milk. The pathophysiology of the metabolic syndrome is characterized by an insulin resistance, a dyslipidaemia, an essential hypertension and adiposity of the central type and frequently leads to early manifestation of type 2 diabetes mellitus and atherosclerosis. Such metabolic disturbances increase in the industrialized countries and in the developing countries, too, and represent an important economical and public-health cost factor. It is necessary to identify the relevant factors of human nutrition and to develop potential avoidance strategies, e.g. by development of functional food. The cow-milk derived substances, which will be used in this study have had influenced individual components of the metabolic syndrome and lowered  the risk of components of the metabolic syndrome in an animal trial.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Change of blood fructosamine concentration during the intervention period</primaryOutcome>
      <secondaryOutcome>1. Insulin sensitivity
2. Endothelial function
3. Blood pressure
4. Waist-to-hip ratio
5. Postprandial concentration of several hormones and blood parameters linked to fat and carbohydrate metabolism</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethic committee of the medical faculty of the Christian-Albrechts-University of Kiel, (Germany), approved on 09.01.2007, Ref: A171/06</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41474531</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>The study is a randomised double-blind placebo-controlled intervention study over 8 weeks</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-02-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-05-23T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c5998fd7-083f-4264-8051-4ba5dfc054b3">
	  <name>Hermann-Weigmann-Str. 1</name>
	  <address/>
	  <city>Kiel</city>
	  <state/>
	  <country>Germany</country>
	  <zip>24103</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Men, 45-70 years old, with a metabolic syndrome as defined by the International Diabetes Federation, 2006 (A new IDF worldwide definition of the metabolic syndrome: the rationale and the results - Diabetes Voice, Vol. 50 Issue 3, 2005)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60 volunteers (30 for each the verum and control group)</totalTarget>
      <exclusion>1. Participation in a clinical study with a medicament or a medicinal product within the last 30 days or simultaneous participation in another clinical examination
2. Intake of nitrate and/or calcium antagonists and/or alpha-blockers, which affect the blood pressure
3. Known metabolic or gastro-intestinal diseases, which affects the absorption, metabolism or excretion of food or food component
4. Condition after operation of the gastro-intestinal tract, which affect gastro-intestinal motility
5. Hemoglobin &lt; 12 g/dL
6. Malfunction of blood coagulation or drugs, leading to malfunction of blood coagulating diabetes
7. Operation within the last 3 months, which still affects the current state of health
8. Illness of thyroid gland, which has metabolic and/or cardiovascular effect
9. Known hepatitis B, hepatitis C, HIV infection or chronic liver damage
10. Kidney insufficiency
11. Hypercalcaemia
12. Drug or alcohol abuse
13. Intake of drugs affecting the absorption, metabolism or excretion of food components or the gastro-intestinal
14. Intake of hormone preparations
15. Vegetarianism, anorexia, bulimia
16. Known milk protein allergy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-02-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-05-23T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Metabolic syndrome</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Metabolic syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The volunteers of the verum group will take one portion of the functional milk-product (product code 966125, a non-registered product) once a day after lunch with a dessert for 56 days. The product of the control group is based on meat protein and is isoenergetic and isonitrogenous.

Primary and secondary outcome measures will be analysed before and at the end of the intervention.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>milk product</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16261-0</funderId>
      <contactId>Contact54216_16261</contactId>
      <sponsorId>Sponsor52770</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54216_16261">
    <title>Prof</title>
    <forename>Juergen</forename>
    <surname>Schrezenmeir</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hermann-Weigmann-Str. 1</address>
      <city>Kiel</city>
      <country>Germany</country>
      <zip>24103</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)431 609  2220</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">juergen.schrezenmeir@bfel.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52770">
    <organisation>Humana GmbH (Germany)</organisation>
    <website>http://www.humana.de</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Bielefelder Strasse 66</address>
      <city>Herford</city>
      <country>Germany</country>
      <zip>32051</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder16261-0">
    <name>Humana GmbH (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-02-26T00:00:00.000Z">31186536</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The efficacy of physiotherapy upon shoulder function following axillary dissection in breast cancer: a pilot study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Physiotherapy is effective in patients with mastectomy and Axillary Lymph Node Dissection (ALND), for shoulder/arm mobility and pain primarily and quality of life secondarily.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Shoulder mobility (flexion [0 - 180°], abduction [0 - 180°]), measured by use of a digital inclinometer under standardised conditions
2. Pain in the shoulder/arm, measured using the VAS score (zero to ten, zero = no pain, ten = unbearable pain)</primaryOutcome>
      <secondaryOutcome>1. Disabilities in daily life, measured by the DASH (Disabilities of the Arm, Shoulder and Hand) questionnaire (zero to 100, zero = no functional problems, 100 = maximal problems)
2. Oedema (ml), measured in both arms by means of water displacement, grip strength (Kg) of both hands, measured using the hand-held dynamometer and quality of life, as measured by the SIP (Sickness Impact Profile-short version) questionnaire (zero to 68, zero = good health status, 68 = sever physically disabled)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Added as of 05/09/2007: The regional medical ethics board approved the study.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN31186536</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, single blinded  multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-11-04T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4b3f34e6-648f-4059-8e70-d4460a5805e4">
	  <name>University Medical Centre Nijmegen (UMCN)</name>
	  <address/>
	  <city>Nijmegen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6500 HB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 18 years of age and older
2. Breast cancer with an ALND
3. A Visual Analogue Scale (VAS)-pain score (zero to ten) of one minimally
4. Moderate shoulder disabilities in daily life (minimal three points on a five points disability score list)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Patients with a previous contra-lateral mastectomy
2. Patients with insufficient knowledge of the Dutch language to fill in the questionnaires</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-11-04T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Breast cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Breast cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients assigned to the treatment group started physiotherapy two weeks following surgery in a private practice of their own choice. The research assistant contacted the physiotherapist who had to comply with the treatment regime and supplied him or her with information regarding the project and treatment guidelines. This information consisted of:
1. A guideline containing advice and exercises for arm/shoulder, posture correction, coordination exercises, exercises for muscular strength and improvement of the general physical condition
2. Exercises to prevent lymph oedema
3. Instruction for scar massage if necessary
4. A registration form to report the content of the treatment sessions and a three-point scale to indicate whether the amount of treatment sessions was sufficient

The total number of treatments was nine (nine being usually covered by the healthcare insurance), once or twice weekly for the first three weeks, thereafter once a fortnight or less. Patients were asked to perform home exercises on a daily basis for approximately ten minutes a day.

Patients assigned to the control group received a leaflet flyer with advice and exercises for the arm/shoulder for the first weeks following surgery and had no further personal contact with a physiotherapist.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17760981 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e870b2e2-73b4-4fee-bcb6-40a79ef1a591" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-08-30T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17760981"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16219-0</funderId>
      <contactId>Contact54174_16219</contactId>
      <sponsorId>Sponsor52728</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54174_16219">
    <title>Dr</title>
    <forename>C H G</forename>
    <surname>Beurskens</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Centre Nijmegen (UMCN)
Afd. Fysiotherapie 645 
P.O. Box 9101</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 HB </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+ 31 (0)24 361 3812</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.beurskens@fysiocss.umcn.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52728">
    <organisation>University Medical Centre Nijmegen (UMCN) (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Physiotherapy</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 HB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.10417.33</gridId>
    <rorId>https://ror.org/05wg1m734</rorId>
  </sponsor>
  <funder id="Funder16219-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-01-16T00:00:00.000Z">41920953</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Naturopathic Care for Low Back Pain: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym>NCLBP</acronym>
      <studyHypothesis>Will naturopathic care including acupuncture, diet counselling, and deep breathing be equally or more effective than a physiotherapy equivalent?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Oswestry, Roland and Morris Disability Questionnaire</primaryOutcome>
      <secondaryOutcome>1. Short Form health survey (SF-36)
2. Spinal Forward Flexion
3. Medication and adjunctive treatment usage</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Internal Review Board of The Canandian College of Naturopathic Medicine. Obtained in January 2005.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41920953</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>LBPT01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="eeca79f8-7369-4c63-ae9a-a8aca0b1e5fa">
	  <name>Department of Clinical Epidemiology</name>
	  <address/>
	  <city>Toronto</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M2K 1E2</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Mentally competent volunteers 18 to 65, male or female
2. Low back pain of more than six weeks duration
3. Normal on physical examination at the pre-study physical</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>75</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>75</totalTarget>
      <exclusion>1. History of spinal operations
2. Current history of herniated disk
3. Current history of systemic rheumatological disease, ankylosing spondylitis, tumors, infection
4. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic low back pain</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Low back pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Active: acupuncture, dietary counseling, relaxation exercises
Control: education on physiotherapy exercises</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://doi.org/10.1371/journal.pone.0000919 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="708e9871-fb4f-41a8-aad3-f78aacb39c4c" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-19T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://doi.org/10.1371/journal.pone.0000919"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15936-0</funderId>
      <funderId>Funder15936-1</funderId>
      <funderId>Funder15936-2</funderId>
      <contactId>Contact53882_15936</contactId>
      <sponsorId>Sponsor52431</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53882_15936">
    <title>Dr</title>
    <forename>Edward</forename>
    <surname>Mills</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Clinical Epidemiology
The Canadian College of Naturopathic Medicine
1255 Sheppard Ave. E.</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M2K 1E2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52431">
    <organisation>The Canadian College of Naturopathic Medicine (Canada)</organisation>
    <website>http://www.ccnm.edu/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>1255 Sheppard Ave E.</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M2K 1E2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418588.8</gridId>
    <rorId>https://ror.org/03pjwtr87</rorId>
  </sponsor>
  <funder id="Funder15936-0">
    <name>Canada Post Corporation</name>
    <fundRef/>
  </funder>
  <funder id="Funder15936-1">
    <name>Canadian Union of Postal Workers</name>
    <fundRef/>
  </funder>
  <funder id="Funder15936-2">
    <name>The Canadian College of Naturopathic Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-01-03T00:00:00.000Z">23191708</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Assessment of Geriatric Team as a new medical technology</title>
      <scientificTitle/>
      <acronym>Geriatric Team</acronym>
      <studyHypothesis>Do home visits have advantages when compared to outpatient or in-hospital assessment of patients referred to a geriatric department?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Hospital admissions
2. Patient satisfaction</primaryOutcome>
      <secondaryOutcome>Cost-effectiveness</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Study is approved by the Local Ethical Committee (the Ethical Committee of Fyen and Vejle Counties), on the 3rd April 2000 (ref. no.: 20000057).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23191708</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>262-67-1999</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Denmark</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c1f6ed6e-6b32-4667-a720-d270c72bb7d3">
	  <name>Department of Geriatric Medicine, G</name>
	  <address/>
	  <city>Odense C</city>
	  <state/>
	  <country>Denmark</country>
	  <zip>DK-5250</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients referred to the geriatric department and able to give informed consent</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>600</totalTarget>
      <exclusion>Patients unable to give informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Multimorbidity, functional decline</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Multimorbidity</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Home visit performed by a multidisciplinary team:
1: Acute patients are randomised to next day home visits by the geriatric team or to next admission to the geriatric wards
2: Elective patients are randomised to home visits by the geriatric team or to the outpatient clinic</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15860-0</funderId>
      <contactId>Contact53800_15860</contactId>
      <sponsorId>Sponsor52354</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53800_15860">
    <title>Dr</title>
    <forename>Lars Erik</forename>
    <surname>Matzen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Geriatric Medicine, G
Odense University Hospital</address>
      <city>Odense C</city>
      <country>Denmark</country>
      <zip>DK-5250</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lars.matzen@ouh.fyns-amt.dk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52354">
    <organisation>National Board of Health (Denmark)</organisation>
    <website>http://www.sst.dk/Planlaegning_og_behandling/Medicinsk_teknologivurdering.aspx?lang=en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Centre for Education and Health Technology Assessment
Sundhedsstyrelsen 
Islands Brygge 67</address>
      <city>Copenhagen</city>
      <country>Denmark</country>
      <zip>DK-2300</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cemtv@sst.dk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416535.0</gridId>
    <rorId>https://ror.org/04r17y386</rorId>
  </sponsor>
  <funder id="Funder15860-0">
    <name>National Board of Health (Denmark) - Center for Evaluation of Medical Technology (ref: 262-67-1999)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-12-29T00:00:00.000Z">32222677</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of smoking cessation advice and nicotene replacement therapy delivered by dental hygienists in a dental setting</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To determine the feasibility and efficacy of a smoking cessation intervention, delivered by dental hygienists in a cohort of periodontal patients attending an outpatient hospital department.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Self -reported quit rates validated by Carbon Monoxide (CO) and salivary cotinine</primaryOutcome>
      <secondaryOutcome>1. Changes in smoking behaviour including reduction in number of cigarettes (and change in cotinine levels), and increase in numbers of quit attempts</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Glasgow Dental Hospital and School Area Dental Ethics Committee in January 2001.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32222677</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Scotland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f2712255-65bc-462e-99b4-b293624b9715">
	  <name>Level 8</name>
	  <address/>
	  <city>Glasgow</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>G2 3JZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult (more than 16 years) smokers of at least ten cigarettes
2. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>1. Adult (more than 16 years) smokers of less than ten cigarettes
2. Currently receiving smoking cessation therapy elsewhere</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Smoking addiction</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Smoking addiction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention arm: smoking cessation advice based on the 5As (Ask, Advise, Assess, Assist, Arrange) and Nicotene Replacement Therapy (NRT)
Control arm: usual care (very brief advice)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17475005 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2263e2ce-0483-48cc-81f9-416b6ec5e93d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-05-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17475005"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15894-0</funderId>
      <funderId>Funder15894-1</funderId>
      <funderId>Funder15894-2</funderId>
      <contactId>Contact53836_15894</contactId>
      <sponsorId>Sponsor52389</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53836_15894">
    <title>Dr</title>
    <forename>Viv </forename>
    <surname>Binnie</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Level 8
Glasgow Dental School
378 Sauchiehall Street</address>
      <city>Glasgow</city>
      <country>United Kingdom</country>
      <zip>G2 3JZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)141 211 9802</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">v.binnie@dental.gla.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52389">
    <organisation>University of Glasgow (UK)</organisation>
    <website>http://www.gla.ac.uk/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>University Avenue</address>
      <city>Glasgow</city>
      <state xmlns:isrctn="http://www.67bricks.com/isrctn">Scotland</state>
      <country>United Kingdom</country>
      <zip>G12 8QQ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">v.binnie@dental.gla.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.8756.c</gridId>
    <rorId>https://ror.org/00vtgdb53</rorId>
  </sponsor>
  <funder id="Funder15894-0">
    <name>The University of Glasgow (UK) - covering the cost of cotinine analysis</name>
    <fundRef/>
  </funder>
  <funder id="Funder15894-1">
    <name>Smoking Concerns (UK) - local NHS Stop smoking body, donating NRT</name>
    <fundRef/>
  </funder>
  <funder id="Funder15894-2">
    <name>All other costs were covered internally by NHS departments taking part in the trial</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-02T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-11-20T00:00:00.000Z">87589121</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Improving patient reassurance through an early intervention prior to exercise stress testing</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Providing information about normal findings prior to a exercise stress test will improve reassurance and reduce anxiety about symptoms following the investigation in patients with a negative test result.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Patients&#146; reported reassurance.
2. Levels of worry about their health and belief that something is seriously wrong with their heart, measured immediately following the test and at one month following testing.</primaryOutcome>
      <secondaryOutcome>Complaints of chest pain and whether continuing to take cardiac medication.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by New Zealand Ministry of Health Ethics Committee (ref AKY/04/05/121) on 21 May, 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87589121</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>New Zealand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="45f157c1-a7e3-4ba6-9321-948f83971b77">
	  <name>Department of Psychological Medicine</name>
	  <address/>
	  <city>Auckland</city>
	  <state/>
	  <country>New Zealand</country>
	  <zip>1001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients referred for exercise stress test with negative findings</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>90</totalTarget>
      <exclusion>1. Aged less than 18 years
2. Previously diagnosed cardiac pathology
3. No symptoms of chest pain
4. Undertaking the stress exercise test as part of a pre-surgical medical examination
5. Positive exercise stress test</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Symptoms of chest pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Chest pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group one: standard information. 
Group two: a pamphlet explaining the function and meaning of negative results from the test.
Group three: the pamphlet and a brief discussion about what normal results of the test mean.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17259186 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="6dcdd103-4dee-4480-a562-3ca5fdf0bb2f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-02-17T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17259186"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15754-0</funderId>
      <contactId>Contact53692_15754</contactId>
      <sponsorId>Sponsor52246</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53692_15754">
    <title>Prof</title>
    <forename>Keith</forename>
    <surname>Petrie</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Psychological Medicine
Faculty of Medical and Health Sciences
University of Auckland
Private Bag 92019</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kj.petrie@auckland.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52246">
    <organisation>University of Auckland (New Zealand)</organisation>
    <website>http://www.auckland.ac.nz/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Private Bag 92019</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kj.petrie@auckland.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.9654.e</gridId>
    <rorId>https://ror.org/03b94tp07</rorId>
  </sponsor>
  <funder id="Funder15754-0">
    <name>University of Auckland (New Zealand)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001537</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-10-30T00:00:00.000Z">34049135</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prospective pilot study: evaluation of a new dressing for patients treated in peritoneal dialysis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Evaluation of a new Peritoneal Dialysis (PD) dressing.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Dressing advantages are evaluated via questionnaires, which have to be filled in at specific time schedule. Comfort and safety evaluation will be performed by the patient at the end of each period of product use (end of PD Immo use and end of usual dressing use).</primaryOutcome>
      <secondaryOutcome>Handling is also evaluated via the patient questionnaire.
The incidence of Adverse Events (AE) will be followed during the study period.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Submitted to CPP Grenoble (reference number: 06-GAMB-1), will receive verdict on 20th September 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34049135</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1445</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Monocentric, open, comparative study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-25T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-11-25T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6ebe2e13-0265-4b93-b0a0-c06abd13656c">
	  <name>AGDUC</name>
	  <address/>
	  <city>Grenoble</city>
	  <state/>
	  <country>France</country>
	  <zip>38 700</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with well healed exit site
2. Patients treated for at least three months in peritoneal dialysis irrespective of the treatment mode
3. Patients with healthy skin judged by investigator
4. Patients aged 18 years and older
5. Patients having signed a written consent (informed consent) to participate in the study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Patients treated in hemodialysis
2. Patients with diagnosed abdominal pain not related with PD-solution
3. Peritonitis within one month prior to the study
4. Presence of exit-site, tunnel infection
5. Patients with ongoing peritonitis
6. Patients participating in other studies during the period of this study
7. Patients practising swimming
8. Patients under guardianship
9. Pregnancy, lactation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-25T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-11-25T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic renal failure</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Chronic renal failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Evaluation of dressing advantages via questionnaires</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15339-0</funderId>
      <contactId>Contact53264_15339</contactId>
      <sponsorId>Sponsor51813</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53264_15339">
    <title>Dr</title>
    <forename>Robert</forename>
    <surname>Milongo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>AGDUC
Hôpital La Tronche</address>
      <city>Grenoble</city>
      <country>France</country>
      <zip>38 700</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51813">
    <organisation>Gambro Industries (France)</organisation>
    <website>http://www.gambro.com/start.aspx?id=752</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Clinical Affairs Department
61 Avenue Tony Garnier</address>
      <city>Lyon</city>
      <country>France</country>
      <zip>69 007</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487322.8</gridId>
    <rorId>https://ror.org/01mgtdr23</rorId>
  </sponsor>
  <funder id="Funder15339-0">
    <name>Gambro Industries (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-09-25T00:00:00.000Z">85753869</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prophylactic fluconazole is effective in preventing fungal colonisation and infection in preterm neonates: a multicentre, randomised trial in Italy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the efficacy of fluconazole prophylaxis in prevention of fungal colonisation and infection (colonisation by Candida spp., or invasive infection caused by Candida spp.) in preterm very low birth weight (i.e., less than 1500 g at birth) infants in Neonatal Intensive Care Units (NICUs).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary objective of the study was to evaluate the effectiveness of  3 and 6 mg/kg fluconazole compared with placebo in the prevention of Candida colonisation and infection in the preterm very low birth weight neonates admitted to the participant NICUs.</primaryOutcome>
      <secondaryOutcome>1. Assessment of the incidence of Gram-positive and Gram-negative sepsis
2. Mortality (overall and Candida-attributable)
3. Rate of progression from colonisation to infection
4. Necrotising enterocolitis
5. Ligation of patent ductus arteriosus
6. Threshold retinopathy of prematurity requiring surgery
7. Severe (grade 3-4) intraventricular haemorrhage
8. Bronchopulmonary dysplasia
9. Alteration of liver function as measured by serum AST, ALT, direct bilirubin and gamma-Glutamyl Transferase (gGT) values at baseline and at the end of all administrations</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Board of the Fondazione Crescere Insieme al Sant'Anna-ONLUS approved of the study on the 15/04/2004. The Fondazione is a Charity and Scientific Foundation of the Sant' Anna Hospital Institution.

Each participating Institution reviewed the protocol and was notified of the Fondazione's approval:
1. Policlinico Umberto I^ of Rome
2. Carlo Poma Hospital of Mantua
3. Mangiagalli Hospital of Milan
4. S. Matteo Hospital of Pavia
5. Arcispedale of Reggio Emilia
6. Fatebenefratelli Hospital of Benevento
7. Department of Pediatrics, University of Messina
8. Department of Pediatrics, University of Bologna</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85753869</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, prospective, randomised, double-blind, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="92bc6f11-696a-4d9c-ab14-03aa71f8a16f">
	  <name>Neonatology and Hospital NICU</name>
	  <address/>
	  <city>Torino</city>
	  <state/>
	  <country>Italy</country>
	  <zip>10126</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All neonates with birth weight less than 1500 g (i.e. Very Low Birth Weight [VLBW]) born within the study period, whether at one of the eight Institutions or elsewhere, were eligible for the study.</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>267</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>267</totalTarget>
      <exclusion>1. Parental refusal
2. Admission after 72 hours of life
3. Death prior to 72 hours of life
4. Liver failure (defined as three-fold elevation of Aspartate Aminotransferase [AST] and/or Alanine Aminotransferase [ALT] above the reference values)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Neonatal fungal infection</description>
	<diseaseClass1>Neonatal Diseases</diseaseClass1>
	<diseaseClass2>Neonatal fungal infection</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The regimens in the two intervention groups was 6 and 3 mg/kg of fluconazole (DIFLUCAN®; Pfizer Italia S.p.A.; Latina/Roma; Italy) every third day for the first two weeks, then every other day. 

Six weeks (in infants with birth weight less than 1000 g, i.e. Extremely Low Birth Weight [ELBW]) and four weeks (in the infants with birth weight 1001 to 1500 g) were chosen as the duration of therapy on the basis of the currently published data, unless earlier discharge or need for systemic antifungal therapy due to the onset of proven or presumed invasive fungal infection.

Prophylaxis started from day of life three via a single dose intravenously or orally (via orogastric tube), depending on the availability of a venous line and/or the tolerance of oral feeding. Infants in the control group received placebo (1 ml saline) in the same way.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Fluconazole prophylaxis</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Other publications in https://pubmed.ncbi.nlm.nih.gov/16326690
2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17568029/</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="067a369d-7d1e-431d-a2a3-ac52967fe8b0" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2006-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16326690"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="4cbb001c-79b6-44a2-9879-b6d1e80f288e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-14T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17568029/"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15399-0</funderId>
      <contactId>Contact53331_15399</contactId>
      <sponsorId>Sponsor51878</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53331_15399">
    <title>Dr</title>
    <forename>Paolo</forename>
    <surname>Manzoni</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Neonatology and Hospital NICU
C. Spezia 60</address>
      <city>Torino</city>
      <country>Italy</country>
      <zip>10126</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0) 113 134 304</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">manzonipaolo@hotmail.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51878">
    <organisation>Saint Anna Foundation (Fondazione Crescere Insieme al Santa Anna [ONLUS]) (Italy)</organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Corso Spezia 60</address>
      <city>Torino</city>
      <country>Italy</country>
      <zip>10126</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)113 134 300</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ggomirato@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487373.c</gridId>
    <rorId>https://ror.org/00k065b17</rorId>
  </sponsor>
  <funder id="Funder15399-0">
    <name>Pfizer Italia S.p.A. (Italy) - supplied study drugs, provided financial support with a grant, but was not involved in the concept, design, enrolment, data collection, analysis and interpretation of its results.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-09-11T00:00:00.000Z">06650826</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Brief alcohol intervention in emergency</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Brief alcohol intervention for hazardous drinkers admitted to the Emergency Department.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. A 20% decrease in number of drinks per week
2. A 20% decrease in monthly binge drinking frequency
3. Number of medical consultations
4. Days hospitalised and days out of work</primaryOutcome>
      <secondaryOutcome>1. Drinking quantity
2. Frequency
3. Hazardous drinking consequences
4. Health related quality of life</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Clinical Research Ethics Committe, Faculty of Medicine, University of Lausannedate on the 8th January 2003 (ref: 193/01).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN06650826</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>3200-067949</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d594436a-87e9-455c-9af9-642b2339aab1">
	  <name>Mont-Paisible 16</name>
	  <address/>
	  <city>Lausanne</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>1011</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Consecutive patients aged 18 and over admitted to the Emergency Department from 11 am to 11 pm daily from January 2003 to June 2004.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>1000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1000</totalTarget>
      <exclusion>1. Patients under 18
2. A history of alcohol-related treatment over the last 12 months
3. Did not qualify for hazardous drinking over the last 30 days
4. Were clinically intoxicated
5. Medical condition that precluded a face-to-face interview</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hazardous drinkers</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Alcohol dependence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A single session 15 minutes brief alcohol intervention including six steps: 
1. Thank the patient for participation and provide reassurance about confidentiality 
2. Provide feedback about patient's alcohol use compared to similar measures for men and women in the Swiss community and ask the patient's opinion of the feedback 
3. Ask the patient to explore the pros and cons of his/her alcohol use 
4. Use a one to ten scale to explore patient's importance and readiness to change his/her drinking pattern 
5. Ask if the patient feels ready to set an objective and provide positive reinforcement about their ability to achieve this objective 
6. Give each patient written material including their Alcohol Screen (AUDIT) score, drinking pattern percentiles compared to the Swiss community, and their drinking pattern objectives.

There were two control groups: 
1. Control group one completed the  two minute lifestyle screener and a 30-minute face-to-face interview including assessment of alcohol use and alcohol-related consequences and a medical history. They were then contacted 12-month later for follow-up
2. Control group two completed the two minute lifestyle screener, signed a consent form and were contacted 12 month later for follow-up

Usual care does not include any intervention regarding alcohol. Alcohol use is generally adressed with a single yes-no question about patients' alcohol use. Neither systematic nor case finding stategies of counseling or referral are conducted routinely.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17565563 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="73bc3b4d-6278-41ff-a2d9-a9c68b10403f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17565563"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15085-0</funderId>
      <contactId>Contact52924_15085</contactId>
      <sponsorId>Sponsor51474</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52924_15085">
    <title>Dr</title>
    <forename>Jean-Bernard</forename>
    <surname>Daeppen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Mont-Paisible 16</address>
      <city>Lausanne</city>
      <country>Switzerland</country>
      <zip>1011</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jean-bernard.daeppen@chuv.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51474">
    <organisation>Swiss National Science Foundation (Switzerland)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Wildhainweg 2</address>
      <city>Bern</city>
      <country>Switzerland</country>
      <zip>3001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">div3@snf.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.425888.b</gridId>
    <rorId>https://ror.org/00yjd3n13</rorId>
  </sponsor>
  <funder id="Funder15085-0">
    <name>Swiss National Science Foundation (Switzerland) (ref: 3200-067949)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001711</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-07-21T00:00:00.000Z">16583435</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A prospective, randomised, double-blinded study to compare bipolar transurethral resection of the prostate (bipolar TURP) versus monopolar transurethral resection of the prostate (monopolar TURP) in terms of safety and efficacy</title>
      <scientificTitle/>
      <acronym>TURP</acronym>
      <studyHypothesis>Bipolar devices will minimise the disadvantages of the monopolar device such as the risk of electrolyte disturbances by using saline irrigation, bleeding and the risk of nervous stimulation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Safety bipolar TURP compared with monoploar TURP by means of  transurethral resection (TUR) syndrome
2. Blood loss
3. Number and severity of adverse events</primaryOutcome>
      <secondaryOutcome>1. Efficacy of bipolar TURP compared with monopolar TURP by means of IPSS or quality of life (QoL) scores
2. International index of erectile function (IIEF) score
3. Qmax
4. Cutting rate
5. Length of catherisation
6. Length of hospital stay
7. Length of operation
8. Impact on prostate specific antigen (PSA) level
9. Number of strictures</secondaryOutcome>
      <trialWebsite>http://www.turp.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN16583435</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective, randomised, double-blinded study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e44d9cb7-c4ea-4ff8-a2f8-cd94d52d2482">
	  <name>Academic Medical Center (AMC)</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Candidates for transurethral resection of the prostate (TURP)
2. Qmax less than 16 ml/sec
3. International Prostate Symptom Score (IPSS) score greater than 14
4. Voided volume greater than 125
5. Patients in retention with an indwelling catheter or intermittent catheterisation
6. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>94</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>94</totalTarget>
      <exclusion>1. If patient is suspected to be suffering from prostate cancer
2. Prior prostate surgery, including minimal invasive therapies
3. Active urinary tract infection
4. Known or suspected neurogenic decompensated bladder (postvoid residual urine volume [PVR] greater than 400ml/sec) or compensated detrusor function
5. Immunosuppression; using prednisone
6. Known or suspected malignant disease affecting the bladder or lower urinary tract
7. 5-alpha-reductase inhibitor within the last three months before baseline
8. Alpha-blockers within the last six weeks before baseline
9. Specific severe heart disease in whom anti-coagulant therapy might jeopardize treatment outcome</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Benign Prostatic Hyperplasia (BPH)</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Hyperplasia of prostate</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be randomised into either:
Group A: who will undergo a bipolar TURP
Group B: who will undergo a monopolar TURP</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15273-0</funderId>
      <funderId>Funder15273-1</funderId>
      <contactId>Contact53176_15273</contactId>
      <sponsorId>Sponsor51721</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53176_15273">
    <title>Dr</title>
    <forename>S.A.</forename>
    <surname>Lagerveld-Zaaijer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center (AMC)
Department of Urology
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5666030</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">S.A.Zaaijer@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51721">
    <organisation>Academic Medical Center (AMC), Department of Urology (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder15273-0">
    <name>Karl Storz (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15273-1">
    <name>Academic Medical Center (AMC) (The Netherlands) - Department of Urology</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-26T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-07-03T00:00:00.000Z">27844532</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Correction of acidosis in hemodialysis patients. Effects on protein metabolism, investigated by tracer technique and messenger-ribonucleic acid determination for ubuquitin and proteasome subunits.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Metabolic acidosis stimulates muscle protein breakdown, correction of acidosis results in decreased protein breakdown.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Muscle protein turnover</primaryOutcome>
      <secondaryOutcome>1. messenger-Ribonucleic Acid (mRNA) for ubuquitin and proteasome subunits
2. Plasma and muscle intracellular amino acid concentrations
3. Serum albumin</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Ethics Committee of Karolinska Institute at Huddinge University Hospital on 11/01/1993, reference number: 196/96</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27844532</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, crossover design</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0e0d4dda-cd65-46c3-be58-d66235aa6a8d">
	  <name>Karolinska University Hospital</name>
	  <address/>
	  <city>Stockholm</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-171 76</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Clinically stable hemodialysis patients
2. &gt;18 Years of age</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>16</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>16</totalTarget>
      <exclusion>1. Clinically obvious malnutrition
2. Ongoing infection
3. Diabetes mellitus
4. Untreated congestive heart failure
5. Treatment with corticosteroids or other immunosuppressive agents</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>End-stage renal failure</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Renal failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Adjustments of acid-base balance - in each patient, protein turnover will be measured twice, at a standard bicarbonate concentration of &lt;19 mmol/l and &gt;25 mmol/l respectively, with an interval between the two measurements (random order) of 3-4 weeks. The acid-base status will be altered by adjusting the dose of bicarbonate (oral and/or via dialysis) and protein turnover will be measured when the predialysis bicarbonate level have been low or normal for at least one week.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16931215 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e1ffa7b4-9243-4ab4-b743-5231026d1d16" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16931215"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14950-0</funderId>
      <funderId>Funder14950-1</funderId>
      <funderId>Funder14950-2</funderId>
      <funderId>Funder14950-3</funderId>
      <contactId>Contact52751_14950</contactId>
      <sponsorId>Sponsor51290</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52751_14950">
    <title>Dr</title>
    <forename>Erland</forename>
    <surname>Löfberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Karolinska University Hospital
Department of Renal Medicine
Solna</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE-171 76</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)85 1773768</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">erland.lofberg@karolinska.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51290">
    <organisation>Karolinska University Hospital (Sweden)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Clinical Science
Karolinska Institute
Huddinge</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE-14186</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)85 8582656</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">anders.alvestrand@ki.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.24381.3c</gridId>
    <rorId>https://ror.org/00m8d6786</rorId>
  </sponsor>
  <funder id="Funder14950-0">
    <name>Swedish Medical Research Council (ref: 11243 and 04210)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14950-1">
    <name>Gambro AB</name>
    <fundRef/>
  </funder>
  <funder id="Funder14950-2">
    <name>Baxter Inc.</name>
    <fundRef/>
  </funder>
  <funder id="Funder14950-3">
    <name>U.S. National Institutes of Health (R01 DK37175)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-17T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-06-07T00:00:00.000Z">21267689</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Preventive health survey in elderly people</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Participation in a health survey for elderly people (60-75 years) on risk factors for cardiovascular diseases, depression, osteoporosis and falls, followed by a subsequent personalized health advice from a community nurse on lifestyle modification and/or reference to local preventive activities, will lead to a decreased risk profile within the surveyed group and to a decrease in an abbreviated risk profile in comparison to a control group.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Percentage of persons with improvement of one step or more in risk profile. Risk profile = combination of risk factors for cardiovascular diseases (4 levels), depression (4 levels), osteoporosis (2 levels) and falls (4 levels), where level 1 = low risk; 4 = high risk.

For the comparison with the control group, an abbreviated risk profile will be constructed from the risk factors that can be assessed by questionnaire.

Outcome will be assessed at start and 12 months later.</primaryOutcome>
      <secondaryOutcome>Health related quality of life (short-form questionnaire-36 [SF-36] and EQ-5D)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21267689</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PGO2006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ea300ff1-d17d-4b43-a511-994e069c9257">
	  <name>GGD Zeeland</name>
	  <address/>
	  <city>Goes</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>4460 AS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Random selection of all community-dwelling elderly persons, aged 60-75 living in the Netherlands in the regions: Zuid-Beveland, Schouwen-Duiveland, Soest and Soesterkwartier (Amersfoort).</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>2000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2000</totalTarget>
      <exclusion>Elderly people living  in residential homes or hospital</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Falls, osteoporosis, cardiovascular disease, depression</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Health survey for risk factors followed by personalized advice on lifestyle and/or advice of to follow course to improve lifestyle. Health survey consists of anamnestic interview consisting of both validated questionnaires and physical examination. Control group will only receive questionnaires by mail.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15128-0</funderId>
      <funderId>Funder15128-1</funderId>
      <funderId>Funder15128-2</funderId>
      <funderId>Funder15128-3</funderId>
      <funderId>Funder15128-4</funderId>
      <funderId>Funder15128-5</funderId>
      <funderId>Funder15128-6</funderId>
      <funderId>Funder15128-7</funderId>
      <funderId>Funder15128-8</funderId>
      <funderId>Funder15128-9</funderId>
      <funderId>Funder15128-10</funderId>
      <contactId>Contact52982_15128</contactId>
      <sponsorId>Sponsor51530</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52982_15128">
    <title>Mr</title>
    <forename>C.</forename>
    <surname>Dingemanse</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>GGD Zeeland
P.O. Box 345</address>
      <city>Goes</city>
      <country>Netherlands</country>
      <zip>4460 AS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)11 3249484</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">christine.dingemanse@ggdzeeland.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51530">
    <organisation>GGD Zeeland (The Netherlands)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 345</address>
      <city>Goes</city>
      <country>Netherlands</country>
      <zip>4460 AS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.491205.b</gridId>
    <rorId>https://ror.org/042s2nd27</rorId>
  </sponsor>
  <funder id="Funder15128-0">
    <name>Community of Soest</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-1">
    <name>Community of Amersfoort</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-2">
    <name>Community of Schouwen-Duiveland</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-3">
    <name>Community of Reimerswaal</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-4">
    <name>Community of Kapelle</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-5">
    <name>Community of Goes</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-6">
    <name>Zorgkantoor</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-7">
    <name>Province of Zeeland</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-8">
    <name>GGD Zeeland</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-9">
    <name>Stichting</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-10">
    <name>Central Fund Reserves of the Former Voluntary National Health Service Administration Insurances (Centraal Fonds van Voormalig Vrijwillige Ziekenfondsverzekeringen [RvvZ])</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-06-02T00:00:00.000Z">19413357</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the use of Chinese herbal medicine in the management of endometriosis: a prospective study</title>
      <scientificTitle/>
      <acronym>Endoherb</acronym>
      <studyHypothesis>The hypothesis is that the formulated Chinese herbal treatment shows no significant difference than a placebo in the management of the symptoms of endometriosis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pain intensity due to endometriosis, measured quantitatively on the VAS and qualitatively as descriptive values.</primaryOutcome>
      <secondaryOutcome>1. Quality of life using the 36-item Short-Form health survey (SF-36) and a study design health survey tool
2. Serum CA 125 levels</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the University of Western Sydney's Ethics Committee on the 8th August 2002 (ref: HEC 02/098).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19413357</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HEC 02/098</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A multicentre, randomised, double-blind, placebo-controlled clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-11-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="dfee35d5-ced3-40b5-970f-305f5c7f08bc">
	  <name>497 South Road</name>
	  <address/>
	  <city>South Australia</city>
	  <state/>
	  <country>Australia</country>
	  <zip>5035</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Women, aged 18 - 43 years 
2. Diagnosed with endometriosis by laparoscopy and the severity staged (grade I - IV) 
3. At least three months of pain measuring more than 30 mm on visual analogue scale (VAS) scale</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100 participants (50 in each arm)</totalTarget>
      <exclusion>1. Menopause
2. Pregnancy
3. Liver diseases
4. Suffering from diabetes mellitus
5. Suffering from malignancies
6. Hormonal treatments
7. Anti-depressant treatments
8. Immunosuppressive conditions and treatments</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-11-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Endometriosis</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Endometriosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A specific Chinese herbal formula (Endoherb) versus placebo.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Endoherb</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15046-0</funderId>
      <contactId>Contact52869_15046</contactId>
      <sponsorId>Sponsor51419</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52869_15046">
    <title>Dr</title>
    <forename>Alex</forename>
    <surname>Liew</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>497 South Road
Ashford </address>
      <city>South Australia</city>
      <country>Australia</country>
      <zip>5035</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)8 83713711</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">endoherb@tpg.com.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51419">
    <organisation>University of Western Sydney (Australia)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Centre for Complementary Medicine
Locked Bag 1797
Penrith South DC
New South Wales</address>
      <city>Sydney</city>
      <country>Australia</country>
      <zip>1797</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.1029.a</gridId>
    <rorId>https://ror.org/03t52dk35</rorId>
  </sponsor>
  <funder id="Funder15046-0">
    <name>University of Western Sydney (Australia)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001776</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-20T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2006-05-26T00:00:00.000Z">61976169</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Therapy of frequent relapsing, steroid-sensitive nephrotic syndrome in childhood: efficacy of mycophenolate mofetil versus cyclosporin A</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Immunosuppressive therapy with mycophenolate mofetil (MMF) is as effective as cyclosporin A in preventing relapses of the nephrotic syndrome.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Number of relapses during the observation period</primaryOutcome>
      <secondaryOutcome>Decrease in GFR, hypertension and hyperlipidemia during the observation period</secondaryOutcome>
      <trialWebsite>http://www.apn-online.de/</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of Charité - University Medicine Berlin (Germany) on the 2nd December 2002 (ref: 1656/Si 238).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN61976169</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ML 16622</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, open-labelled, cross-over trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d182562d-8754-4caa-aa6a-9fa2e271f914">
	  <name>Augustenburger Platz 1</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>13353</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children aged 3 - 17 years 
2. Frequent relapses of steroid-sensitive nephrotic syndrome, associated with minimal changes on renal biopsy
3. Glomerular Filtration Rate (GFR) greater than 70 ml/min</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="3.0"/>
      <upperAgeLimit unit="Years" value="17.0"/>
      <gender>Both</gender>
      <targetEnrolment>55</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>55</totalTarget>
      <exclusion>1. Other histological findings on renal biopsy
2. Other severe concomittant diseases
3. Decreased GFR</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Idiopathic nephrotic syndrome</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Nephrotic syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Immunosuppressive therapy with MMF versus cyclosporin A.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mycophenolate mofetil, cyclosporin A</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14753204 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="b8f56bdc-6919-479a-a245-199e53920f87" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14753204"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14931-0</funderId>
      <funderId>Funder14931-1</funderId>
      <contactId>Contact52728_14931</contactId>
      <sponsorId>Sponsor51266</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52728_14931">
    <title>Mrs</title>
    <forename>Jutta</forename>
    <surname>Gellermann</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Augustenburger Platz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>13353</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51266">
    <organisation>Hoffmann-La Roche AG (Germany)</organisation>
    <website>http://www.roche.de</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Emil-Barell-Strasse 1</address>
      <city>Grenzach-Wyhlen</city>
      <country>Germany</country>
      <zip>79639</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.424277.0</gridId>
    <rorId>https://ror.org/00sh68184</rorId>
  </sponsor>
  <funder id="Funder14931-0">
    <name>Hoffmann La Roche AG (Germany)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14931-1">
    <name>Charité - University Medicine Berlin (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-20T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-05-24T00:00:00.000Z">67656669</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase I, single-dose, double-blind, randomised, dose escalation study to assess the safety, tolerability and pharmacokinetics of NNZ-2566 when administered as a 10-minute infusion</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Based on pre-clinical studies, NNZ-2566 is shown to have the potential to prevent the neurological damage that can occur as a result of the traumatic brain injury. Objectives of this study are:
1. To determine the safety and tolerability of a single intravenous dose of NNZ 2566 in healthy volunteers when administered as a 10-minute infusion
2. To determine the single dose pharmacokinetics of NNZ-2566 after a 10-minute infusion</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To determine the safety and tolerability of a single intravenous dose of NNZ 2566 when administered as a 10-minute infusion.</primaryOutcome>
      <secondaryOutcome>To determine the single dose pharmacokinetics of NNZ 2566 after a 10-minute infusion.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Alfred Ethics Committee on the 13th February 2006 (ref: 7/06).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67656669</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Neu-2566-HV-001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Placebo-controlled, double-blind, randomised, single-dose, dose escalation, phase I study in healthy volunteers</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-10-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
	<country>New Zealand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="488bbe4f-8510-4c31-9239-8b3ee97f4e65">
	  <name>Center for Clinical Studies</name>
	  <address/>
	  <city>Melbourne</city>
	  <state/>
	  <country>Australia</country>
	  <zip>3004</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged between 18 years and 50 years (inclusive)
2. Male only: males must also agree to use adequate contraceptive precautions (unless the subject is surgically sterilised) for the duration of the study and for at least 30 days thereafter
3. Body mass index (BMI) of 18 to 30 kg/m^2
4. Healthy - this will be determined by a medical history with particular attention to:
4.1. A drug history identifying any known drug allergies and the presence of drug abuse
4.2. Any chronic use of medication
4.3. A thorough review of body systems. This will also be determined by having no clinically significant abnormal findings on physical examination, which includes an electrocardiogram (ECG), which in the opinion of the investigator would jeopardise the safety of the subject or impact on the validity of the study results
5. Volunteers with adequate venous access in their left and right arm to allow collection of blood samples and drug administration
6. Fluency in the English language
7. Have voluntarily given written informed consent to participate in this study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Male</gender>
      <targetEnrolment>35</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>35 males</totalTarget>
      <exclusion>1. History of allergy and/or hypersensitivity to any of the stated ingredients of the formulations (including lactose intolerance). A known hypersensitivity to lidocaine or any surgical dressing which may be used in the study procedures.
2. Medical conditions:
2.1. History of clinically significant gastrointestinal, hepatic, renal, cardiovascular, dermatological, immunological, respiratory, endocrine, oncological, neurological, metabolic, psychiatric disease or haematological disorders
2.2. Any history of asthma during the last 10 years
2.3. A creatinine clearance of less than 75 ml/min calculated using Cockroft and Gault Formula
2.4. Any predisposing condition that might interfere with the absorption, distribution, metabolism, and/or excretion of drugs
2.5. History of abnormal bleeding tendencies or thrombophlebitis unrelated to venepuncture or intravenous cannulation
2.6. History of hepatitis B, a positive test for hepatitis B surface antigen, a history of hepatitis C, a positive test for hepatitis C antibody, a history of human immunodeficiency virus (HIV) infection or demonstration of HIV antibodies
3. Any evidence of organ dysfunction, or any clinically significant clinical laboratory value which, in the opinion of the investigator would jeopardise the safety of the subject or impact on the validity of the study results, including a liver function test (LFT) greater than 1.5 x upper limit of normal (ULN)
4. Those who may have difficulty abstaining from alcohol during the 48 hours prior to dose administration and until completion of blood sampling on day 7
5. History of, or current evidence of, abuse of alcohol or any drug substance, licit or illicit, or positive urine drug screen for drugs of abuse
6. Medication:
6.1. Difficulty in abstaining from any prescription medications for 14 days prior to dose administration and for the duration of the study
6.2. Difficulty in abstaining from over-the-counter (OTC) medications or herbal supplements for 14 days prior to dose administration and for the duration of the study, (with the exception of occasional analgesia, vitamin and other nutrient supplement use, at the discretion of the investigator)
7. Difficulty in abstaining from food and/or beverages that contain caffeine or other xanthines (e.g., coffee, tea, cola and chocolate) during the 24 hours prior to dose administration and whilst confined at the clinical facility
8. History of any psychiatric illness which may impair the ability to provide written informed consent
9. Poor compliers or those unlikely to attend
10. Receipt of any drug as part of a research study within 30 days of initial dose administration in this study
11. Standard blood donation (usually 550 ml) within the 12-week period before dose administration
12. Unusual dietary habits, including vegetarian diets and excessive or unusual vitamin intakes
13. Vaccination or immunisation within 30 days of initial dose administration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-10-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Traumatic brain injury</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Traumatic brain injury</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects will undergo screening to confirm eligibility. Subsequently, subjects will be admitted to the clinical facility for administration of either placebo or the active drug in a 2:5 fashion in each of the five cohorts. This in-house stay will involve collection of blood samples for pharmacokinetic (PK) analysis.  Subjects will stay for a minimum of 24 hours after initial dosing. A dose-escalation schema has been chosen to maximise safety for participants based on preclinical toxicology studies. The pre-defined dose levels are: 0.1 mg/kg, 1.0 mg/kg, 10.0 mg/kg, 20.0 mg/kg, 30.0 mg/kg. The dosing scheme will consist of a single fixed-dose intravenous infusion of NNZ-2566 over 10 minutes. Dose escalation is subject to the Data Safety Monitoring Committee's (DSMC's) recommendation.  A review time period of two to three weeks from end of dosing of each cohort is estimated to enable PK analysis prior to starting the next cohort. The study design precludes intra-subject dose-escalation. 

Subjects will then return to the unit on day 7 for an exit evaluation, which will include collection of additional blood samples for safety laboratory testing and safety monitoring.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I</phase>
	<drugNames>NNZ-2566</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15059-0</funderId>
      <funderId>Funder15059-1</funderId>
      <funderId>Funder15059-2</funderId>
      <contactId>Contact52884_15059</contactId>
      <sponsorId>Sponsor51434</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52884_15059">
    <title>Dr</title>
    <forename>Minh</forename>
    <surname>Pham</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Center for Clinical Studies
Level 5 Burnet Tower
Amrep Precinct
89 Commercial Road</address>
      <city>Melbourne</city>
      <country>Australia</country>
      <zip>3004</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)3 9207 1930</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.pham@nucleusnetwork.com.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51434">
    <organisation>Neuren Pharmaceuticals (New Zealand)</organisation>
    <website>http://www.neurenpharma.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Level 3
2-6 Park Avenue
Grafton</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 (0)9 367 7167</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mscott@neurenpharma.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487323.9</gridId>
    <rorId>https://ror.org/0503fq502</rorId>
  </sponsor>
  <funder id="Funder15059-0">
    <name>Technology New Zealand (TechNZ) (New Zealand) - grant</name>
    <fundRef/>
  </funder>
  <funder id="Funder15059-1">
    <name>Foundation for Research Science and Technology (FoRST) (New Zealand) - grant (grant ref: NRNZ0301, NRNZ0402, NRNZ0502)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15059-2">
    <name>Neuren Pharmaceuticals Limited (New Zealand) - internally funded</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-05-12T00:00:00.000Z">03256458</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety of an aerosol attenuated measles vaccine in healthy subjects with Omron's nebuliser, Aerogen's clinical nebuliser and Trudell's nebuliser</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Respiratory administration of live measles vaccine closely mimics the natural route of measles infection. It is already established that current measles vaccines are more effective or equivalent in inducing antibody production when delivered by nebulisation compared to when delivered parenterally. Maternal antibody interference might be avoided or mucosal immunity might be enhanced. No increase in adverse side effects of respiratory administration has been noted compared to current injection practice. Aerosol delivery devices are available or being developed and could be used by lay people with limited training. Administration of the current measles vaccine via the respiratory route should now be comprehensively studied to achieve licensure for international use.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Evaluation of the safety of aerosol administration of live Edmonston Zagreb attenuated measles vaccine given to healthy volunteers.</primaryOutcome>
      <secondaryOutcome>Evaluation of the serum plaque reduction neutralisation titres before and after aerosol administration of live attenuated measles vaccine given to healthy volunteers.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the:
1. Research Ethics Review Committee (ERC) of the World Health Organization on the 4th April 2006
2. Health Ministry Screening Committee (HMSC) of the Ministry of Health (India) on the 17th January 2006</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN03256458</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WHO/MAP/IN/001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, open, non-controlled, sequential by age group, parallel trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fbc92db9-2f29-4eef-b9e9-e6db12fb8d94">
	  <name>Initiative for Vaccine Research</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male subject, 18 to 35 years old for first group
2. Male or female at the age of 1 to 17 years for second and third group
3. Residence in the study area
4. Measles immune, as determined by Plaque Reduction Neutralisation (PRN) titre greater than 120 mIU/ml
5. Healthy on the day of the visit as supported by physical examination and laboratory evaluation on preset parameters
6. Signed informed consent (subject and/or parent/guardian/legal representative)
7. Expressed interest and availability to fulfil the study requirements
8. Non pregnant as certified by pregnancy test and agreement to avoid pregnancy for at least 30 days after vaccination (women of childbearing age)
9. Willing not to receive any experimental drug or vaccine within 90 days after study vaccination</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60 subjects for 3 sequential age groups; 20 participants in each</totalTarget>
      <exclusion>1. Human Immunodeficiency Virus (HIV) positive (serology test)
2. Pregnant (based on positive pregnancy test)
3. Immunodeficiency or suppression (disease or iatrogenic induced), seizure disorder and progressive neurological disorder
4. Enrolled in any experimental drug or vaccine study within 30 days prior to vaccination
5. Known hypersensitivity to any component of the study vaccine
6. History of thrombocytopenia or immune thrombocytopenia purpura
7. Significant psychiatric or medical illness, including pulmonary disease (such as asthma requiring medication)
8. Severe malnutrition, as indicated by current guidelines by Indian Academic of Paediatrics
9. Axillary temperature greater than 38.3°C or other acute illness on the day of scheduled vaccination
10. Household contact who has a medical history suggestive of disease or drug induced immunodeficiency or suppression (e.g. ongoing treatment with an immunosuppressive agent, chronic diarrhoea for greater than one month, fever for greater than one month, chronic cough for greater than one month, generalised dermatitis or lymphadenopathy, gastrointestinal candidiasis)
11. Receipt of any licensed vaccine within 30 days prior to vaccination</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Measles infection</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Measles infection</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Attenuated measles aerosol vaccine administrated via the following devices: 
1. Omron's nebuliser
2. Aerogen's clinical nebuliser
3. Trudell's nebuliser</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Measles vaccine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15057-0</funderId>
      <contactId>Contact52881_15057</contactId>
      <sponsorId>Sponsor51431</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52881_15057">
    <title>Dr</title>
    <forename>Ana-Maria Henao</forename>
    <surname>Restrepo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Initiative for Vaccine Research
World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51431">
    <organisation>World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int/vaccine_research/en/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Initiative for Vaccine Research
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder15057-0">
    <name>World Health Organization (WHO) (Switzerland)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-06T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-04-24T00:00:00.000Z">27914471</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparison of the efficacy and effectiveness of dihydroartemisinin-piperaquine and artesunate-mefloquine in the treatment of falciparum malaria</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Non-inferiority of efficacy and effectiveness of dihydroartemisinin-piperaquine compared to mefloquine-artesunate for the treatment of uncomplicated falciparum malaria in adults and children in western Myanmar.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Polymerase chain reaction (PCR) adjusted parasitological failure rates by day 42</primaryOutcome>
      <secondaryOutcome>1. Vivax appearances
2. Gametocytaemia (person gametocyte weeks between day 0 and 42)
3. Whole blood piperaquine levels at day 7
4. Adverse effects</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by Doctors Without Borders (Medecins sans Frontieres [MSF]) Ethical Review Board on 05/12/2003</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27914471</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>An open randomised comparison</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-12-08T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-03-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Myanmar</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1363b470-5dde-430b-bdc0-0e1ce5679d5c">
	  <name>Thanlwin Road 62 A</name>
	  <address/>
	  <city>Yangon</city>
	  <state/>
	  <country>Myanmar</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with fever (axillary temperature &gt;37.5°C), or a history of fever within 48 hours
2. Confirmed falciparum malaria (mixed infection P. falciparum with P. vivax and/or P. malariae were included), with more than 500 but less than 100,000 asexual parasites per ml</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>640</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>640</totalTarget>
      <exclusion>1. Signs of severe and complicated malaria
2. Children below one-year-old
3. Pregnant women
4. Patients with a history of taking mefloquine during the previous two months
5. Patients taken any other antimalarial drugs in the previous 48 hours
6. Patients with a history of psychiatric diseases</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-12-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-03-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Falciparum malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Falciparum malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Comparison of two different treatment regimes: dihydroartemisinin-piperaquine and mefloquine-artesunate. Both treatment regimes were given observed or not observed; total of four study groups.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Dihydroartemisinin-piperaquine and artesunate-mefloquine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16798391 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="50837bb6-41aa-45f4-8f02-fa9d7daa68de" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-06-24T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16798391"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14551-0</funderId>
      <contactId>Contact52284_14551</contactId>
      <sponsorId>Sponsor50768</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52284_14551">
    <title>Dr</title>
    <forename>Frank</forename>
    <surname>Smithuis</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Thanlwin Road 62 A</address>
      <city>Yangon</city>
      <country>Myanmar</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+95 1 534679</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">msfh_yangon@mptmail.net.mm</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50768">
    <organisation>Doctors Without Borders (Medecins sans Frontieres [MSF]) (The Netherlands)</organisation>
    <website>http://www.artsenzondergrenzen.nl</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Plantage Middenlaan 14</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1018DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5208700</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@amsterdam.msf.org</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.452780.c</gridId>
    <rorId>https://ror.org/04237en35</rorId>
  </sponsor>
  <funder id="Funder14551-0">
    <name>Internally funded by Doctors Without Borders (Artsen zonder Grenzen MSF) (Holland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-03-31T00:00:00.000Z">08525528</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effectiveness and pharmacovigilance of Lapdap™ and Coartem® for the treatment of uncomplicated falciparum malaria in northeastern Tanzania</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Lapdap™ is likely to be as effective as Coartem® in malaria management when used in an unsupervised situation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To assess the effectiveness of Lapdap™ and Coartem® through clinical and parasitological responses.</primaryOutcome>
      <secondaryOutcome>1. To document the frequency and type of potential drug related adverse events
2. To assess community compliance and acceptability of Lapdap™ and Coartem® use
3. To determine the prevalence and to monitor the development of dhfr/dhps gene mutations which are markers of resistance</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received on the 10th July 2005.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08525528</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A40744</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
	<country>Tanzania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f746c5b1-9957-428d-b8b8-74f355bc2bb4">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age between 6 and 59 months (although the lower age limit for Lapdap™ use is three months according to the label, malaria is rare among those below six months of age)
2. Weight of 5 - 16 kg
3. Presence of fever (axillary temperature greater than or equal to 37.5°C) and/or history of fever within two days
4. Uncomplicated malaria, slide-confirmed mono-infection of P. falciparum with 1000 - 100,000 rings/µl
5. The ability to attend follow-up visits
6. Informed consent provided by parent or guardian</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Months" value="59.0"/>
      <gender>Both</gender>
      <targetEnrolment>2600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2600</totalTarget>
      <exclusion>1. Malnutrition, defined as a child whose weight-for-height is below -3 SDs or less than 70% of the median of the National Center for Health Statistics (NCHS)/World Health Organization (WHO) normalised reference values
2. Known history of G6PD defficiency, methaaemogloin reductase deficiency, Haemoglobin M or E, or porphyria
3. Evidence of severe malaria as defined in WHO 2000
4. Hb equal to or less than 7 g/dl
5. Hypersensitivity to biguanides (e.g. proguanil, chlorproguanil) or sulphonamides such as fancidar and septrin
6. Evidence of concomitant fibrile infection
7. Treatment with antimalarial drugs within the past 14 days or 7 days with quinine (full course), proguanil, artemisinins, tetracycline doxycycline or clindamycin. Patient shall not be excluded on the basis of reported prior treatment with other anti-malarial drugs within the past 24 hours if they have a temperature and parasitemia.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Lapdap™ versus Coartem®.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Lapdap™, Coartem®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14960-0</funderId>
      <funderId>Funder14960-1</funderId>
      <contactId>Contact52763_14960</contactId>
      <sponsorId>Sponsor51306</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52763_14960">
    <title>Dr</title>
    <forename>Ahmed</forename>
    <surname>Bellah</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51306">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14960-0">
    <name>Gates Foundation (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14960-1">
    <name>Glaxo SmithKline (GSK) (USA) - donating the Lapdap™ free of charge</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-17T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-03-29T00:00:00.000Z">83323477</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Bioavailability of the fixed dose formulation Rifafour containing isoniazid, rifampicin pyrazinamide, ethambutol and the World Health Organization (WHO) recommended first line antiretroviral drugs zidovudine, lamivudine, efavirenz administered to new Tuberculosis (TB) patients at different levels of immunosuppression</title>
      <scientificTitle/>
      <acronym>PK-TB-HAART</acronym>
      <studyHypothesis>The optimal time to initiate concomitant therapies is currently not known but is based on balancing the risk of HIV disease progression against the discontinuation of therapies due to toxicities, side effects and/or unforeseen drug-drug interactions. 

The study will investigate the bioavailability of anti-tuberculosis drugs and anti-retroviral drugs administered in fixed dose combinations to HIV/TB co-infected immuno-compromised individuals commencing concomitant HIV and TB therapy compared with anti-retroviral drugs administered to HIV-infected patients without clinical TB and anti-tuberculosis drugs to TB patients with HIV commencing TB therapy only, thereby determining the effects of the level of immunosuppression on the bioavailability of the drugs and any drug interactions.

Please note that ethics approval and secondary outcome measures were added to this record on 17th September 2007. Any changes are noted under this date.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To investigate the bioavailability of anti-tuberculosis drugs and anti-retroviral drugs administered in fixed dose combinations to HIV/TB co-infected immuno-compromised individuals commencing concomitant HIV and TB therapy compared with anti-retroviral drugs administered to HIV-infected patients without clinical TB and anti-tuberculosis drugs to TB patients with HIV commencing TB therapy only thereby determining the effects of the level of immunosuppression on the bioavailability of the drugs and any drug interactions.</primaryOutcome>
      <secondaryOutcome>1. Bioavailability of both Antiretroviral drugs and anti-TB drugs (rifampicin and isoniazid) as affected by CD4 count levels in co-infected TB-HIV patients (Comparison of drug levels of HAART by CD4 count stratum, stratified by presence/absence of ARVs) 
2. Bioavailability of anti TB- drugs as affected by drug-drug interactions with anti-retroviral drugs in co-infected TB-HIV patients (comparison of TB drug levels between subjects given both ARVs and anti-TB drugs and those given anti-TB drugs alone, stratified by CD4 count stratum)
3. Homogeneity between drug-drug interactions over the two CD4 strata, or extent of modification by CD4 count of the effect of drug-drug interaction
4. Bioavailability of anti-retroviral drugs as affected by drug-drug interactions with anti-TB medications (comparison of ARV drug levels between HIV infected non TB infected individuals with CD4 count less than 200 cells/ µl given only ARVs and TB/HIV co-infected subjects at the same CD4 count given both anti-TB and HAART)
5. Safety parameters - including biochemical and haematological Adverse Events (AE) and Serious Adverse Events (SAE)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Amended as of 17/09/2007:
Ethics approval received from the MRC South Africa on the 17th May 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83323477</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A40607</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-30T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b3ddc1d7-4df9-4396-87ef-a653029efb45">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 18 to 65 years
2. Human Immunodeficiency Virus (HIV) treatment-naive patients (established by history)
3. No history of previous anti-TB chemotherapy within the previous 24 months
4. A traceable home address and contact details to facilitate home visits with a firm commitment to remain traceable and to be able to access a defined treatment/service point for 24 months
5. Not currently enrolled in any other drug or treatment trials
6. Informed consent for HIV testing and PK testing
7. Informed consent to participate in the trial
8. For female subjects, the following conditions are to be met:
8.1. Has been post-menopausal for at least one year, or
8.2. Is surgically incapable of bearing children, or
8.3. Is of childbearing potential and all of the following conditions are met:
8.3.1. Has a negative pregnancy test (urine) immediately before study entry (and later confirmed by a another pregnancy test)
8.3.2. Must agree to use an accepted method of contraception (i.e. barrier methods or intrauterine device [IUD]). The subject must agree to continue with the same method throughout the study
Note: If a patient is using a long-acting hormonal contraceptive (such as Depot-Provera), the patient can be enrolled in the study, however she should be advised to use it in conjunction with a barrier method or IUD due to the known pharmacokinetic interaction between the various study medications and hormonal contraceptives. If an oral hormonal agent is in use, the patient will be advised to change the method of contraception in favour of barrier methods. No patient will be enrolled who does not accept to use barrier methods or IUD for contraception.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>1. Evidence (laboratory and clinical history) of pre-existing non-tuberculosis disease likely to affect the response to, or assessment of treatment effects or represent contraindications to the study medication:
1.1. Diabetes mellitus
1.2. Liver impairment (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] greater than 2.5 x the upper limit of normal value)
1.3. Renal failure (serum creatinine greater than 1.5 x the upper limit of normal value)
1.4. Epilepsy
1.5. Optical neuritis
1.6. Pancreatitis (lipase greater than 1.5 x the upper limit of normal value)
1.7. Neutropenia (total neutrophil count less than 1200 cells/l)
1.8. Anaemia (haemoglobin less than 8 g/dl)
1.9. Any other condition that in the view of the country Principal Investigator represents a contraindication to the study medication
2. Mental illness (clinical suspicion of schizophrenia, manic-depressive illness, dementia)
3. Stage IV disease requiring concomitant medications that may potentially interact with study drugs (according to WHO staging system)
4. Weight below 30 kg
5. Moribund or clinical evidence of severe illness
6. Patients exposed to other medication that may (on the basis a known interaction, or a strong theoretical basis) affect study drug levels. Exclusion of a volunteer on the basis of a potential interaction will be at the discretion of the principal investigator
7. Of childbearing age and refusing to use either barrier or IUD method of contraceptive for the duration of the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tuberculosis (TB) and Human immunodeficiency virus (HIV)</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Human immunodeficiency virus (HIV)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are assigned to the following groups:
1. TB/HIV co-infected (220 - 349 CD4 T cells/µl) treated with anti-TB chemotherapy and Highly Active Anti-Retroviral Therapy (HAART)
2. TB/HIV co-infected (220 - 349 CD4 T cells/µl) treated with anti-TB chemotherapy
3. TB/HIV co-infected (350 - 500 CD4 T cells/µl) treated with anti-TB chemotherapy and HAART
4. TB/HIV co-infected (350 - 500 CD4 T cells/µl) treated with anti-TB chemotherapy
5. TB/HIV co-infected (less than 200 CD4 T cells/µl) receiving anti-TB chemotherapy and HAART
6. HIV infected without active TB (less than 200 CD4 T cells/µl) receiving HAART

There are 20 patients in each arm. Patients are randomised to groups 1 - 4. In groups 5 and 6 the first 20 patients in each arm meeting the inclusion/exclusion criteria and consenting to be in the study will be included.

The trial aims:
1. To investigate whether the bioavailability of both anti-retroviral drugs and anti-TB drugs (rifampicin and isoniazid) are affected by CD4 count levels in co-infected TB-HIV patients (comparison of drug levels of highly active anti-retroviral therapy [HAART] by CD4 count stratum, stratified by presence/absence of Anti-Retrovirals [ARVs])
2. To investigate whether the bioavailability of anti-TB drugs are affected by drug-drug interactions with anti-retroviral drugs in co-infected TB-HIV patients (comparison of TB drug levels between subjects given both ARVs and anti-TB drugs and those given anti-TB drugs alone, stratified by CD4 count stratum)
3. To investigate whether the bioavailability of anti-retroviral drugs is affected by drug-drug interactions with anti-TB medications (comparison of ARV drug levels between HIV infected non-TB infected individuals with CD4 count less than 200 cells/µl given only ARVs and TB/HIV co-infected subjects at the same CD4 count given both anti-TB and HAART)

For further information please contact Dr Onyebujoh at the address listed below or Dr Melba Gomes at gomesm@who.int</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rifafour containing isoniazid, rifampicin pyrazinamide, ethambutol and zidovudine, lamivudine, efavirenz</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14949-0</funderId>
      <funderId>Funder14949-1</funderId>
      <funderId>Funder14949-2</funderId>
      <contactId>Contact52749_14949</contactId>
      <sponsorId>Sponsor51288</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52749_14949">
    <title>Dr</title>
    <forename>Philip</forename>
    <surname>Onyebujoh</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 4478</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">onyebujohp@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51288">
    <organisation>World Health Organization (WHO) (Switzerland)</organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 4478</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">onyebuhjohp@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14949-0">
    <name>World Health Organization (WHO) (Switzerland)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
  <funder id="Funder14949-1">
    <name>GlaxoSmithKline (GSK) - drug supply</name>
    <fundRef/>
  </funder>
  <funder id="Funder14949-2">
    <name>Merck &amp; Co Inc. - drug supply</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-02-08T00:00:00.000Z">48902136</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Surgical excision versus antibiotic treatment for non-tuberculous mycobacterial cervicofacial lymphadenitis in children (CHIMED): a multicentre randomised controlled trial</title>
      <scientificTitle/>
      <acronym>CHIMED</acronym>
      <studyHypothesis>Non-tuberculous mycobacteria (NTM) are a common cause of chronic cervicofacial lymphadenitis in children, especially between the age of 1 and 5 years.The disease is usually unilateral, occurring in the submandibular or preauricular area. The nodes suppurate and form a chronic sinus tract.

The optimal treatment of Non-Tuberculous Mycobacterial (NTM) cervical lymphadenitis in children has not been established. Until recently surgical excision was the standard treatment, but the number of reports of successful antibiotic treatment is increasing, questioning surgery as the preferred treatment. In this randomised, multicenter trial we compared surgical excision to antibiotic treatment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary endpoint was cure, defined as regression of the enlarged lymph node by at least 75%, with cure of the fistula and total skin closure without local recurrence or de novo lesions at six months, as assessed by clinical and ultrasound evaluation.</primaryOutcome>
      <secondaryOutcome>Secondary outcome measures were surgical complications and side effects of the medication.</secondaryOutcome>
      <trialWebsite>http://www.mycobacterie.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from Medical Ethics Committee (MEC) ont he 1st November 2001 (ref: 00/182).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48902136</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>945-02-019</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, multicentre clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fd15643f-60f0-44ba-bef6-321398bbdb96">
	  <name>A1-1</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1105  AZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Children between 0 - 15 years old with a possible NTM lymphadenitis were referred by pediatricians, otolaryngologists, oral and maxillofacial surgeons and general practitioners from all over the country.

Inclusion criteria: an enlarged cervicofacial lymphadenitis for a period longer than three weeks, with negative serology for other infectious causes of chronic lymphadenitis (Cytomegalo Virus [CMV], Epstein-Barr Virus [EBV], adenovirus, bartonella and toxoplasmosis).</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="0.0"/>
      <upperAgeLimit unit="Years" value="15.0"/>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100 patients with NTM cervical lymphadenitis</totalTarget>
      <exclusion>Excluded were immunocompromised patients and patients using immunosuppressive drugs.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic cervicofacial lymphadenitis</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Lymphadenitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>To compare surgical excision of involved lymph nodes with antibiotic therapy consisting of a three-month course of Clarithromycin and Rifabutin.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Clarithromycin, rifabutin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Other publications in https://pubmed.ncbi.nlm.nih.gov/15184446
2005 Other publications in https://pubmed.ncbi.nlm.nih.gov/15705324
2005 Other publications in https://pubmed.ncbi.nlm.nih.gov/16267728</publicationDetails>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c06f78b0-23f9-4b6d-b2bd-7a01213f9410" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2004-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15184446"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="312d1825-d233-4e77-94d8-5c92630ccf04" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2005-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15705324"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="bce4b393-ba21-44f7-9daf-c53baa357b87" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2005-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16267728"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14731-0</funderId>
      <contactId>Contact52493_14731</contactId>
      <sponsorId>Sponsor51008</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52493_14731">
    <title>Dr</title>
    <forename>Jerome</forename>
    <surname>Lindeboom</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>A1-1
Meibergdreef 9
Department of Oral and Maxillofacial Surgery
Academic Medical Center</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105  AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51008">
    <organisation>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands) </organisation>
    <website>http://www.zonmw.nl</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Laan van Nieuw Oost-Indie 334</address>
      <city>Den Haag</city>
      <country>Netherlands</country>
      <zip>2509 AE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)70 3495259</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bijlsma@zonmw.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.438427.e</gridId>
    <rorId>https://ror.org/01yaj9a77</rorId>
  </sponsor>
  <funder id="Funder14731-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands) (ref: 945-02-019)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-01-25T00:00:00.000Z">87984926</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Atorvastatin treatment and vaccination efficacy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Statin treatment may modulate, either negatively or positively, antibody responses to vaccination antigens.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The main outcome variable was the achievement of antibody levels greater than 20 IU/l against the hepatitis A virus one month after vaccination.</primaryOutcome>
      <secondaryOutcome>1. A secondary outcome variable was the mean log-transformed antibody titre 
2. To document the effects of atorvastatin on total blood cholesterol, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C), triglycerides, and high-sensitivity C-Reactive Protein (hs-CRP)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The protocol was approved by the Ethics Committee of the Geneva University Hospital (CE-04-029) and written informed consent was obtained from all participants</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87984926</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, double-blind, randomised, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="891ab170-269e-4c50-87af-e41c413a0510">
	  <name>Cardiology Division</name>
	  <address/>
	  <city>Geneva</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Men and women who were greater than 18 years old were eligible for inclusion if they had neither morbidities nor immunity to hepatitis A</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>312</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>312</totalTarget>
      <exclusion>1. Anti-hepatitis A antibodies greater than 10 IU/l
2. Hypercholesterolemia
3. Hepatitis
4. Myositis
5. Chronic alcohol abuse
6. Pregnant or breast-feeding women
7. Volunteers on drug therapy except oral contraceptives</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hepatitis A</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Hepatitis A</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects were immunised against hepatitis A and subsequently received atorvastatin (40 mg per day) or placebo for a period of 28 days after immunisation.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Atorvastatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14628-0</funderId>
      <funderId>Funder14628-1</funderId>
      <contactId>Contact52385_14628</contactId>
      <sponsorId>Sponsor50896</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52385_14628">
    <title>Prof</title>
    <forename>Francois</forename>
    <surname>Mach</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Cardiology Division
Geneva University Hospital
24 Rue Micheli-du-Crest</address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 382 72 34</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">francois.mach@medecine.unige.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50896">
    <organisation>Geneva University Hospital (Switzerland)</organisation>
    <website>http://www.cardiology-geneva</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Cardiology Division
24 rue Micheli-du-Crest</address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 372 72 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">marjorie.burkhard@hcuge.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.150338.c</gridId>
    <rorId>https://ror.org/01m1pv723</rorId>
  </sponsor>
  <funder id="Funder14628-0">
    <name>Geneva University Hospital (Switzerland) - Department of Medicine</name>
    <fundRef/>
  </funder>
  <funder id="Funder14628-1">
    <name>University of Geneva Cardiology Foundation (GECOR) (Switzerland) - had no role in the study design, analysis of data or report writing</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-03T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-01-18T00:00:00.000Z">46117662</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of the equivalence of ceftriane plus azithromycin or doxycycline for the treatment of pelvic inflammatory disease</title>
      <scientificTitle/>
      <acronym>DAZ</acronym>
      <studyHypothesis>1 g of azithromycin once a week for two weeks is equivalent to 14 days of 200 mg doxycycline per day.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome for the trial is clinical cure, defined as improvement or absence of the initial pain at day 14 compared to baseline.</primaryOutcome>
      <secondaryOutcome>1. A clinical cure, defined as 70% or greater reduction in the total tenderness score at day 14 compared to baseline
2. Histological cure defined as absence of plasma cell per X120 field in the endometrial stroma and &lt;5 neutrophils per X400 field in the endometrial surface
3. Absence of Neisseria gonorrhea and Chlamydia trachomatis on endometrial samples on day 30 by PCR techniques</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Hospital de Clinicas de Porto Alegre (HCPA) Institutional Review Board (ref: IRB0000921)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46117662</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>03-006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized double-blinded placebo trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="60d73c57-815a-413d-8764-5f05f2e6165e">
	  <name>Rua Ramiro Barcelos, 2350/1125</name>
	  <address/>
	  <city>Porto Alegre</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>90035-003</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. A history of pelvic discomfort for a period of 30 days or less
2. Findings of pelvic organ tenderness (uterine or adnexal) on bimanual examination
3. Leukorrhea and/or mucopurulent cervicitis and/or untreated known positive gonococcal or chlamydial cervicitis</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>112</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>112</totalTarget>
      <exclusion>1. Current pregnancy as demonstrated by beta-Human Chorionic Gonadotrophin (HCG) or ultrasonography
2. Inability to tolerate an outpatient oral regimen as demonstrated by the vomiting of eight ounces of water one hour after taking 10 mg of metoclopramide
3. Presence of tubo-ovarian abscess, appendicitis or hemorrhagic ovarian cysts confirmed by ultrasound or laparoscopy
4. Pelvic pain over 30 days duration
5. Allergy to ceftriaxone, azithromycin or doxycycline
6. Antimicrobial therapy within seven days of recruitment
7. Delivery, abortion or gynecological surgery within 30 days
8. Prior hysterectomy or bilateral salpingectomy
9. Homelessness
10. Fever
11. Abdominal rebound tenderness</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pelvic inflammatory disease</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Pelvic inflammatory disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Eligible patients were invited to participate in the doxycycline azithromycin protocol (DAZ). After giving written consent, a standardized interview, examination and specimen collection techniques were taken. Only three researchers will perform the physical exams. Whenever possible, the researcher that performed the first clinical examination on the first visit also did follow up on that patient.
A standardized screening examination, including a visual pain scale (0-10), and the McCormick modified pain scale was performed in the same sequence by the three researchers. A complete blood count, endometrial biopsy, urinalysis, and erythrocyte sedimentation rate will be performed on the first visit.
Endometrial samples will be divided into two equal amounts. One will be snap frozen in liquid nitrogen for Polymerase Chain Reaction (PCR) analysis and the other will be fixed in formaldehyde for histological analysis.
After the initial interview, the patient will receive a parenteral 250 mg ceftriaxone injection and will be randomly allocated to one of two treatment groups.

Randomization and treatment:
A restricted randomization sequence list was generated by computer, and was kept concealed from the researcher until the moment of assignment. We will consider subjects in blocks of four at a time to create the allocation sequence. After the patient is enrolled in the protocol, she will be blindly assigned to a coded treatment, either 14 days doxycycline or 1 g of azithromycin per week for two weeks. To avoid bias, the medication will be manipulated by the hospital pharmacy and will be put in identically coded blisters (treatment A, treatment B). To confirm compliance, a treatment of just seven days will be given to the patient, forcing her to return in seven days to receive the rest of the treatment. Because of the difference in the amount of capsules in each treatment, the azithromycin blister was filled up with placebo.
In the first visit, the patient will receive 250 mg intramuscular ceftriaxone and a blister for seven days treatment. The first dose of the medication (1 g of azythromycin, or 200 mg of doxycycline) will be taken in front of the physician. She will receive a leaflet and instructions of how she should take the rest of the medication. Special attention was taken about warning against taking the medication on an empty stomach, using analgesics, and abstaining from sexual intercourse until the treatment was completed. All women will be advised to have their partner treated with 1 g of azithromycin.

Endometrial biopsy and definition of endometritis:
The endometrial biopsy was performed at the office using a Karman plastic curette (MedGyn Products Inc., Lombard, IL, USA). Histopathological endometritis was defined by the presence of  ≥1 plasma cell per X120 field in the endometrial stroma plus ≥5 neutrophils per X400 field in the endometrial surface.
PCR techniques will be used to investigate the presence of Neisseria gonorrhea and Chlamydia trachomatis in the endometrial samples.

Follow-up and adherence:
Participants will be monitored with in-person visits at 2, 7, 14 and 30 days. In each visit, the gynecological examination and the assessment of the pain will be registered. On day 7, the patient will return the first blister and receive the second one. Again, the first dose will be taken in front of the physician. On day 14, she will return the second blister. Adherence will be checked by absence of capsules in each blister. On day 30, another endometrial biopsy will be performed to measure histological cure and blood tests will be repeated.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ceftriane, azithromycin and doxycycline</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17601896 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="46de5042-8aab-407e-824e-7cd7f0713018" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17601896"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14275-0</funderId>
      <contactId>Contact52016_14275</contactId>
      <sponsorId>Sponsor50476</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52016_14275">
    <title>Prof</title>
    <forename>Ricardo</forename>
    <surname>Savaris</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Ramiro Barcelos, 2350/1125</address>
      <city>Porto Alegre</city>
      <country>Brazil</country>
      <zip>90035-003</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rsavaris@hcpa.ufrgs.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50476">
    <organisation>Foundation for the Incentive of Research (Fundacao de Incentivo a Pesquisa) (FIPE) (Brazil)</organisation>
    <website>http://www.hcpa.ufrgs.br/default.asp?sacao=Institucional&amp;sPagina=96&amp;gSysCodigoConexao=</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Rua Ramiro Barcelos 2350/2
Andar</address>
      <city>Porto Alegre</city>
      <country>Brazil</country>
      <zip>90035-003</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">l-cpesquisas@hcpa.ufrgs.br</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.470786.a</gridId>
    <rorId>https://ror.org/040y74d88</rorId>
  </sponsor>
  <funder id="Funder14275-0">
    <name>Foundation for the Incentive of Research (Fundacao de Incentivo a Pesquisa) (FIPE) (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-01-09T00:00:00.000Z">67437862</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised, double-blind, placebo-controlled study of Glypromate® in patients undergoing coronary artery bypass graft surgery</title>
      <scientificTitle/>
      <acronym>SNUG (Studying Neurons Using Glypromate®)</acronym>
      <studyHypothesis>Study is designed:
1. To determine the pharmacokinetics of Glypromate® in patients undergoing Coronary Artery Bypass Graft (CABG) surgery with/without valve replacement/repair
2. To show that Glypromate® use is not associated with major adverse events when compared to placebo in people undergoing CABG surgery</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To determine the pharmacokinetics of Glypromate® in patients undergoing CABG surgery to assess dose-response relationships.</primaryOutcome>
      <secondaryOutcome>To monitor the safety profile of Glypromate® treatment compared to placebo in patients undergoing CABG. Data will be collected through to discharge or day 14 whichever comes first.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67437862</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Neu-GPE-CABG-001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-09-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>New Zealand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0a0f92a8-60ad-4e6c-965a-e0d6dad614f8">
	  <name>University of Auckland</name>
	  <address/>
	  <city>Auckland</city>
	  <state/>
	  <country>New Zealand</country>
	  <zip>1031</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Participants must meet all of the following criteria:
1. Be at least 60 years of age
2. Be scheduled for non-urgent, on-pump CABG surgery
3. Be willing to provide written informed consent
4. Be agreeable to be undergo all study tests (collection of blood for PK assessment)

The Glypromate®/placebo infusion will be commenced at the start of chest closure providing the following criteria are met:
1. The patient has been successfully weaned off the bypass pump
2. The patient does not have an Intra-Aortic Balloon Pump (IABP)
3. The anaesthetist has assessed the patient as having no contraindications to receiving Glypromate®/placebo medication</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>A participant will be ineligible if he/she meets any of the following criteria:
1. Body weight less than 55 kg or more than 120 kg
2. Scheduled to undergo a significant concomitant surgical procedure (e.g. carotid endarterectomy, aortic root repair or replacement, Deep Hypothermic Circulatory Arrest [DHCA] or pulmonary resection)
3. Has a pre or perioperative mechanical assist device or IABP inserted for shock/low output syndrome
4. Renal insufficiency (serum creatinine greater than 0.17 mmol/l) or renal failure requiring dialysis
5. Chronic hepatic failure and/or cirrhosis
6. History of significant haematologic or coagulation disorders, including thrombocytopenia (platelet count less than 50,000), known hypercoagulable state, or recurrent deep vein thrombosis
7. Current participation or participation within the seven days prior to the start of this study in another investigational drug or device study
8. History of or any current condition that in the investigator's opinion would interfere with study participation or evaluation of results</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-09-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Coronary Artery Bypass Graft (CABG) surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Coronary Artery Bypass Graft (CABG) surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This phase two study will be conducted in two stages:

In stage 1 (conducted at the Principal Investigator's site only), patients will be randomised in a 1:1 fashion to receive intravenous (IV) Glypromate® 1 mg/kg/hr for four hours or 3 mg/kg/hr for four hours. Two to four patients are expected to be enrolled into this open-label stage of the study.

In stage 2, participants from five centres will be randomised in a 1:1:1 fashion to receive IV Glypromate® 1 mg/kg/hr for four hours or IV Glypromate® 3 mg/kg/hr over four hours or IV Placebo (normal saline) for four hours. The Glypromate®/Placebo infusion will commence at the start of chest closure.

Participants will be observed from randomisation through to discharge or day 14, whichever comes sooner.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Glypromate®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13735-0</funderId>
      <funderId>Funder13735-1</funderId>
      <funderId>Funder13735-2</funderId>
      <funderId>Funder13735-3</funderId>
      <contactId>Contact51422_13735</contactId>
      <sponsorId>Sponsor49825</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51422_13735">
    <title>Prof</title>
    <forename>Alan</forename>
    <surname>Merry</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Auckland
Mercy Hospital
98 Mountain Road
Epsom</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 (0)9 623 5700</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.merry@auckland.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49825">
    <organisation>Neuren Pharmaceuticals Limited (New Zealand)</organisation>
    <website>http://www.neurenpharma.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 9923
Newmarket</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 (0)9 367 7167 ext 89771</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mscott@neurenpharma.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487323.9</gridId>
    <rorId>https://ror.org/0503fq502</rorId>
  </sponsor>
  <funder id="Funder13735-0">
    <name>Grant from a New Zealand Government Agency, Foundation for Research Science and Technology.</name>
    <fundRef/>
  </funder>
  <funder id="Funder13735-1">
    <name>Grant type: Technology for Business Growth</name>
    <fundRef/>
  </funder>
  <funder id="Funder13735-2">
    <name>Grant title: Implementation for Phase II for Glypromate</name>
    <fundRef/>
  </funder>
  <funder id="Funder13735-3">
    <name>Study is also internally funded by Neuren Pharmaceuticals Limited (New Zealand)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-03T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">12757724</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Creating and maintaining functional residual capacity in preterm neonates with Respiratory Distress Syndrome (RDS)</title>
      <scientificTitle/>
      <acronym>EFURCI</acronym>
      <studyHypothesis>A sustained inflation with a mechanical device and early nasal continuous positive airway pressure is a more effective management strategy for RDS in preterm infants than conventional intervention with a self-inflating mask and bag, and reduces the requirement for mechanical ventilation and surfactant treatment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Need of endotracheal intubation within 3 days after birth.</primaryOutcome>
      <secondaryOutcome>1. Death
2. Bronchopulmonary Dysplasia (BPD)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12757724</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="14ef1c34-e6e3-44e6-8f6b-968666e96b35">
	  <name>Department of Pediatrics, Leiden University Medical Center, J6-S, P.O. Box 9600</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2300 RC</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Preterm neonates
2. Gestational age range 25 - 32 weeks (more than 24 weeks and 6 days and not more than 32 weeks and 6 days)</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>Antenatal diagnosed congenital anomalies of the cardio or respiratory system or anomalies incompatible with survival.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Respiratory Distress Syndrome, Preterm neonates</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Respiratory Distress Syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Resuscitation at birth when necessary:
Group A: Prolonged inflation of 10 seconds with a mechanical device (Neopuff t-piece resuscitator) and early CPAP treatment.
Group B: Inflation with self-inflating mask and bag conform international resuscitation guidelines.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17671058 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="10d2d3c0-fcd0-4102-b651-126e23bb21fb" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17671058"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14353-0</funderId>
      <contactId>Contact52101_14353</contactId>
      <sponsorId>Sponsor50754</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52101_14353">
    <title>Dr</title>
    <forename>Arjan B.</forename>
    <surname>Pas, te</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Pediatrics, Leiden University Medical Center, J6-S, P.O. Box 9600</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)71 5262909</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.b.te_pas@lumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50754">
    <organisation>Leiden University Medical Centre (LUMC) (Netherlands)</organisation>
    <website>http://www.lumc.nl/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Albinusdreef 2
P.O. Box 9600</address>
      <city>Leiden</city>
      <state/>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5132.5</gridId>
    <rorId>https://ror.org/027bh9e22</rorId>
  </sponsor>
  <funder id="Funder14353-0">
    <name>Leiden University Medical Centre  (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-12-14T00:00:00.000Z">55070842</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of estradiol on cognitive function in elderly men with mild cognitive impairment</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The hypothesis was that oral micronised estradiol (1 mg once a day [QD]) taken for three months would produce symptomatic improvement in memory in men with mild cognitive impairment, as compared to placebo.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Mini-Mental Status Exam (MMSE)
2. Alzheimer's Disease Assessment Scale (ADAS)
3. Neuropsychatric Inventory (NPI)
4. Clinicial impression based on interview (CIBIC)</primaryOutcome>
      <secondaryOutcome>Blood test results.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received on the 16th November 2000 (ref: 99-061).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN55070842</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Intreventional - randomised, double-blind, placebo-controlled, cross-over design.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-07-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9f1081e0-0138-4889-a393-43fbf2ad3169">
	  <name>Jewish General Hospital</name>
	  <address/>
	  <city>Montreal, PQ</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H3T 1E2</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male with mild cognitive impairment (Mini-Mental State Examination [MMSE] of 26 to 30)
2. Between the ages of 55 to 98
3. Hypertension was well controlled 
4. Had a caregiver</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Male</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40 men with mild cognitive impairment</totalTarget>
      <exclusion>1. Carcinoma of the prostate, hypercalcaemia, metabolic diseases, severe Chronic Obstuctive Pulmonary Disease (COPD) and renal insufficiency
2. Clotting abnormality, hyper-coagulable states, sleep apnoea
3. Patients on coumadin with Deep Vein Thrombosis (DVT) (or with a known clotting disorder) and diabetes (if uncontrolled)
4. Liver disease, unstable coronary artery disease, history of cerebrovascular accident, recent classical migraines, thrombophlebitis or thromboembolic disease
5. Must not be on any other cognitive enhancing treatment.  If so, must be washed-out for 30 days</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-07-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mild cognitive impairment</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Cognitive disorder</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Comparing the results of participants on three months of estradiol versus three months on placebo.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Estradiol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14223-0</funderId>
      <contactId>Contact51940_14223</contactId>
      <sponsorId>Sponsor50370</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51940_14223">
    <title>Dr</title>
    <forename>Howard</forename>
    <surname>Chertkow</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Jewish General Hospital
3755 Cote Aaint Catherine Road</address>
      <city>Montreal, PQ</city>
      <country>Canada</country>
      <zip>H3T 1E2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514 340 8260</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">howard.chertkow@mcgill.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50370">
    <organisation>Institute for the Study of Aging (USA)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>767 Fifth Avenue, Suite 4600</address>
      <city>New York City, NY</city>
      <country>United States of America</country>
      <zip>10153</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 212 572 4116</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tlee@rslmgmt.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.419475.a</gridId>
    <rorId>https://ror.org/049v75w11</rorId>
  </sponsor>
  <funder id="Funder14223-0">
    <name>Institute for the Study of Aging (ISOA) (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-11-16T00:00:00.000Z">22914223</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of the effects of sevoflourane and ketamine on intraocular pressure (IOP) in healthy patients and patients with glaucoma</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Glaucoma is a slowly progressive optic neuropathy which may rarely be seen in children, and is a leading cause of visual loss in adults. The effects of ketamine and sevoflourane, two commonly used anesthetic agents, on intraocular pressure, are not well known. Serial measurements of IOP in patients randomised to one of the two anesthetic agents will be evaluated. Eyes may be glaucomatous or healthy. Confounding variables, including pulse, blood pressure, oxygenation, will be recorded and evaluated.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Change in intraocular pressure after administration of anesthetic agent: 
1. How greatly does the IOP change? 
2. What percentage of patients in each group have a statistically significant change?</primaryOutcome>
      <secondaryOutcome>Effect of pulse, blood pressure, oxygenation, baseline IOP, baseline eye disease on intraocular pressure.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN22914223</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2dae2994-eb97-4f41-885b-9ee9010bc4ed">
	  <name>600 N. Wolfe Street</name>
	  <address/>
	  <city>Baltimore</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>21287</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients undergoing general anesthesia.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Patients unwilling/unable to give informed consent
2. Patients with irregular corneas or other ocular abnormalities not allowing for an adequate IOP measurement</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Glaucoma</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Glaucoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intraocular pressure measurements will be recorded in patients with glaucoma and in healthy patients. 

Both sevoflourane and ketamine are commonly used anaesthetic agents. Patients will be randomised to one of the two groups unless the anaesthesiologist or patient prefer one of the agents.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Sevoflourane and ketamine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14149-0</funderId>
      <contactId>Contact51843_14149</contactId>
      <sponsorId>Sponsor50267</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51843_14149">
    <title>Dr</title>
    <forename>Nathan</forename>
    <surname>Congdon</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>600 N. Wolfe Street
Wilmer 120</address>
      <city>Baltimore</city>
      <country>United States of America</country>
      <zip>21287</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 410 614 5561</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ncongdon@jhmi.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50267">
    <organisation>Wilmer Eye Institute (USA)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>600 N. Wolfe Street</address>
      <city>Baltimore</city>
      <country>United States of America</country>
      <zip>21287</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 410 614 5561</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ncongdon@jhmi.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411935.b</gridId>
    <rorId>https://ror.org/05cb1k848</rorId>
  </sponsor>
  <funder id="Funder14149-0">
    <name>Wilmer Eye Institute (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-11-07T00:00:00.000Z">70535562</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Moxonidine for the treatment of fibromyalgia: a prospective double-blind, randomised, single-centre, placebo-controlled, parallel group study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Fibromyalgia (FM) is a common illness that affects ~ 2.5% of the general population, of which the majority (9/1) are female.  FM is characterized by chronic widespread pain and by sleeping problems. Patients with FM frequently have other symptoms such as headaches, nocturnal jaw tightness, morning stiffness, tingling and numbness of arms and legs, irritable bowel, urinary urgency, dryness in the mouth and eyes, cold swollen hands, anxiety and/or depression. Another characteristic of FM is tenderness at palpation in defined points at the neck and lower back areas.

Hypothesis:
Sympathetic nervous system function in fibromyalgia seems overactivated. I1-Imidazoline agonist Moxonidine decreases sympathetic nerve activity. This study assess the efficacy and safety of Moxonidine in patients with fibromyalgia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome was improvement in the pain score (10-cm visual analog scale [VAS]) at 24 weeks.</primaryOutcome>
      <secondaryOutcome>1. Fibromyalgia Impact Questionnaire (FIQ)
2. The tender point score
3. The Hamilton Anxiety and Depression Scale (HADS)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN70535562</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>BP3/2005</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective double-blind, randomised, single-centre, placebo-controlled, parallel group study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-08-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="86bb35fd-ed47-44f6-a846-b38faac52c42">
	  <name>Paseo Manuel Girona, 33</name>
	  <address/>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>08034</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Ages eligible for study: 30 - 60 years
2. Genders eligible for study: both
3. Diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) criteria</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Psychiatric illness
2. Depression
3. Suicidal risk
4. Substance abuse
5. Pulmonary dysfunction
6. Renal impairment
7. Active cardiac disease
8. Liver disease
9. Autoimmune disease
10. Cancer
11. Sleep apnea
12. Chronic Fatigue Syndrome
13. Inflammatory bowel disease
14. Contraindication of Moxonidine</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-08-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Fibromyalgia</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Fibromyalgia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Moxonidine 0.2 mg/12 hours
2. Placebo/12 hours</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14144-0</funderId>
      <contactId>Contact51838_14144</contactId>
      <sponsorId>Sponsor50260</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51838_14144">
    <title>Dr</title>
    <forename>Ferran J</forename>
    <surname>Garcia-Fructuoso</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Paseo Manuel Girona, 33
Clinica CIMA</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08034</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor50260">
    <organisation>Foundation for Fibromyalgia and Chronic Fatigue Syndrome (Spain)</organisation>
    <website>http://www.fundacionfatiga.org</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Joan Guell
184 Dp. 27</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08028</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@fundacionfatiga.org</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487280.1</gridId>
    <rorId>https://ror.org/03p4nrj93</rorId>
  </sponsor>
  <funder id="Funder14144-0">
    <name>Foundation for Fibromyalgia and Chronic Fatigue Syndrome (Fundacion para la Fibromialgia y el Síndrome de Fatiga Crónica) (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-06T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-11-03T00:00:00.000Z">34123170</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Increasing tuberculosis case detection and reducing gender disparities through sputum submission instructions: a randomised controlled trial in Pakistan</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Giving women instructions on how to provide sputum samples will increase the yield of smear positive tuberculosis diagnoses in a chest clinic.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure was specimen smear-positivity.</primaryOutcome>
      <secondaryOutcome>The secondary outcome, specimen quality, was determined by visual assessment of specimens and microscopic assessment of Ziehl-Neelsen (ZN) stained smears, using a modification of the rating system of Bartlett.
Specimens with a purulent/mucoid/blood-stained visual appearance and/or containing polymorphoneutrophils (PMNs) on microscopic inspection were designated &#145;sputum&#146;.
Specimens with a clear/watery appearance containing squamous epithelial cells, but no PMNs were designated &#145;saliva&#146;.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34123170</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>Pakistan</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="63ef6448-7235-4481-929c-bcfb54678d7b">
	  <name>Keppel Street</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>WC1E 7HT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>New male and female tuberculosis (TB) suspects, who were referred by TB centre physicians for initial diagnostic sputum testing, were eligible to participate in the trial. According to the National Tuberculosis Control programme guidelines, the criteria for enrolment were:
1. History of a cough for &gt;3 weeks and/or fever for 1 month
2. Blood in sputum
3. Night sweats
4. Weight loss
5. Loss of appetite</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>2600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2600</totalTarget>
      <exclusion>1. Age over 75 or below 14 years
2. History of TB diagnosis or treatment
3. Intake of oral steroids in the 3 months leading up to presentation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tuberculosis</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Tuberculosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients in the intervention arm were referred to a designated room at the TB centre where they received guidance from a female health worker who was trained by the researcher and a senior TB control officer to provide sputum submission instructions. The female health worker was not involved in recruitment or randomisation. The following points were explained in detail to patients:
1. The importance of submitting sputum rather than saliva, and a description of visual difference between the two
2. The technique that should be used to produce a good sputum specimen (&#145;take three deep breaths, followed by a deep cough to bring up sputum from your lungs&#146;)
3. The necessity of filling at least one-quarter of the container (5 ml), shown by pointing out the required level on a demonstration container
4. The importance of providing one &#145;spot&#146; specimen and returning the next day with another specimen which has been expectorated on awakening that morning

Following instructions, which lasted between 2-3 min, patients in the intervention group were directed to the laboratory to obtain sputum submission containers.

Control group: usual procedure</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17560448 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3f202d0d-84ce-4eb0-9e17-4f5975cbb5c1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-09T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17560448"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13699-0</funderId>
      <contactId>Contact51373_13699</contactId>
      <sponsorId>Sponsor49777</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51373_13699">
    <title>Dr</title>
    <forename>Peter</forename>
    <surname>Godfrey-Faussett</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Keppel Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1E 7HT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pgf@lshtm.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49777">
    <organisation>London School of Hygiene and Tropical Medicine (UK)</organisation>
    <website>http://www.lshtm.ac.uk/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Keppel Street</address>
      <city>London</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>WC1E 7HT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.8991.9</gridId>
    <rorId>https://ror.org/00a0jsq62</rorId>
  </sponsor>
  <funder id="Funder13699-0">
    <name>Department for International Development (DFID) (UK) - Knowledge Programme on Tuberculosis</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-17T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-10-21T00:00:00.000Z">52577337</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The effects of a supplementary Arginine-Vasopressin (AVP) infusion on microcirculation in advanced vasodilatory shock and postoperative multiple organ dysfunction syndrome are unknown.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Differences in the area under the concentration-time Area Under Curve (AUC) of the Doppler signal and the reactive hyperemic response to forearm ischaemia between AVP/NE and NE patients.</primaryOutcome>
      <secondaryOutcome>Differences in the oscillation frequency of the Doppler signal between groups.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52577337</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Austria</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8dd66de6-4a71-47f8-a33a-4cb381bef492">
	  <name>Anichstrasse 35</name>
	  <address/>
	  <city>Innsbruck</city>
	  <state/>
	  <country>Austria</country>
	  <zip>6020</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Critically ill patients suffering of severe multiple organ dysfunction syndrome after cardiac or major surgery with a mean arterial blood pressure less than 65 mmHg despite adequate volume resuscitation, and Norepinephrine (NE) requirements greater than 0.5 µg/kg/min.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>18</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>18</totalTarget>
      <exclusion>Patients with arterial vascular occlusive disease or insulin-dependent diabetes mellitus.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Severe multiple organ dysfunction syndrome</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Multiple organ failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>NE plus supplementary AVP (Pitressin®; Pfizer, Karlsruhe, Germany) infused at a continuous rate of 4 IU/hour versus NE alone.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Arginine-Vasopressin (AVP)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16542484 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="57687e64-cd84-4d51-a0e2-78650f107b7c" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16542484"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14143-0</funderId>
      <contactId>Contact51835_14143</contactId>
      <sponsorId>Sponsor50257</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51835_14143">
    <title>Dr</title>
    <forename>Guenter</forename>
    <surname>Luckner</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Anichstrasse 35</address>
      <city>Innsbruck</city>
      <country>Austria</country>
      <zip>6020</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor50257">
    <organisation>Innsbruck Medical University (Austria)</organisation>
    <website>http://www.i-med.ac.at </website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Christoph-Probst-Platz
Innrain 52 </address>
      <city>Innsbruck </city>
      <country>Austria</country>
      <zip>6020</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5361.1</gridId>
    <rorId>https://ror.org/03pt86f80</rorId>
  </sponsor>
  <funder id="Funder14143-0">
    <name>Innsbruck Medical University (Austria)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-10-21T00:00:00.000Z">50665418</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised, double-blind, placebo-controlled, multi-centre, parallel group study to investigate the safety and tolerability as well as the immunological and clinical effects of multiple subcutaneous doses of DiaPep277 in latent autoimmune diabetes in adults (LADA) patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Investigate the safety and tolerability and the immunological and clinical effects of multiple doses of DiaPep277.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pancreatic beta-cell function, insulin independency or change in insulin dose, metabolic control: most parameters at every 6 months.</primaryOutcome>
      <secondaryOutcome>Immune response (every 6 months), clinical safety and tolerability at each visit.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN50665418</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>601/PO</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-04-17T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>Germany</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6493049c-4910-4960-8e89-666a3d721a11">
	  <name>University of London</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>EC1A 7BE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with a diagnosis of diabetes mellitus according to World Health Organisation (WHO) classification for more than 2 months and less than 5 years before enrolment
2. Diabetes controlled by diet, oral antidiabetics or insulin therapy
3. Positive for glutamic acid decarboxylase (GAD) autoantibodies
4. Male caucasian patients, aged 30 to 50 years, or female caucasian patients, aged 30 to 50 years, who are not pregnant and use safe contraceptive methods</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>41</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>41 - study completed as of Dec'06</totalTarget>
      <exclusion>1. Patients with secondary diabetes mellitus
2. Any previous insulin treatment before the first injection of study drug
3. History of intolerance or contraindications to oral hypoglycaemic medications
4. Clinical evidence of any severe diabetes-related complication
5. Allergy to investigational drug
6. History of severe allergy or asthma
7. Known immune deficiency from any disease, or a condition associated with an immune deficiency
8. Use of immunosuppressive or immunomodulating agents or cytotoxic therapy, or any medication which, in the opinion of the investigator, might interfere with the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-04-17T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Latent autoimmune diabetes in adults.</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment with subcutaneous injections of DiaPep277 or placebo in three different treatment groups with different schedules for a period of approximately 18-20 months. Follow up until 2 years after the first administration of study drug.

Group A: Administration of 1 mg DiaPep277 or placebo at the start of the study and 1 month, 6 months, 12 months and 18 months later. In total five administrations.
Group B: Administration of 1 mg DiaPep277 or placebo at the start of the study and 2 weeks, 4 weeks, 6 weeks and 8 weeks later. Further administrations in intervals of approximately 3 months. In total 10 administrations.
Group C: Administration of 0.2 mg DiaPep277 or placebo at the start of the study and 2 weeks, 4 weeks, 6 weeks and 8 weeks later. This course is repeated 6 months, 12 months and 18 months after the first administration. In total 20 administrations.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>DiaPep277</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13608-0</funderId>
      <contactId>Contact51280_13608</contactId>
      <sponsorId>Sponsor49679</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51280_13608">
    <title>Prof</title>
    <forename>David</forename>
    <surname>Leslie</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of London
Department of Diabetes and Immunology
St Bartholomew's Hospital
3rd Floor Dominion House
59 Bartholomew Close</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>EC1A 7BE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49679">
    <organisation>DeveloGen AutoImmune GmbH (Germany)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Max-Planck-Str. 15b</address>
      <city>Erkrath</city>
      <country>Germany</country>
      <zip>40699</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.428240.8</gridId>
    <rorId>https://ror.org/03d3v3e93</rorId>
  </sponsor>
  <funder id="Funder13608-0">
    <name>DeveloGen AutoImmune GmbH (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-24T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2005-10-12T00:00:00.000Z">05585365</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>An Open-label, Randomized Study Comparing 3 Years Tamoxifen Versus 3 Years Letrozole as Continuation of Adjuvant Treatment of Postmenopausal Women with Estrogen Receptor (ER) Positive and/or Progesterone Receptor (PR) Positive Early Breast Cancer Who Already Completed 2 years Adjuvant Tamoxifen. A Large Thai Multicenter Study.</title>
      <scientificTitle/>
      <acronym>LOTUS trial</acronym>
      <studyHypothesis>Letrozole is more effective than tamoxifen in first line treatment of metastatic breast cancer. 
In advanced disease, letrozole has been associated with significantly more tumor regression than anastrozole, especially in patients with unknown ER status. Letrozole has also been shown to be more effective than tamoxifen in the neoadjuvant treatment of breast cancer. Recently, anastrozole has been shown to induce a reduction in the rate of relapse as compared with tamoxifen in the adjuvant setting. Extended adjuvant therapy with letrozole after 5 years tamoxifen has been demonstrated to reduce the risk of recurrence and to improve significantly the disease&#150;free survival of postmenopausal women with early breast cancer. International studies are investigating the effect of letrozole compared to tamoxifen in the adjuvant treatment of early breast cancer patients. Few Asian patients are included. A large number of early breast cancer patients in Thailand are currently being treated with tamoxifen as adjuvant treatment.
It is not yet clear whether aromatase inhibitor can replace tamoxifen as adjuvant treatment for early breast cancer. Sequence and timing of tamoxifen and aromatase inhibitor treatment in adjuvant treatment still needs to be determined as well.
The goals of this study are the following:
1. To determine whether the replacement, as adjuvant therapy, of tamoxifen by letrozole for the last 3 years of a standard 5 year treatment period can reduce the risk of treatment failure in early breast cancer patients
2. To conduct this study in a Thai population
3. To compare the 2 treatments in terms of safety and tolerability

Approximately 1000 patients from up to 15 centers across Thailand will be enrolled into this study. The patient population will include postmenopausal women with resected Stage I, II, or IIIa, ER+ and/or PR+ breast cancer who have received 2 years of adjuvant tamoxifen and who have no clinical or radiological evidence of recurrent or metastatic disease before randomization. Pre-menopausal women who are/become amenorrheic due to either chemotherapy or Luteinizing Hormone Releasing Hormone (LHRH) use may participate in the study. Patients must have undergone complete tumor resection and margins of the resected specimen must be microscopically free of tumor.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Compare these treatment regimens in terms of disease free survival (DFS)</primaryOutcome>
      <secondaryOutcome>1. Compare these treatment regimens in terms of overall survival (OS)
2. Compare these treatment regimens in terms of safety and tolerability in the Thai patient population</secondaryOutcome>
      <trialWebsite>https://www.lotus-f.net/portal</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN05585365</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CFEM345DTH01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open-label, Randomized Study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2012-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Thailand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="297bc024-a885-48cb-ac9e-8c320c7606e3">
	  <name>Department of Radiology</name>
	  <address/>
	  <city>Bangkok</city>
	  <state/>
	  <country>Thailand</country>
	  <zip>10330</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with stage I, II or IIIa  adenocarcinoma of the breast at diagnosis. Patients with breast cancer whose tumor has been completely removed macroscopically and margins of the resected tumor have been microscopically free of tumor. If appropriate, additional local (e.g. radiotherapy) and/or systemic (i.e. adjuvant chemotherapy) treatments are allowed.
2. Postmenopausal status defined by one of the following:
a. Age ≥55 years with cessation of menses
b. Age &lt;55 but no spontaneous menses for at least 1 year
c. Age &lt;55 and spontaneous menses within the past 1 year, but currently amenorrheic (e.g. spontaneous, or secondary to hysterectomy), and with postmenopausal gonadotrophin levels (luteinizing hormone and follicle stimulating hormone levels &gt;40 IU/l) or postmenopausal estradiol levels (&lt;5 ng/dl) or according to the definition of 'postmenopausal range' for the laboratory involved
d. Bilateral oophorectomy
3. Patients whose tumors are either ER+  and/or PR+ (defined as ER and/or PR ≥10 fmol/mg cytosol protein; or ≥10% of the tumor cells positive by immunohistochemical evaluation)
4. Under tamoxifen therapy for 2 years before randomization
5. At randomization, patients must have no clinical or radiological evidence of distant metastasis, and no other concomitant malignancy (confirmed by mammography, chest X-ray or computed tomography [CT] scan, bone scan and liver US)
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0&#150;2
7. No prior treatment with letrozole
8. Patients must be accessible for follow-up
9. Signed written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>1000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1000</totalTarget>
      <exclusion>1. Patients with any clinical or radiological evidence of distant spread of their disease at any point before randomization
2. Patients with other non-malignant systemic diseases including uncontrolled infections, uncontrolled type 2 diabetes mellitus, uncontrolled thyroid dysfunction, cardiovascular, renal, hepatic, and lung diseases which would prevent prolonged follow-up. Patients with previous history of thrombosis or thromboembolism can be included only if medically suitable.  Patients with a known history of human immunodeficiency virus (HIV) are excluded.
3. Total serum calcium &gt;2.75 mmol/l (11.0 mg/dl)
4. White Blood Cell Count (WBC) &lt;3.0 x 10^9/l or granulocytes &lt;1.5 x 10^9/l, platelets &lt;100 x 10^9/l
5. Aspartate amino transferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and/or alanine amino transferase (ALT)/serum glutamic pyruvic transaminase (SGPT) &gt;3 upper limit of normal (ULN) in combination with other laboratory and clinical abnormalities indicating liver insufficiency to a degree that precludes dosing with letrozole (Child-Pugh grade C)
6. Patients with abnormal renal function as defined by a serum creatinine ≥3 mg/dl (265.2 mmol/l)
7. Previous history of fracture within 2 years
8. Patients treated with other systemic investigational drug(s) and/or device(s) within the past 30 days
9. History of non-compliance to medical regimens and patients who are considered potentially unreliable
10. Mental illness that precludes the patient from giving informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2012-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>ER positive and/or PR positive early breast cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Breast</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After providing consent, patients will be screened for eligibility. 
Eligible patients will be registered at any time up to 2 years (+/- 3 months) of tamoxifen treatment. Tamoxifen treatment had to be started at a dose of 20 mg/day for 2 years. After that, patients event-free will be randomly assigned to continue receiving tamoxifen for an additional 3 years or receiving letrozole 2.5 mg/day for 3 years.
After completion of treatment, patients should be followed up for study end points for 3 years.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Letrozole, tamoxifen</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13743-0</funderId>
      <contactId>Contact51430_13743</contactId>
      <sponsorId>Sponsor49834</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51430_13743">
    <title>Dr</title>
    <forename>Prasert</forename>
    <surname>Lertsaguansinchai</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Radiology
Wongwanich Building
Chulalongkorn University Hospital
Rama IV Street
Pratumwam</address>
      <city>Bangkok</city>
      <country>Thailand</country>
      <zip>10330</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+66 22564590, 91203311, 4736842</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Prasert@chularcancer.net</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49834">
    <organisation>Thai Breast Cancer Study Group (Thailand)</organisation>
    <website>http://www.chulacancer.net</website>
    <sponsorType>Other</sponsorType>
    <contactDetails>
      <address>Department of Radiation Oncology
Chulalongkorn University Hospital
Rama 4 Street. Pratumwan</address>
      <city>Bangkok</city>
      <country>Thailand</country>
      <zip>10330</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+66 22564590, 91203311, 4736842</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Prasert@chularcancer.net</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder13743-0">
    <name>Partially sponsored by Novartis Thailand</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-27T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-10-10T00:00:00.000Z">98554309</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Optimisation of vitamin A dosing schedules in infancy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Early high-dose vitamin A supplementation of mothers and infants improves vitamin A status and protects against mucosal infections, growth faltering and illness compared to the standard World Health Organisation (WHO) regimen.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Vitamin A status in mothers and infants
2. Heliobacter pylori infection in infants
3. Nasopharyngeal pneumococcal carriage in mothers and infants
4. Gut permeability in infants assessed by Dual Pugar Permeability Test (DSPT)</primaryOutcome>
      <secondaryOutcome>1. Infant growth
2. Infant morbidity
3. Breast milk sodium-potassium ratios
4. Breast-milk oligosaccharides</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN98554309</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>Gambia</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b368821c-109c-4084-8d95-c9e6ad2f99dd">
	  <name>MRC International Nutrition Group</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>WC1E 7HT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Consenting mothers and new born infants in six villages in the West Kiang region of The Gambia.</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>220</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>220</totalTarget>
      <exclusion>1. Congenital defects
2. Birthweight under 2200 g</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vitamin A deficiency</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Vitamin A supplementation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Early high dose Vitamin A schedule versus standard WHO schedule.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin A</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17586304 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="34fa6ac7-f9ea-40a0-9f2c-62582a95f12e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-23T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17586304"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13439-0</funderId>
      <contactId>Contact51085_13439</contactId>
      <sponsorId>Sponsor49481</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51085_13439">
    <title>Prof</title>
    <forename>Andrew</forename>
    <surname>Prentice</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>MRC International Nutrition Group
London School of Hygiene and Tropical Medicine</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1E 7HT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7958 8140</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">andrew.prentice@lshtm.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49481">
    <organisation>Medical Research Council (UK)</organisation>
    <website>http://www.mrc.ac.uk</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>20 Park Crescent</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>W1N 4AL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7636 5422</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">corporate@headoffice.mrc.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.14105.31</gridId>
    <rorId>https://ror.org/03x94j517</rorId>
  </sponsor>
  <funder id="Funder13439-0">
    <name>Medical Research Council (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-27T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-09-30T00:00:00.000Z">97327133</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect on participants, and experience of a psychological group therapy programme for women with the Mayer-Rokitansky-Kuster-Hauser syndrome: a randomised controlled treatment trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>How does psychological group therapy affect women with Mayer-Rokitansky-Kuster-Hauser (MKHR) syndrome?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To evaluate the effect of a psychological group therapy programme on women with MRKH</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN97327133</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0016152852</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-27T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-11-16T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ef91d190-eb32-460e-985f-0a8d042d6d1b">
	  <name>National Centre for Adolescent and Adult Women with Congenital Abnorma</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>W12 0HS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Women affected with MRKH</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-27T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-11-16T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mayer-Rokitansky-Kuster-Hauser Syndrome</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Mayer-Rokitansky-Kuster-Hauser Syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomised controlled psychological group therapy trial.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17584749/ Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="299704a9-953b-48b8-b99e-1747cdca09c5" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17584749/"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13871-0</funderId>
      <funderId>Funder13871-1</funderId>
      <contactId>Contact51749_13871</contactId>
      <sponsorId>Sponsor50215</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51749_13871">
    <title>Ms</title>
    <forename>Jacoline</forename>
    <surname>Heller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>National Centre for Adolescent and Adult Women with Congenital Abnorma
Queen Charlottes
Queen Charlottes
Hammersmith Hospital, Du Cane Road</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>W12 0HS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 8383 5363</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">k1m2erley@aol.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50215">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder13871-0">
    <name>Hammersmith Hospital NHS Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13871-1">
    <name>NHS R&amp;D Support (UK) (Funding 2004/05)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-13T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-09-21T00:00:00.000Z">03012627</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Variations of Internet-assisted cognitive behaviour therapy: a randomized community trial of MoodGYM users</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To investigate whether the length of the MoodGYM program (i.e. the number and combination of modules undertaken by the user) is related to treatment outcome, and which sub-components of the program are associated with anxiety and depression reduction.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The change in participants' symptoms of depression and anxiety after completing their version of the MoodGYM program.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite>http://www.moodgym.anu.edu.au</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Added as of 13/08/2007: Approved by the Australian National University Human Ethics Committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN03012627</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d81250b7-dc60-4649-b594-761f488d3afa">
	  <name>Centre for Mental Health Research</name>
	  <address/>
	  <city>Canberra</city>
	  <state/>
	  <country>Australia</country>
	  <zip>0200</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Participants will be individuals who register on the MoodGYM website and who consent to be randomised to a condition in the trial.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>500</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>500</totalTarget>
      <exclusion>Individuals who register on the MoodGYM website and who do not consent to participation in the trial. These individuals will be directed to the 'full' MoodGYM site, rather than a version of the site being evaluated in this trial. Individuals who consent to participation in the research project but who opt to choose their treatment condition are also not included in the randomised controlled trial (RCT).</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depression</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The MoodGYM website, an evidence-based depression prevention program. Six versions of the website will be evaluated.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16938144 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="efa9f103-4ba4-4beb-8814-1ef82ccf0885" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16938144"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13386-0</funderId>
      <contactId>Contact51015_13386</contactId>
      <sponsorId>Sponsor49407</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51015_13386">
    <title>Prof</title>
    <forename>Helen</forename>
    <surname>Christensen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centre for Mental Health Research
Australian National University</address>
      <city>Canberra</city>
      <country>Australia</country>
      <zip>0200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)261258409</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">helen.christensen@anu.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49407">
    <organisation>Australian National University - Centre for Mental Health Research</organisation>
    <website>http://www.anu.edu.au/cmhr</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>Canberra</city>
      <country>Australia</country>
      <zip>0200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)261258409</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">helen.christensen@anu.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.1001.0</gridId>
    <rorId>https://ror.org/019wvm592</rorId>
  </sponsor>
  <funder id="Funder13386-0">
    <name>Australian National Health and Medical Research Council (NHMRC) Program Grant to the Centre for Mental Health Research</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-25T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-09-14T00:00:00.000Z">15819627</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Sucrose as Procedural Analgesia for Infants Receiving Venipuncture in a Pediatric Emergency Department</title>
      <scientificTitle/>
      <acronym>SWEET Study</acronym>
      <studyHypothesis>Pain scores will be significantly reduced for infants who either recieve sucrose, pacifier or both prior to venipuncture as compared to placebo</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Score on the Faces Legs Arms Crying and Consolability (FLACC) Scale</primaryOutcome>
      <secondaryOutcome>Crying Time, Heart Rate</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15819627</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="585505da-71c1-4959-92ba-9057bc76308d">
	  <name>Room 7217B, Second Floor</name>
	  <address/>
	  <city>Edmonton,  Alberta</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T6G 2J3</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Any infant 0-6 months requiring venipuncture as part of their emergency department management</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="0.0"/>
      <upperAgeLimit unit="Months" value="6.0"/>
      <gender>Both</gender>
      <targetEnrolment>132</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>132</totalTarget>
      <exclusion>Infants deemed too critically ill or otherwise ineligible at the discretion of the attending physician</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are randomly assigned to one of four groups as follows:
a. Sucrose orally (PO)
b. Sucrose PO &amp; pacifier
c. Placebo PO
d. Placebo PO &amp; pacifier</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Sucrose</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17640375 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="13476211-8c7f-478b-9ae3-638513a342aa" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17640375"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13361-0</funderId>
      <contactId>Contact50984_13361</contactId>
      <sponsorId>Sponsor49376</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50984_13361">
    <title>Dr</title>
    <forename>Sarah</forename>
    <surname>Curtis</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Room 7217B, Second Floor
Aberhart Centre One</address>
      <city>Edmonton,  Alberta</city>
      <country>Canada</country>
      <zip>T6G 2J3</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49376">
    <organisation>University of Alberta, Department of Pediatrics (Canada)</organisation>
    <website>http://www.med.ualberta.ca/pediatrics/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Aberhart Centre One
11402 University Avenue</address>
      <city>Edmonton, Alberta</city>
      <country>Canada</country>
      <zip>T6G 2J3</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.17089.37</gridId>
    <rorId>https://ror.org/0160cpw27</rorId>
  </sponsor>
  <funder id="Funder13361-0">
    <name>Department of Pediatrics, University of Alberta</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-30T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-09-13T00:00:00.000Z">59878178</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Exploratory randomised double-blind controlled trial of breast milk fortifier with and without long chain polyunsaturated fatty acid (LCPUFA) supplementation on body composition in preterm infants</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Breast milk fortifier containing LCPUFA has a measurable effect upon body composition at term when compared with non-LCPUFA supplemented fortifier</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Body composition at age term-equivalent</primaryOutcome>
      <secondaryOutcome>Growth, metabolic profile, intrahepatocellular lipid content, brain growth and development, neurological examination</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN59878178</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>Germany</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="942a8880-3bc3-4164-8a49-63b35e2db31d">
	  <name>Imperial College London</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SW10 9NH</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Infants born at or below 32 weeks gestational age</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>42</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120 of whom 42 will be randomised</totalTarget>
      <exclusion>1. Major congenital abnormality

2. Mother does not wish to provide breast milk or to use donor milk
3. Baby requires gastrointestinal surgery</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Preterm infants</description>
	<diseaseClass1>Neonatal Diseases</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Infants will receive maternal +/- donor breast milk; should breast milk fortifier be indicated in accordance with normal clinical practice, infants will be randomised to receive standard fortifier or LCPUFA supplemented fortifier.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13507-0</funderId>
      <contactId>Contact51162_13507</contactId>
      <sponsorId>Sponsor49560</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51162_13507">
    <title>Prof</title>
    <forename>Neena</forename>
    <surname>Modi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Imperial College London
Chelsea &amp; Westminster Hospital
369 Fulham Road</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW10 9NH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49560">
    <organisation>Milupa GmbH, Numico Research (Germany)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Bahnstrasse 14-30</address>
      <city>Friedrichsdorf</city>
      <country>Germany</country>
      <zip>61381</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.433367.6</gridId>
    <rorId>https://ror.org/00aj77a24</rorId>
  </sponsor>
  <funder id="Funder13507-0">
    <name>Numico Research Germany</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-07T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-09-07T00:00:00.000Z">81615611</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The safety and efficacy of posterior juxta-scleral (40 mg) or intra-vitreal (4 mg)  triamcinolone acetonide, in addition to verteporfin photodynamic therapy for choroidal neovascularization (CNV), in age-related macular degeneration (AMD): a randomised controlled trial - STUDY STOPPED</title>
      <scientificTitle/>
      <acronym>TPDT</acronym>
      <studyHypothesis>To compare the effectiveness of (a) intra-vitreal and (b) posterior juxta-scleral triamcinolone acetonide as an adjunt to verteporfin photodynamic therapy for CNV secondary to AMD with (c) verteporfin photodynamic therapy alone.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Number of patients losing more than 15 letters (3 lines) of visual acuity (ETDRS logMAR chart at 2m) at 1 year.</primaryOutcome>
      <secondaryOutcome>1. Change in lesion size at one year
2. Number of re-treatments required in one year
3. Incidence of serious complications
4. Quality of life measures: NEIVFQ(25); SF-36
5. Contrast sensitivity threshold (Pelli-Robson contrast sensitivity chart)
6. Change in retinal thickness as shown on Ocular coherence tomography</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN81615611</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NRR Pub ID N0503172670 (03428)</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride>Stopped</overallStatusOverride>
      <reasonAbandoned/>
      <overallStartDate>2005-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ba131a36-111c-4efc-a426-125d9c1e5a35">
	  <name>Dept. Ophthalmology</name>
	  <address/>
	  <city>Newcastle upon Tyne</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>NE1 4LP</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. The patient must be willing to give written informed consent
2. The patient must be able to undertake the necessary tests and treatment and be willing to be followed up
3. Age 50 years or older
4. Clinical diagnosis of AMD
5. Predominantly classic CNV on fluorescein angiography
6. Logarithm of the minimum angle of resolution (LogMAR) visual acuity of &gt;35 letters on 2 m Early Treatment Diabetic Retinopathy Study (ETDRS) chart
7. Does not have open angle glaucoma</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>400</totalTarget>
      <exclusion>1. Inability to understand or sign consent form
2. The patient has a current medical condition or history of a medical condition that would be likely to preclude scheduled study visits such as unstable angina, dialysis, active cancer
3. Patient has a current ophthalmic condition or history of an ophthalmic condition that might compromise the assessment of the treatment such as diabetic retinopathy, uveitis, amblyopia, ischaemic optic neuropathy
4. Signs of a myopic retina or refraction of ≥8 diopters in their current or any previous glasses prescription
5. Signs of other retinal conditions that may have caused the CNV such as angiod streaks, choroidal rupture, old chorio-retinitis
6. Open angle glaucoma
7. At increased risk of developing glaucoma such as having pigment dispersion syndrome or pseudoexfoliation
8. Unable to have a good quality fluorescein angiogram taken e.g. due to head tremor or media opacity
9. Allergic to fluorescein or verteporfin or triamcinolone acetonide
10. Previous treatment for a retinal detachment
11. Judged by the examining clinician to be at increased risk of retinal detachment due to weaknesses in the peripheral retina
12. Previous photodynamic therapy or other therapy for a CNV including argon laser treatment
13. Patient is currently participating or has participated in a clinical trial that utilized an investigational drug or treatment within 30 days prior to enrolment to this study
14. On anticoagulation therapy such as warfarin, with the exception of aspirin and other anti-platelet therapy
15. &lt;35 letters on the ETDRS logMAR chart
16. Inability to read a logMAR chart
17. Intraocular surgery in study eye within 60 days prior to planned enrolment in study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride>Stopped</recruitmentStatusOverride>
    </participants>
    <conditions>
      <condition>
	<description>Choroidal neovascularization (CNV) secondary to Age-related macular degeneration (AMD)</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Macular degeneration</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Posterior juxta-scleral (40 mg) triamcinolone acetonide + verteporfin photodynamic therapy
2. Intra-vitreal (4 mg) triamcinolone acetonide + verteporfin photodynamic therapy
3. Verteporfin photodynamic therapy alone</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Triamcinolone acetonide</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13189-0</funderId>
      <contactId>Contact50761_13189</contactId>
      <sponsorId>Sponsor49148</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50761_13189">
    <title>Mr</title>
    <forename>James</forename>
    <surname>Talks</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept. Ophthalmology
Claremont Wing
Royal Victoria Infirmary
Queen Victoria Rd</address>
      <city>Newcastle upon Tyne</city>
      <country>United Kingdom</country>
      <zip>NE1 4LP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)191 282 5452</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">james.talks@nuth.nhs.uk </email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49148">
    <organisation>The Newcastle upon Tyne Hospitals NHS Trust (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Royal Victoria Infirmary
Queen Victoria Rd</address>
      <city>Newcastle Upon Tyne</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>NE1 4LP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)191 282 5213</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Craig.MacKerness@trvi.nuth.northy.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.420004.2</gridId>
    <rorId>https://ror.org/05p40t847</rorId>
  </sponsor>
  <funder id="Funder13189-0">
    <name>Internally funded by participating centres. This study, although a separate randomised controlled trial requiring all the usual approvals, is nested within the UK Verteporfin Photodynamic therapy Cohort study. It will utilise the infrastructure of that study.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-24T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-08-25T00:00:00.000Z">10342533</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised controlled trial of a brief, activating treatment by social workers and usual general practitioner care for patients with minor mental disorders leading to sickness absence</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Is a brief, activating treatment by social workers more successful in reducing long term absenteeism and in increasing patient well-being than General Practitioners' (GPs') usual care in patients with minor mental disorders ((e.g. mild depression, generalised anxiety disorder, adjustment disorder) who are on sick leave?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The groups did not differ at baseline, nor after three, six or 18 months with respect to levels of depression, anxiety, somatisation, distress, functional status or sick leave duration. In both groups, well-being improved significantly in the first months after baseline, regardless of treatment.</primaryOutcome>
      <secondaryOutcome>Patients who received the brief activating treatment by social workers reported higher satisfaction than patients who received GPs' usual care.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN10342533</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2200.0100</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-03-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="293c4a9c-612f-4b5c-bd29-4406e5c9b473">
	  <name>PO Box 1568</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3513 CR</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Included were primary care patients who:
1. Were suffering from minor mental disorder(s) according to GP and patient
2. Had paid employment
3. Were on sick leave or planning to be directly after visit to GP, but had not been on sick leave for longer than three months
4. Were aged 18 to 60 years
5. Were Dutch speaking</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>370</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>370 primary care patients</totalTarget>
      <exclusion>Excluded were patients who were already receiving psychotherapy, or who, according to the Composite International Diagnostic Interview (CIDI), had a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of:
1. Moderately severe or severe mood disorder
2. Agoraphobia
3. Panic disorder
4. Social phobia</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-03-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Minor mental disorders</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Minor mental disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Usual GP care or five sessions in ten weeks with a social worker trained in the technique, including homework assignments and a focus on early work resumption. The main aims of the experimental treatment were:
1. To focus on the most recent and actual problems
2. To regain functionality and control
3. To resume work as early as possible</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16837516</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="01be8ae3-3164-42da-98a9-0e1b017a0988" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16837516"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13194-0</funderId>
      <contactId>Contact50771_13194</contactId>
      <sponsorId>Sponsor49159</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50771_13194">
    <title>Dr</title>
    <forename>Peter</forename>
    <surname>Verhaak</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>PO Box 1568</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3513 CR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 272 9735</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.verhaak@nivel.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49159">
    <organisation>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands) </organisation>
    <website>http://www.zonmw.nl</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Laan van Nieuw Oost Indië 334
PO Box 93245</address>
      <city>The Hague</city>
      <country>Netherlands</country>
      <zip>2509 AE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)70 349 5111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@zonmw.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.438427.e</gridId>
    <rorId>https://ror.org/01yaj9a77</rorId>
  </sponsor>
  <funder id="Funder13194-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands) (ref: 2200.0100)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-06-14T00:00:00.000Z">26365328</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A cluster randomised trial to assess the impact of opinion leader endorsed evidence summaries on improving quality of prescribing for patients with chronic cardiovascular disease</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We propose having locally-nominated opinion leaders generate and endorse one-page evidence summaries for two common and chronic cardiovascular conditions. These evidence summaries, linked with specific patient-level medication profiles (generated at the community pharmacy), will be distributed to practicing physicians and attached to their patients&#146; chart. Our hypothesis is that this will act as both a source of credible and convincing information and a specific reminder for action at the next patient encounter. Our study is designed to test this hypothesis, by assessing the impact of this intervention on the quality of prescribing for patients with Heart Failure (HF) or Ischaemic Heart Disease (IHD).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure will be the 'improvement' of prescribing for efficacious therapies in patients with a chronic cardiovascular disease within 6 months of the intervention. By study design, none of the study patients will be taking the medications of interest. For HF, starting any ACE inhibitor or angiotensin receptor blocker will be considered a positive outcome. For IHD, starting any statin will be considered a positive outcome. For the primary outcome all positive study-related medication changes will be pooled for an overall estimate of effect, compared with usual care controls.</primaryOutcome>
      <secondaryOutcome>1. Condition-specific 'improvement' in prescribing after 6 months
2. 'Optimization' of dosage for each of the medications prescribed (i.e. ACE inhibitors or angiotensin receptor blockers and statins)
3. Patient adherence (using prescription refill rates based on dispensing records) 
4. Potential influence of age and sex on outcomes</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26365328</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber>NCT00175279</clinicalTrialsGovNumber>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b83937f4-0d14-4508-bffc-eb57785923ee">
	  <name>2E3.07 WMC</name>
	  <address/>
	  <city>Edmonton, Alberta</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T6G 2B7</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with HF or IHD who are not currently taking the study medications of interest (Angiotensin-Converting Enzyme [ACE] inhibitors/angiotensin receptor blockers for HF or statins for IHD), and whose primary care physician of record is part of the study.  For patients who happen to be eligible for both HF and for IHD, only one condition will be selected at random.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Decline enrolment
2. Unable or unwilling to give informed consent
3. Have previously taken the study medications according to dispensing records
4. Have a documented allergy or intolerance to study medications according to pharmacist records
5. Are in long-term care facilities or institutions
6. Do not confirm on the basis of self-report that they have a diagnosis of either HF or IHD
7. Primary care physician has already contributed 5 patients to the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Heart failure, ischaemic heart disease</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Chronic ischaemic heart disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention consists of a disease-specific and patient-specific one-page evidence summary. It will be a patient-specific letter addressed to the patients&#146; primary care physician, along with a description of the potential risks of undertreatment and current evidence-based treatment recommendations. The letter will be signed and endorsed by all five of the study opinion leaders. Accompanying the letter will be the most recent pharmacy record of medications dispensed to the study patient.  It is intended that the evidence summary and the pharmacy medication profile will become part of the patients&#146; medical record and act as a reminder or prompt at the next patient visit.  These materials will be faxed to the primary care physician directly from the patients&#146; community pharmacy.

Control: usual care</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Protocol article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982421 Protocol
2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17174632 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="bfe4be5e-64a6-464c-827a-42da206259d7" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2005-06-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982421"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
      <output id="11a05035-6f03-44a7-be33-6f96c89f24b0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17174632"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13137-0</funderId>
      <funderId>Funder13137-1</funderId>
      <contactId>Contact50683_13137</contactId>
      <sponsorId>Sponsor49068</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50683_13137">
    <title>Dr</title>
    <forename>Sumit R.</forename>
    <surname>Majumdar</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>2E3.07 WMC
University of Alberta Hospital
8440-112th Street</address>
      <city>Edmonton, Alberta</city>
      <country>Canada</country>
      <zip>T6G 2B7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">me2.majumdar@ualberta.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49068">
    <organisation>Alberta Heritage Foundation for Medical Research (Canada)</organisation>
    <website>http://www.ahfmr.ab.ca</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Suite 1500, 10104-103 Avenue</address>
      <city>Edmonton, Alberta</city>
      <country>Canada</country>
      <zip>T5J 4A7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 780 423 5727</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ahfmrinfo@ahfmr.ab.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.484182.3</gridId>
    <rorId>https://ror.org/006b2g567</rorId>
  </sponsor>
  <funder id="Funder13137-0">
    <name>Alberta Heritage Foundation for Medical Research (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003179</fundRef>
  </funder>
  <funder id="Funder13137-1">
    <name>Institute of Health Economics (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-27T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-04-26T00:00:00.000Z">31571714</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised trial to evaluate the effects of didgeridoo playing on snoring</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Epworth scale
2. Pittsburgh Sleep Quality Index
3. 36-item Short Form health survey (SF-36)
4. Proxy evaluation
5. Apnoea-hypopnea-index</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN31571714</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9a103cc9-e68f-4fd7-87ce-f851962c2ccf">
	  <name>Horten Centre</name>
	  <address/>
	  <city>Zurich</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>8091</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>30 patients of at least 18 years of age with snoring and apnoea-hypopnea-index 15-30.</inclusion>
      <ageRange>Not Specified</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Treatment for sleep apnoea (e.g. with continuous positive airway pressure [CPAP])
2. Body Mass Index greater than 30
3. More than seven drinks per week
4. Regular intake of psychostimulating drugs and current or planned weight reduction intervention</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Snoring and apnoea-hypopnea-index 15-30</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Breathing difficulties</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Playing Didgeridoo for a period of four months, at least five times a week. Regular instructions by professional Didgeridoo-Teacher.
Control group: No Didgeridoo playing for a period of four months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16377643 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="85e7602e-dd18-4d48-aafd-848d61e363f0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-02-04T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16377643"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12909-0</funderId>
      <funderId>Funder12909-1</funderId>
      <funderId>Funder12909-2</funderId>
      <contactId>Contact50419_12909</contactId>
      <sponsorId>Sponsor48789</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50419_12909">
    <title>Dr</title>
    <forename>Milo</forename>
    <surname>Puhan</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Horten Centre
University Hospital
Postfach Nord</address>
      <city>Zurich</city>
      <country>Switzerland</country>
      <zip>8091</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 1 255 87 09</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">milo.puhan@evimed.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48789">
    <organisation>Zürcher Höhenklinik Wald (Switzerland)</organisation>
    <website>http://www.zhw.ch/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>Faltigberg-Wald</city>
      <country>Switzerland</country>
      <zip>8639</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@zhw.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder12909-0">
    <name>Zürcher Höhenklinik Wald (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12909-1">
    <name>Zürcher Lungenliga (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12909-2">
    <name>Praxis Alex Suarez (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-27T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-04-26T00:00:00.000Z">67999735</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Influence of support on intra-abdominal pressure, hepatic kinetics of indocyanine green and extravascular lung water during Prone Positioning (PP) in ARDS patients: a randomised crossover study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The aim of the present study was to investigate whether the evolution of Intra-Abdominal Pressure (IAP), liver function assessed by the Plasma Disappearance Rate of Indocyanine Green (PDRICG) and extravascular lung water is related to the type of support during PP. We therefore prospectively compared, in a population of medical-Acute Respiratory Distress Syndrome (ARDS) patients, the effects of an air-cushioned mattress and a conventional foam mattress during PP.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Intra-Abdominal Pressure (IAP)
2. Plasma Disappearance Rate of Indocyanine Green (PDRICG)
3. Extravascular Lung Water (EVLW)
4. Partial Pressure of Oxygen in Arterial Blood (PaO2)/Fraction of Inspired Oxygen (FiO2) ratio
5. Central Venous Pressure (CVP)
6. Mean pulmonary arterial pressure
7. Pulmonary artery occlusion pressure</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67999735</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="02ff6869-3f33-4b29-8452-ffe829515ec5">
	  <name>Département d'Anesthésie Réanimation</name>
	  <address/>
	  <city>Marseille</city>
	  <state/>
	  <country>France</country>
	  <zip>13009</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Twenty consecutive patients with ARDS were included and turned prone in the medical intensive care unit of Sainte Marguerite University Hospital in Marseille, France. Patients were prospectively included in this study after obtaining written informed consent from the next of kin. The study design was approved by the Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale of Marseille. ARDS was defined in accordance with the recommendations of the American/European Consensus Conference.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Patients with unstable cardiovascular function, cerebral injury or unstable spinal fractures, patients subjected to major abdominal surgery and patients with a history of neuromuscular disease were excluded.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute Respiratory Distress Syndrome (ARDS)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Respiratory disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Baseline measurements were performed in the supine position after one hour of steady-state conventional mechanical ventilation. Then the following two periods of PP were randomised: 
1. 6 hours of PP on the moulded foam mattress
2. 6 hours of PP on the air-cushioned mattress

A period of 18 hours in the supine position separated the two periods in the prone position. Each patient was his or her own control. Measurements were achieved in the supine position, after 1 and 6 hours of PP.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15987398 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f8bb5111-7677-45b4-9c00-51ef3a45e216" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15987398"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13016-0</funderId>
      <contactId>Contact50545_13016</contactId>
      <sponsorId>Sponsor48923</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50545_13016">
    <title>Dr</title>
    <forename>Pierre</forename>
    <surname>Michelet</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Département d'Anesthésie Réanimation
Sainte Marguerite Hospital</address>
      <city>Marseille</city>
      <country>France</country>
      <zip>13009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pierre.michelet@mail.ap-hm.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48923">
    <organisation>Sainte Marguerite Hospital (France)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>Marseille</city>
      <country>France</country>
      <zip>13009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pierre.michelet@mail.ap-hm.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.414438.e</gridId>
    <rorId>https://ror.org/0338wkj94</rorId>
  </sponsor>
  <funder id="Funder13016-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-04-20T00:00:00.000Z">63574530</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised controlled trial of Dihydrocodeine (DHC) and methadone in the treatment of opiate dependent patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To determine the efficacy of dihdrocodeine compared to methadone in the treatment of opiate dependence.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Survival
2. Retention in treatment
3. Continued drug use (particularly injecting)
4. Criminal behaviour</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite>http://www.show.scot.nhs.uk/CSO/Publications/ExecSumms/JanFeb05/9.8%20Robertson.pdf</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN63574530</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>K/OPR/2/2/D399</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Scotland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4ef08696-ee8d-41bc-8716-8a47a4dc6837">
	  <name>Muirhouse Medical Group</name>
	  <address/>
	  <city>Edinburgh</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>EH4 4PL</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Opiate dependent patients</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>250</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>250</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Opiate dependence</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Opiate dependence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Substitute treatment with methadone or dihydrocodeine.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Dihydrocodeine (DHC), methadone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/17156174 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a9d31684-264c-4821-8671-88f7067e0ec8" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17156174"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12921-0</funderId>
      <contactId>Contact50439_12921</contactId>
      <sponsorId>Sponsor48811</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50439_12921">
    <title>Dr</title>
    <forename>Roy</forename>
    <surname>Robertson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Muirhouse Medical Group
1 Muirhouse Avenue</address>
      <city>Edinburgh</city>
      <country>United Kingdom</country>
      <zip>EH4 4PL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)131 537 4343</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Roy.Robertson@ed.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48811">
    <organisation>Chief Scientist Office (UK) - Scottish Executive Health Department </organisation>
    <website>http://www.sehd.scot.nhs.uk/cso/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>St Andrew's House
Regent Road</address>
      <city>Edinburgh</city>
      <country>United Kingdom</country>
      <zip>EH1 3DG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)131 244 2077</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Peter.craig@scotland.gsi.gov.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.450637.3</gridId>
    <rorId>https://ror.org/01bw7zm61</rorId>
  </sponsor>
  <funder id="Funder12921-0">
    <name>Chief Scientist Office (UK) - Scottish Executive Health Department</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-03T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-02-21T00:00:00.000Z">61514736</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of PRIME-MD on the detection and referral-for-treatment of occult psychiatric treatment in the Emergency Department (ED).</title>
      <scientificTitle/>
      <acronym>UCLA PRIME MD-2</acronym>
      <studyHypothesis>Not provided at time of registration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN61514736</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1c91592c-e440-499b-95e3-0df87d1ec828">
	  <name>924 Westwood Blvd Suite 300</name>
	  <address/>
	  <city>Los Angeles, CA</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>90024-2924</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>ED patients who present with a somatic (non-psychiatric) complaint that is of long duration, is chronic, or is not of a severity to warrant emergency care.
Resident physicians in Emergency Medicine and their faculty.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration.</totalTarget>
      <exclusion>Not provided at time of registration.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depression, anxiety and other psychiatric conditions</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients take the computerized PRIME-MD in the ED waiting room.  They are randomized to three groups: PRIME-MD results shared with no one, shared with the patient only, or shared with the patient and the treating ED physician.
Low cost/no cost psychiatric referral sheet made available in the ED.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15882462 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="bd714197-02e3-42f2-abe8-97b1e80795a4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-05-09T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15882462"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12897-0</funderId>
      <contactId>Contact50405_12897</contactId>
      <sponsorId>Sponsor48774</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50405_12897">
    <title>Dr</title>
    <forename>David</forename>
    <surname>Schriger</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>924 Westwood Blvd Suite 300</address>
      <city>Los Angeles, CA</city>
      <country>United States of America</country>
      <zip>90024-2924</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 310 794 0593</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">schriger@ucla.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48774">
    <organisation>University of California, Los Angeles (UCLA) (USA)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>924 Westwood Blvd Suite 300</address>
      <city>Los Angeles, CA</city>
      <country>United States of America</country>
      <zip>90024 2924</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.19006.3e</gridId>
    <rorId>https://ror.org/046rm7j60</rorId>
  </sponsor>
  <funder id="Funder12897-0">
    <name>The Pfizer Corporation provided a $60,000 gift (not grant) in support of this research.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-03T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-01-19T00:00:00.000Z">24484328</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Half versus full suction drainage after mastectomy for breast cancer</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN24484328</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="390cd09a-ac9b-4164-8451-dc3bc6243a01">
	  <name>DII/131, West Kidwai Nagar</name>
	  <address/>
	  <city>New Delhi</city>
	  <state/>
	  <country>India</country>
	  <zip>110023</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>85 fine needle aspiration cytology (FNAC) proven cases of locally advanced breast cancer were randomised into two groups. The groups were comparable in respect of age, weight and type of operation i.e. modified radical mastectomy (MRM)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>85</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>85</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Breast cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Breast</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: 50 patients randomised to full vacuum suction (pressure = 700 g/m^2)
Group 2: 35 patients randomised to half vacuum suction (pressure = 350 g/m^2)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15676064 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="10cab4b5-b5a4-4d4a-a82d-28f3e713ccd0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-01-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15676064"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12859-0</funderId>
      <funderId>Funder12859-1</funderId>
      <funderId>Funder12859-2</funderId>
      <contactId>Contact50349_12859</contactId>
      <sponsorId>Sponsor48719</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50349_12859">
    <title>Dr</title>
    <forename/>
    <surname>Chintamani</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>DII/131, West Kidwai Nagar </address>
      <city>New Delhi</city>
      <country>India</country>
      <zip>110023</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)98 10064920</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">chintamani7@rediffmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48719">
    <organisation>Safdarjang Hospital - Vardhman Mahavir Medical College and Indian Council of Medical Research (India)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>New Delhi</city>
      <country>India</country>
      <zip>110033</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)11 26268336 104</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">chintamani@doctor.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416888.b</gridId>
    <rorId>https://ror.org/03zj0ps89</rorId>
  </sponsor>
  <funder id="Funder12859-0">
    <name>Institutions controlled by the government:</name>
    <fundRef/>
  </funder>
  <funder id="Funder12859-1">
    <name>Vardhman Mahavir Medical College, Safdarjang Hospital (India)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12859-2">
    <name>Indian Council Of Medical Research (India)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001411</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-03T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-11-30T00:00:00.000Z">21676344</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21676344</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>New Zealand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b02bc080-b9e9-47ac-84cc-3de1bc7fbbb6">
	  <name>Department of Medicine</name>
	  <address/>
	  <city>Auckland</city>
	  <state/>
	  <country>New Zealand</country>
	  <zip>1001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients admitted to hospital with an acute exacerbation of chronic obstructive pulmonary disease.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic obstructive pulmonary disease</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Pulmonary disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>N-acetylcysteine 600 mg twice daily or matching placebo.
All participants received standard care including oxygen, nebulised salbutamol, oral prednisone and antibiotics (if indicated).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15581425 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="7dc28042-3969-4ac2-be6e-d3d75a7f5103" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-12-06T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15581425"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12815-0</funderId>
      <contactId>Contact50288_12815</contactId>
      <sponsorId>Sponsor48659</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50288_12815">
    <title>Dr</title>
    <forename>Peter</forename>
    <surname>Black</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Medicine
University of Auckland
Private Bag 92019</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 93737599 ext 89797</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pn.black@auckland.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48659">
    <organisation>Health Research Council of New Zealand</organisation>
    <website>http://www.hrc.govt.nz/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>PO Box 5541
Wellesley St</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 93035200</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@hrc.govt.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.452999.a</gridId>
    <rorId>https://ror.org/00zbf3d93</rorId>
  </sponsor>
  <funder id="Funder12815-0">
    <name>Health Research Council of New Zealand (ref: HRC 01/206)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001505</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-03T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-11-30T00:00:00.000Z">40455708</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised trial comparing digital and live lecture formats</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN40455708</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="42293375-1a1b-4aed-9e08-2ec242e9217f">
	  <name>A-202 E Fee Hall</name>
	  <address/>
	  <city>E Lansing, MI</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>48840</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Medical students</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Impact on learning</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Digital versus live lectures</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15569389 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="b3baca68-2e17-41ec-8343-7cfb934ed43e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-11-29T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15569389"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11234-0</funderId>
      <contactId>Contact41672_11234</contactId>
      <sponsorId>Sponsor39417</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41672_11234">
    <title>Dr</title>
    <forename>David</forename>
    <surname>Solomon</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>A-202 E Fee Hall
MSU</address>
      <city>E Lansing, MI</city>
      <country>United States of America</country>
      <zip>48840</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dsolomon@msu.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39417">
    <organisation>Michigan State University (USA)</organisation>
    <website>http://www.msu.edu/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>E Lansing, MI</city>
      <country>United States of America</country>
      <zip>48824</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dsolomon@msu.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.17088.36</gridId>
    <rorId>https://ror.org/05hs6h993</rorId>
  </sponsor>
  <funder id="Funder11234-0">
    <name>Division of Medicine, Bureau of Health Professions, Health Services and Resources Administration (USA) (grant no.: 1 D16 HP 00119 01)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-07T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-11-29T00:00:00.000Z">70292892</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The efficacy of Chinese herbal recipe versus diclofenac in symptomatic treatment of 
osteoarthritis of the knee</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN70292892</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>67/2002</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Thailand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1e7b8976-8a5b-40dc-ba9d-b6e1788578e4">
	  <name>Department of Pharmacology</name>
	  <address/>
	  <city>Chiang Mai</city>
	  <state/>
	  <country>Thailand</country>
	  <zip>50200</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients who had been suffering from unilateral or bilateral OA of the knee according to the criteria of the American College of Rheumatology for more than 3 months</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis (OA) of the knee</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Arthropathies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1st Group: Chinese herbal medicine (6 capsules after meal, 3 times a day) plus placebo of diclofenac (1 capsule after meal, 3 times a day)
2nd Group: Placebo of Chinese herbal medicine (6 capsules after meal, 3 times a day) plus diclofenac (1 capsule after meal, 3 times a day)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Chinese herbal recipe versus diclofenac</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15588333 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="26a0b4d9-891b-490c-8dd0-db7560776299" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-12-13T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15588333"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12811-0</funderId>
      <contactId>Contact50284_12811</contactId>
      <sponsorId>Sponsor48655</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50284_12811">
    <title>Dr</title>
    <forename>Supanimit</forename>
    <surname>Teekachunhatean</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Pharmacology
Faculty of Medicine
Chiang Mai University</address>
      <city>Chiang Mai</city>
      <country>Thailand</country>
      <zip>50200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">steekach@mail.med.cmu.ac.th</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48655">
    <organisation>Chiang Mai University - Faculty of Medicine (Thailand)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>Chiang Mai</city>
      <country>Thailand</country>
      <zip>50200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">nimit@mail.med.cmu.ac.th</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7132.7</gridId>
    <rorId>https://ror.org/05m2fqn25</rorId>
  </sponsor>
  <funder id="Funder12811-0">
    <name>Chiang Mai University (Thailand) - Endowment Fund for Medical Research, Faculty of Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-14T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-11-02T00:00:00.000Z">52870636</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The role of mitomycin C (MMC) in Endoscopic Sinus Surgery (ESS) to the frontonasal recess: a prospective randomised trial</title>
      <scientificTitle/>
      <acronym>Mitomycin C Project</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52870636</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="87d11317-b56c-4261-a2b7-b1b24f656a88">
	  <name>Professorial Unit</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>WC1X 8DA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients who will be undergoing normal surgical procedure following the failure of medical treatment.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic Rhinosinusitis (CRS) of the frontonasal recess</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Chronic rhinosinusitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Application of MMC/placebo following ESS and assessment for impact on symptoms of CRS</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/17181099 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ef26b54e-b057-44d6-8366-d1e00d141d98" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17181099"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11361-0</funderId>
      <contactId>Contact43833_11361</contactId>
      <sponsorId>Sponsor41579</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact43833_11361">
    <title>Prof</title>
    <forename>Valerie J</forename>
    <surname>Lund</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Professorial Unit
330 Gray's Inn Rd
Royal National Throat, Nose and Ear Hospital</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1X 8DA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor41579">
    <organisation>Royal National Throat, Nose and Ear Hospital (UK)</organisation>
    <website>http://www.royalfree.nhs.uk/default.aspx?top_nav_id=3&amp;sel_left_nav=40&amp;tab_id=121</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Professor VJ Lund
Professorial Unit
330 Gray's Inn Road</address>
      <city>London</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>WC1X 8DA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.439342.b</gridId>
    <rorId>https://ror.org/03pf5zs64</rorId>
  </sponsor>
  <funder id="Funder11361-0">
    <name>Royal National Throat, Nose and Ear Hospital (UK) - funded internally</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-07T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2004-11-02T00:00:00.000Z">22569553</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>An adaptogenic role for omega-3 fatty acids in stress: a randomised placebo controlled double blind intervention study (pilot)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN22569553</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f477319e-8699-4f68-9072-c0dcf97d6a37">
	  <name>P.O. Box 157</name>
	  <address/>
	  <city>Lismore</city>
	  <state/>
	  <country>Australia</country>
	  <zip>2480</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>University staff who scored ≥17 on the Perceived Stress Scale</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Perceived stress</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Stress</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: 6 g fish oil per day, containing 1.5 g docosahexaenoic acid (DHA)
Control: 6 g a day of olive oil (placebo)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15566625 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f51e799f-3e6a-4899-a21b-fdf5735e91a3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-11-28T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15566625"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12787-0</funderId>
      <contactId>Contact50253_12787</contactId>
      <sponsorId>Sponsor48624</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50253_12787">
    <title>Prof</title>
    <forename>Stephen</forename>
    <surname>Myers</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>P.O. Box 157</address>
      <city>Lismore</city>
      <country>Australia</country>
      <zip>2480</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48624">
    <organisation>Australian Centre for Complementary Medicine, Education and Research (ACCMER)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>P.O. Box 157</address>
      <city>Lismore</city>
      <country>Australia</country>
      <zip>2480</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder12787-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-20T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-10-19T00:00:00.000Z">25858715</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of Nocturnal Haemodialysis (NHD) compared to conventional haemodialysis on progression of Left Ventricular (LV) mass: a randomised controlled pilot study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Nocturnal haemodialysis and conventional three times per week haemodialysis will not differ with respect to progression of LV mass (measured using Cardiac Magnetic Resonance [CMR]) at 6 months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Change in left ventricular mass (measured by CMR) at 6 months.</primaryOutcome>
      <secondaryOutcome>1. Mean change in systolic Blood Pressure (BP)
2. Change in HRQOL (Health-Related Quality-Of-Life)
3. Mean change in Haematocrit (Hct)/Erythropoietin (Epo) ratio
4. Mean change in calcium - phosphorus product</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25858715</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d59c4f8b-846b-4dfd-9b45-e66de8f86425">
	  <name>Foothills Hospital</name>
	  <address/>
	  <city>Calgary</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T2N 2T9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All adult haemodialysis patients in Alberta, Canada are eligible.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>38</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>38 subjects</totalTarget>
      <exclusion>Patients who are unable to perform NHD due to physical or mental incapacity.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>End-stage kidney disease</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Renal disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects are randomised to nocturnal haemodialysis or conventional three times per week haemodialysis (controls).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17878421 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a392267e-e580-46b5-be05-207f0f6f6709" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-19T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17878421"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11347-0</funderId>
      <contactId>Contact41810_11347</contactId>
      <sponsorId>Sponsor39557</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41810_11347">
    <title>Dr</title>
    <forename>Bruce</forename>
    <surname>Culleton</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Foothills Hospital
1403-29th ST NW</address>
      <city>Calgary</city>
      <country>Canada</country>
      <zip>T2N 2T9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 403 944 8166</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bruce.culleton@calgaryhealthregion.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39557">
    <organisation>Kidney Foundation of Canada (Canada) </organisation>
    <website>http://www.kidney.ca/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>300-5165 Sherbrooke ST W</address>
      <city>Montreal, Quebec</city>
      <country>Canada</country>
      <zip>H4A 1T6</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">research@kidney.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453960.d</gridId>
    <rorId>https://ror.org/019a0gk53</rorId>
  </sponsor>
  <funder id="Funder11347-0">
    <name>Kidney Foundation of Canada (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000191</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-10-05T00:00:00.000Z">84128484</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Central Serous Retinopathy (CSR) is a retinal disorder affecting young adults, characterized clinically by a well-defined, translucent, circumscribed detachment of neurosensory retina at the posterior pole, usually involving the macula. The detachment results from accumulation of transparent fluid in the potential space between retinal pigment epithelial layer and the neurosensory retina.

Hypothesis:
To evaluate the efficacy of diode laser photocoagulation in patients with central serous retinopathy (CSR) and to compare it with the effects of argon green laser.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84128484</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d9e2f7d4-7e11-410b-a172-3d17526d3df0">
	  <name>E- 18, Hudco palace</name>
	  <address/>
	  <city>New Delhi</city>
	  <state/>
	  <country>India</country>
	  <zip>110049</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients of unilateral type 1 CSR</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Central Serous Retinopathy (CSR)</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Diseases of the retina</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Diode Laser photocoagulation
2. Argon green laser photocoagulation
3. Fluorescein Angiography</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15516262 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="b187c672-8753-4d4c-b596-4f9465e12385" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-10-29T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15516262"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12764-0</funderId>
      <contactId>Contact50221_12764</contactId>
      <sponsorId>Sponsor48589</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50221_12764">
    <title>Dr</title>
    <forename>Lalit</forename>
    <surname>Verma</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>E- 18, Hudco palace
Andrews ganj</address>
      <city>New Delhi</city>
      <country>India</country>
      <zip>110049</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lalitverma@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48589">
    <organisation>All-India Institute of Medical Sciences (AIIMS) (India) </organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Ansari Nagar</address>
      <city>New Delhi</city>
      <country>India</country>
      <zip>110029</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lalitverma@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.413618.9</gridId>
    <rorId>https://ror.org/02dwcqs71</rorId>
  </sponsor>
  <funder id="Funder12764-0">
    <name>All-India Institute of Medical Sciences (AIIMS) (India)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-27T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2004-09-22T00:00:00.000Z">50377687</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Alternative vaccination schedules with pneumococcal polysaccharide/protein conjugate vaccine: immunogenicity of the prime-booster approach among Gambian infants</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Following previous encouraging findings from safety and immunogenicity studies using conjugate Pnc and Hib vaccines in the Gambia, we propose to evaluate the safety and immunogenicity of 7-valent Pnc conjugate (4, 6B, 9V 14 18C 19F 23F) manufactured by Wyeth Lederle Vaccine USA, using different vaccination schedules. The aim is to determine whether fewer doses started earlier in life with or without a booster dose of Pnc polysaccharide can induce a protective antibody response throughout infancy and early childhood. 675 young infants, residing in sites where the large efficacy (Pnc) trial is on-going, will be randomly allocated to one of 3 vaccination schedules using the 7-valent conjugate vaccine to assess the magnitude, duration and quality of the antibody- response to 1-2 doses with or without a booster dose in Upper River Division of The Gambia. The impact of this vaccination schedule on carriage of pneumococci will also be determined.

The data from this immunogenicity study and the larger on-going efficacy trial could provide important data for an informed policy decision in developing countries. We propose to use 7-valent vaccine since it is licensed and available, but would be guided by WHO as to the suitability and availability of other possible conjugate vaccines.

General objectives:
Evaluating the safety and antibody response to 1 or 2 doses of 7-valent conjugate  pneumococcal (Pnc) vaccine given early in life with a booster dose of polysaccharide, compared with a standard 3-dose regimen. 

Specific primary objectives:
1. To determine the immunogenicity of a 7-valent Pnc Conjugate vaccine at ages 18 weeks and 9 months, after one, two and three doses of conjugate vaccines
2. To evaluate the secondary immune response (antibody) to Pnc polysaccharide vaccine at age 10 months after one, two or three doses of 7-valent conjugate vaccine

Secondary objectives:
1. To evaluate persistence of antibody at age 15 months
2. To evaluate evidence of memory response following Conjugate vaccines using assays of antibody avidity and affinity
3. To determine naso-pharyngeal  carriage of vaccine and non-vaccine serotypes at ages 6 weeks, 18 weeks, 10 and 15 months</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Immunogenicity of 7-valent pneumococcal conjugate vaccine at ages 18 weeks and 11 months after one, two and three doses of conjugate vaccines, measuring for antibody concentrations greater than or equal to 0.35 ug/ml
2. Secondary immune response (antibody) to pnuemococcal polysaccharide vaccine at age 11 months after one, two or three doses of 7-valent conjugate vaccine (antibody concentrations greater than or equal to 0.35 ug/ml)</primaryOutcome>
      <secondaryOutcome>1. Persistence of antibody at age 15 months of age
2. Evidence of memory response following Conjugate vaccines using assays of antibody avidity and affinity 
3. Naso-pharyngeal carriage of vaccine and non-vaccine serotypes at ages 18 weeks, 11 and 15 months of age
4. Monitoring for safety and local reaction up to 15 months of age. Two main aspects of the safety surveillance will be analysed:
4.1. Serious Adverse Events (SAE) 
4.2. Local and Systemic reactions

Antibody concentrations to serotypes covered by the 7-valent conjugate vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F) as well as antibody concentration to selected serotypes covered by the polysaccharide vaccine (1, 3, 5 and 12) will be measured.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Gambia Government/Medical Research Council (MRC) Laboratories Joint Ethics Committee on the 5th October 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN50377687</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WHO/RPC033</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Gambia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6a0cbfa2-b064-45bf-a72f-a07a115b7f30">
	  <name>Medical Research Council Laboratories</name>
	  <address/>
	  <city>Banjul</city>
	  <state/>
	  <country>Gambia</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Babies will be recruited when they present for first dose of Diphtheria, Pertussis, Tetanus (DPT)-Haemophilus influenzae type b (Hib) vaccine and written informed consent obtained at that time</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>675</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>675</totalTarget>
      <exclusion>1. Babies born to known human immunodeficiency virus (HIV) positive mothers
2. Those with neurological abnormality
3. No parental consent
4. Established pneumococcal disease</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pneumococcus/vaccines</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: Infants here will receive their only dose of a 7-valent pneumococcal conjugate vaccine at 6 weeks of life and a dose of polysaccharide vaccine at 9 months.
Group 2: A dose of conjugate vaccine will be offered at 6 and 14 weeks, and a dose of polysaccharide at 9 months.

The third group (3) will be recruited and vaccinated at 6, 10 and 14 weeks of life with the study conjugate vaccine and with the polysaccharide vaccine at 9 months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pneumococcal polysaccharide/protein conjugate vaccine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder11312-0</funderId>
      <contactId>Contact41763_11312</contactId>
      <sponsorId>Sponsor39508</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41763_11312">
    <title>Dr</title>
    <forename>Richard</forename>
    <surname>Adegbola</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical Research Council Laboratories 
Fajara</address>
      <city>Banjul</city>
      <country>Gambia</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">radegbola@mrc.gm</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39508">
    <organisation>Medical Research Council Laboratories (The Gambia) </organisation>
    <website/>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>Fajara </address>
      <city>Banjul</city>
      <country>Gambia</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.415063.5</gridId>
    <rorId>https://ror.org/025wfj672</rorId>
  </sponsor>
  <funder id="Funder11312-0">
    <name>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-13T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-09-22T00:00:00.000Z">52829313</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Neonatal immunisation with pneumoccal conjugate vaccines: immunogenicity and the generation memory (Kenya)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Current hypothesis as of 13/09/2007: 
In Kenyan children under 2 years of age, 23% of deaths from invasive pneumococcal disease occur in the first 14 weeks of life. Expanded Programme on Immunisation (EPI) vaccines are administered at 6, 10 and 14 weeks. Earlier vaccination against pneumococcus may prevent deaths of very young infants. This study examines whether 7-valent Pneumococcal Conjugate Vaccine (PCV) given on the first 72 hours of life is safe and whether it provides an adequate immunological response, including development of immunological memory, when compared to a regime in which the first dose is given at 6 weeks. 300 children will be randomised to one of two regimes; PCV at birth (up to 72 hours), 10 and 14 weeks or PCV at 6, 10 and 14 weeks. The safety and basic immunogenicity data will be analysed after a first phase of 60 children and a further phase of 240 children will be recruited if the results are found to be satisfactory.

Please note that the change to this hypothesis was made due to an initial protocol modification, where the 'birth' dose was amended from 24 hours to 72 hours. No other area of this trial was amended. 

Previous hypothesis:
In Kenyan children under 2 years of age, 23% of deaths from invasive pneumococcal disease occur in the first 14 weeks of life. Expanded Programme on Immunisation (EPI) vaccines are administered at 6, 10 and 14 weeks. Earlier vaccination against pneumococcus may prevent deaths of very young infants. This study examines whether 7-valent Pneumococcal Conjugate Vaccine (PCV) given on the first day of life is safe and whether it provides an adequate immunological response, including development of immunological memory, when compared to a regime in which the first dose is given at 6 weeks. 300 children will be randomised to one of two regimes; PCV at birth, 10 and 14 weeks or PCV at 6, 10 and 14 weeks. The safety and basic immunogenicity data will be analysed after a first phase of 60 children and a further phase of 240 children will be recruited if the results are found to be satisfactory.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Clinical safety data in children vaccinated at birth compared to children vaccinated first at 6 weeks of life
2. Immunogenicity as measured by anti-capsular Immunoglobulin G (IgG) Enzyme-Linked Immuno-Sorbent Assay (ELISA) to serotypes in the vaccine, measured after a complete primary course at 18 weeks.</primaryOutcome>
      <secondaryOutcome>1. Immunogenicity as measured by anti-capsular IgG ELISA after one or two doses of vaccine, of which one was given at birth
2. Immunological memory measured as IgG response to a booster vaccine dose (either PCV or 1/5th dose pneumococcal polysaccharide vaccine with a 50% probability of each) at 36 weeks
3. Functional immune response to first vaccination at birth as measured by prevalence of nasopharyngeal colonisation with S. pneumoniae at 18 and 36 weeks
4. Interference with immune response to diphtheria and tetanus attributable to vaccination with PCV at birth as measured by diphtheria and tetanus antibody concentration at 18 weeks
5. Interference with immune response to measles vaccine given at 36 weeks measured by anti-measles antibodies at 37 weeks
6. Effect of (maternal) pre-existing pneumococcal, diphtheria and tetanus antibody levels at birth on immune response to the primary course of PCV, and Diphtheria Pertussis Tetanus (DPT) vaccine.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. Kenya Medical Research Institute (KEMRI)/National Ethical Review Committee on the 27th October 2003
2. World Health Organization (WHO) Ethics Review Committee on the 18th September 2003 (renewed annually)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52829313</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WHO/RPC028</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Kenya</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b78530b2-f1b7-4bc4-954f-7f1cc1edba78">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Healthy infants born to mothers tested human immunodeficiency virus (HIV) negative in the voluntary counselling and testing service
2. Not known to have congenital immune deficiency
3. Birth weight greater than 2500 g
4. Informed consent</inclusion>
      <ageRange>Child</ageRange>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>1. Infants requiring ongoing hospitalisation after birth
2. Suspected immune deficiency
3. Participation in another clinical trial

Any child who suffers a serious adverse event directly attributable to pneumococcal vaccination will be excluded from continued participation.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pneumococcus/vaccines</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Infants will receive 7-valent conjugate pneumococcal vaccine (PCV7) at birth (up to 72 hours - see point mentioned in hypothesis above), 6 and 10 weeks (group 1) or at 6, 10 and 14 weeks (group 2) along with routine Expanded Program of Immunisation (EPI) vaccines. Infants in each group will be randomised to receive either PCV7 or 23-valent pneumococcal polysaccharide vaccine at 9 months of age. Blood will be collected for measurement of antibody response prior to vaccine, 4 weeks after the primary series and pre- and 4 weeks post-booster dose. All infants will have Nasopharyngeal (NP) swabs collected at 18 weeks and 9 months of age that will be cultured for pneumococcus.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pneumococcal Conjugate Vaccine (PCV)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder11314-0</funderId>
      <contactId>Contact41765_11314</contactId>
      <sponsorId>Sponsor39510</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41765_11314">
    <title>Dr</title>
    <forename>Thomas</forename>
    <surname>Cherian</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cheriant@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39510">
    <organisation>Kenya Medical Research Institute (Kenya)</organisation>
    <website>http://www.kemri.org/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>PO Box 54840</address>
      <city>Nairobi</city>
      <country>Kenya</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.33058.3d</gridId>
    <rorId>https://ror.org/04r1cxt79</rorId>
  </sponsor>
  <funder id="Funder11314-0">
    <name>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-07T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-09-10T00:00:00.000Z">32203485</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial to determine the effect on response of including a lottery incentive in health surveys</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32203485</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f7128135-dc10-458a-a498-bcf364608eea">
	  <name>Department of General Practice</name>
	  <address/>
	  <city>Birmingham</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>B15 2TT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>General adult population receiving health survey</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>8645</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>8645</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Health survey incentives</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Lottery style incentive versus no incentive</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15533256 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ef263ca9-2ea2-4d91-bb0f-c0916c5ef6cc" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-11-08T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15533256"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11346-0</funderId>
      <contactId>Contact41809_11346</contactId>
      <sponsorId>Sponsor39556</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41809_11346">
    <title>Dr</title>
    <forename>Lesley</forename>
    <surname>Roberts</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of General Practice
University of Birmingham
Edgbaston</address>
      <city>Birmingham</city>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)121 414 3356</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">l.m.roberts@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39556">
    <organisation>University of Birmingham (UK)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Edgbaston</address>
      <city>Birmingham</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)121 414 3356</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">l.m.roberts@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.6572.6</gridId>
    <rorId>https://ror.org/03angcq70</rorId>
  </sponsor>
  <funder id="Funder11346-0">
    <name>Internally funded by the Department of Primary Care and General Practice, University of Birmingham (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-07T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-09-08T00:00:00.000Z">41238928</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Outpatient care compared with hospitalisation in low-risk patients with community-acquired pneumonia: a randomised trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41238928</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>FIS 00/0438</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="313518bc-7c3a-4b8b-ae2a-f3b26c85b90c">
	  <name>Hospital Universitari de Bellvitge</name>
	  <address/>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>08907</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>224 immunocompetent adults in risk classes II or III (Pneumonia Severity Index ≤90 points), without extenuating conditions diagnosed with community-acquired pneumonia in the emergency department.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>224</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>224</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Community-Acquired Pneumonia</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Pneumonia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomly assigned to outpatient care or hospitalisation, and received oral or switch therapy with levofloxacin, respectively.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15684204 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ace0fe9d-d1da-4129-8d7f-231c0d3ca2d4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15684204"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11340-0</funderId>
      <funderId>Funder11340-1</funderId>
      <funderId>Funder11340-2</funderId>
      <contactId>Contact41801_11340</contactId>
      <sponsorId>Sponsor39547</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41801_11340">
    <title>Dr</title>
    <forename>Jordi</forename>
    <surname>Carratala</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hospital Universitari de Bellvitge
Feixa Llarga s/n
L´Hospitalet</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08907</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 932607625</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jcarratala@wanadoo.es</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39547">
    <organisation>National Health Service (Spain)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Sinesio Delgado 4</address>
      <city>Madrid</city>
      <country>Spain</country>
      <zip>28029</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.417198.2</gridId>
    <rorId>https://ror.org/04t4b6y41</rorId>
  </sponsor>
  <funder id="Funder11340-0">
    <name>Fondo de Investigacion Sanitaria (FIS) (Spain) - ref: 00/0438</name>
    <fundRef/>
  </funder>
  <funder id="Funder11340-1">
    <name>Aventis (Spain)</name>
    <fundRef/>
  </funder>
  <funder id="Funder11340-2">
    <name>University of Barcelona (Spain) - Fellowship grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-09T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-08-31T00:00:00.000Z">45683816</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomised trial</title>
      <scientificTitle/>
      <acronym>Saffron Project</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45683816</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>555</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="00cd315c-e93a-49f2-b8a7-60f220bfcaa6">
	  <name>Roozbeh Psychiatric Hospital</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>13337</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Thirty adult outpatients who met the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV) for major depression based on the structured clinical interview for DSM IV participated in the trial
2. Patients have a baseline Hamilton Rating Scale for Depression score of at least 18</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Major depression</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>In this double-blind, single-centre trial, patients were randomly assigned to receive capsule of saffron 30 mg/day (10 mg three times a day [TDS]) (Group 1) and capsule of imipramine 100 mg/day (33.3 mg TDS) (Group 2) for a 6-week study.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Crocus sativus L., imipramine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15341662 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="df316b15-fbb5-4d6f-b588-0b98f3578e47" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-09-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15341662"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11335-0</funderId>
      <contactId>Contact41794_11335</contactId>
      <sponsorId>Sponsor39540</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41794_11335">
    <title>Prof</title>
    <forename>Shahin</forename>
    <surname>Akhondzadeh</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Roozbeh Psychiatric Hospital</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>13337</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 21 5412222</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sakhond@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39540">
    <organisation>Roozbeh Psychiatric Hospital (Iran)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>South Kargar</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>13337</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 21 5412222</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sakhond@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416042.5</gridId>
    <rorId>https://ror.org/019mzt973</rorId>
  </sponsor>
  <funder id="Funder11335-0">
    <name>Tehran University of Medical Sciences (Iran)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-08-31T00:00:00.000Z">67363048</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhoea: a randomised, double-blind, placebo controlled clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67363048</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1991-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1992-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Peru</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6cf75c4b-5a07-4d6f-a3ee-242275b665b7">
	  <name>Av. El Polo 740 Of. C-410</name>
	  <address/>
	  <city>Lima</city>
	  <state/>
	  <country>Peru</country>
	  <zip>033</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Male infants aged 3 - 36 months brought for treatment of acute watery diarrhoea with mild-moderate dehydration</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>179</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>179</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1991-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1992-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute watery diarrhoea</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Diarrhoea</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Oral rehydration
2. Feeding with age-appropiate infant's food
3. Randomised to receive a milk formula with or without Lactobacillus casei strain GG</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15345099 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="86c488cd-ab70-4372-b632-29228fafb583" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-09-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15345099"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11338-0</funderId>
      <contactId>Contact41799_11338</contactId>
      <sponsorId>Sponsor39545</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41799_11338">
    <title>Dr</title>
    <forename>Eduardo</forename>
    <surname>Salazar-Lindo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Av. El Polo 740 Of. C-410</address>
      <city>Lima</city>
      <country>Peru</country>
      <zip>033</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+51 1 435 7800</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">edsalaza@ec-red.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39545">
    <organisation>Universidad Peruana Cayetano Heredia (Peru)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Av. Honorio Delgado 430</address>
      <city>Lima</city>
      <country>Peru</country>
      <zip>031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">postmaster@upch.edu.pe</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.11100.31</gridId>
    <rorId>https://ror.org/03yczjf25</rorId>
  </sponsor>
  <funder id="Funder11338-0">
    <name>The study was supported by a grant from Valio Ltd, Helsinki (Finland) to the Child Health Foundation, Columbia, Maryland (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-09T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-08-03T00:00:00.000Z">74278823</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Explaining computation of predictive values: 2 x 2 table versus frequency tree - a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74278823</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0327785d-2236-4e61-8d2a-1306cef04c57">
	  <name>Martin-Luther-King Platz 6</name>
	  <address/>
	  <city>Hamburg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>20146</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Students without prior statistical training</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>184</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>184</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Statistical analyses: patients in decision making on diagnostic procedures</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Comparison of two visual helps to support computations of predictive values: 2x2 table versus frequency tree</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15301689 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="703e7e75-52cd-4150-ae9d-03ad8775c53d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-08-10T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15301689"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11308-0</funderId>
      <contactId>Contact41759_11308</contactId>
      <sponsorId>Sponsor39504</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41759_11308">
    <title>Mrs</title>
    <forename>Anke</forename>
    <surname>Steckelberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Martin-Luther-King Platz 6</address>
      <city>Hamburg</city>
      <country>Germany</country>
      <zip>20146</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)40 42838 3528</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ASteckelberg@uni-hamburg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39504">
    <organisation>Robert-Bosch Stiftung (Robert-Bosch Foundation) (Germany) </organisation>
    <website>http://www.bosch-stiftung.de/content/language1/html/12760.asp</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Heidehofstr. 31</address>
      <city>Stuttgart</city>
      <country>Germany</country>
      <zip>70005</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Ingrid.Wuenning@bosch-stiftung.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.418579.6</gridId>
    <rorId>https://ror.org/012kqkf58</rorId>
  </sponsor>
  <funder id="Funder11308-0">
    <name>Robert-Bosch Stiftung (Robert-Bosch Foundation) (Germany)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001646</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-07-27T00:00:00.000Z">36478292</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of bright light and exercise for depressive symptoms</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36478292</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-11-25T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-01-25T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="26505dac-a093-4519-a20b-99cdad17d177">
	  <name>National Public Health Institute</name>
	  <address/>
	  <city>Helsinki</city>
	  <state/>
	  <country>Finland</country>
	  <zip>FIN-00300</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>120 - 124 healthy, working-age volunteers recruited through occupational health centres</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>98</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>98</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-11-25T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-01-25T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depressive symptoms</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Aerobic exercise in bright light, aerobic exercise in normal gym lighting, stretching/relaxation in bright light</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15306031 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e418b103-dfba-47ae-b03d-bdf5c01336a7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-08-11T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15306031"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11302-0</funderId>
      <funderId>Funder11302-1</funderId>
      <contactId>Contact41753_11302</contactId>
      <sponsorId>Sponsor39498</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41753_11302">
    <title>Dr</title>
    <forename>Timo</forename>
    <surname>Partonen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>National Public Health Institute
Department of Mental Health and Alcohol Research
Mannerheimintie 166</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>FIN-00300</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">timo.partonen@ktl.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39498">
    <organisation>National Public Health Institute (Finland)</organisation>
    <website>http://www.ktl.fi/portal/english/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Department of Mental Health and Alcohol Research
Mannerheimintie 166</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>FIN-00300</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jouko.lonnqvist@ktl.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.14758.3f</gridId>
    <rorId>https://ror.org/03tf0c761</rorId>
  </sponsor>
  <funder id="Funder11302-0">
    <name>The Signe and Ane Gyllenberg Foundation (Finland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder11302-1">
    <name>The Finnish Foundation for Psychiatric Research (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-07-20T00:00:00.000Z">72263357</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Misoprostol for treating postpartum haemorrhage: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72263357</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CRHS010215a</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8f87ff49-d857-4203-8579-57dbf58192b5">
	  <name>P Bag X9047</name>
	  <address/>
	  <city>East London</city>
	  <state/>
	  <country>South Africa</country>
	  <zip>5201</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Women with postpartum haemorrhage defined as vaginal bleeding after childbirth considered to be excessive, and considered likely to be due to inadequate uterine contraction</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Postpartum haemorrhage</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Intervention group: Misoprostol 200 µg tablets. Each woman receives 1 tablet orally, 2 tablets sublingually and 2 tablets rectally.
2. Control group: identical placebo tablets. Each woman receives 1 tablet orally, 2 tablets sublingually and 2 tablets rectally.
(All women receive routine accepted treatment for postpartum haemorrhage)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Misoprostol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15298718 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4aa01149-6a07-4376-ae7f-99ba16586d7a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-08-06T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15298718"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11288-0</funderId>
      <contactId>Contact41739_11288</contactId>
      <sponsorId>Sponsor39484</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41739_11288">
    <title>Prof</title>
    <forename>G Justus</forename>
    <surname>Hofmeyr</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>P Bag X9047</address>
      <city>East London</city>
      <country>South Africa</country>
      <zip>5201</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+27 (0)832809402</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gjh@global.co.za</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39484">
    <organisation>University of the Witwatersrand (South Africa)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>7, York Rd
Parktown</address>
      <city>Johannesburg</city>
      <country>South Africa</country>
      <zip>2193</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+27 (0)11 717 2000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gjh@global.co.za</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.11951.3d</gridId>
    <rorId>https://ror.org/03rp50x72</rorId>
  </sponsor>
  <funder id="Funder11288-0">
    <name>University of the Witwatersrand (South Africa) - No external funding; this trial was funded from the existing research unit budget, using full-time research staff.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-07-12T00:00:00.000Z">88246634</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88246634</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="53cfa744-2de9-437b-8d56-40a0e3ef93fa">
	  <name>Albert Schweitzerplaats 25</name>
	  <address/>
	  <city>Dordrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3318AT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with primary biliary cirrhosis or primary sclerosing cholangitis and chronic significant fatigue.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>33</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>33</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Primary biliary cirrhosis and primary sclerosing cholangitis</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Diseases of liver</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Fluvoxamine treatment (150 mg/day) for a six-week period versus treatment with placebo. A double-blind placebo-controlled randomised trial.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Fluvoxamine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15251034 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2d12b9dd-bc3a-4e3c-8c77-630caf943cea" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-07-13T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15251034"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11281-0</funderId>
      <contactId>Contact41732_11281</contactId>
      <sponsorId>Sponsor39477</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41732_11281">
    <title>Dr</title>
    <forename>Pieter</forename>
    <surname>ter Borg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Albert Schweitzerplaats 25</address>
      <city>Dordrecht</city>
      <country>Netherlands</country>
      <zip>3318AT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)786541111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pterborg@zonnet.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39477">
    <organisation>Foundation for Liver Research (Stichting Lever Onderzoek) (The Netherlands)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Erasmus Medical Centre
Dr. Molewaterplein 40</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015GD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 463 9222</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">h.vanbuuren@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.488303.4</gridId>
    <rorId>https://ror.org/04hzejq44</rorId>
  </sponsor>
  <funder id="Funder11281-0">
    <name>Gastrostart foundation (The Netherlands) (ref: EUR 4537)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-10T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-07-02T00:00:00.000Z">31137309</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Impact of a community-based participatory intervention to improve essential newborn care (ENC) in rural Nepal: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym>MIRA (Mother and Infant Research Activities - a Nepali non-governmental organisation [NGO]) Makwanpur  Study</acronym>
      <studyHypothesis>Neonatal deaths in developing countries make the largest contribution to global mortality in children younger than 5 years. 90% of deliveries in the poorest quintile of households happen at home. We postulated that a community-based participatory intervention could significantly reduce neonatal mortality rates.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Neonatal mortality rate</primaryOutcome>
      <secondaryOutcome>1. Stillbirths and maternal deaths
2. Uptake of antenatal and delivery services
3. Home care practices
4. Infant morbidity
5. Health-care seeking</secondaryOutcome>
      <trialWebsite>http://www.ich.ucl.ac.uk/ich/academicunits/International_perinatal_care_unit</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Nepal Health Research Council and the ethics committee of the Institute of Child Health and Great Ormond Street Hospital for Children.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN31137309</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>98-CH-06</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>Nepal</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="26ae5925-aceb-4d42-a690-8dd9bfbf5f7c">
	  <name>30 Guilford Street</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>WC1N 1EH</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Married women aged 15 to 49 in 24 rural Village Development Committees (VDCs) in Makwanpur District, Nepal</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24 village development committees</totalTarget>
      <exclusion>No exclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Neonatal mortality</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Neonatal mortality</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>12 local female facilitators work within VDCs in the Makwanpur District in Nepal to explore perinatal health issues, with one in each of the 12 intervention VDCs. Their role is to act as a change agent rather than a teacher, to activate and strengthen existing mothers' groups, support them in identifying and prioritising maternal and neonatal problems, help to identify possible solutions and support the planning, implementation and monitoring of the solution strategies in the community. Each women's group moves through a participatory planning cycle of assessment, sharing experiences, planning, action and reassessment with the aim of improving essential maternal and newborn care. We have also trained women identified by local community groups as baby monitors to spot high risk newborn infants soon after birth.

The study will compare outcomes including neonatal and perinatal mortality rates, perinatal care practices and health service utilisation in 12 village development committee areas (8,000 people per VDC), compared with 12 matched areas where the intervention is not implemented.

Married women of reproductive age (15-49 years) within the study area have been identified and are visited monthly by study personnel. All pregnancies occurring within the cohort will be followed until at least six weeks after delivery to determine the outcome of birth.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15364188
2006 Other publications in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16776818</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="264aa026-a8bd-4785-8320-429ba29e3e62" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-09-11T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15364188"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="346ba55d-2400-49a5-a168-138e9a7b032c" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2006-06-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16776818"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11243-0</funderId>
      <funderId>Funder11243-1</funderId>
      <funderId>Funder11243-2</funderId>
      <contactId>Contact41683_11243</contactId>
      <sponsorId>Sponsor39428</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41683_11243">
    <title>Prof</title>
    <forename>Anthony</forename>
    <surname>Costello</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>30 Guilford Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1N 1EH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7905 2261</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ipu@ich.ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39428">
    <organisation>Institute of Child Health (UK)</organisation>
    <website>http://www.ich.ucl.ac.uk/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>30 Guilford Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1N 1EH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.83440.3b</gridId>
    <rorId>https://ror.org/02jx3x895</rorId>
  </sponsor>
  <funder id="Funder11243-0">
    <name>Department for International Development (DFID)</name>
    <fundRef/>
  </funder>
  <funder id="Funder11243-1">
    <name>The Department of Child and Adolescent Health and Development (CAH)/World Health Organization (WHO) (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder11243-2">
    <name>United Nations Children's Fund (UNICEF)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-10T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-06-08T00:00:00.000Z">11871179</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomised clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The aim of the present study was to investigate the efficacy, adverse effect and cost of ofloxacin plus rifampicin therapy, and doxycycline plus rifampicin therapy and evaluate in the treatment of brucellosis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11871179</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Türkiye</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6665e5a3-ae07-4a54-aa6a-a10401d75830">
	  <name>Izzet Baysal Faculty of Medicine</name>
	  <address/>
	  <city>Bolu</city>
	  <state/>
	  <country>Türkiye</country>
	  <zip>14280</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients suspected to have brucella infection on the basis of clinical (fever, limb and back pains, sweating, fatigue, hepatomegaly, splenomegaly, arthritis, sacroileitis, spondylitis, orchitis and headache) and laboratory findings were hospitalised. The diagnosis was based on the presence of signs and symptoms compatible with brucellosis including a positive agglutination titre (greater than or equal to 1/160) and/or a positive culture. All sera obtained from the patients were examined by serial dilution (from 1:10 to 1:1280) using bacterial antigen.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>29</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>29</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Brucellosis</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Zoonotic bacterial diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This study was carried out in the Social Security Duzce Hospital and Abant Izzet Baysal Universty Duzce Medical School in Turkey. After obtaining informed consent, a detailed medical history was taken from each patient and a complete physical examination was performed. 

Patients who met the criteria for entry were randomly assigned to receive in a 1:1 ratio doxycycline plus rifampicin or ofloxacin plus rifampicin:
1. The doxycycline plus rifampicin group had 14 patients who received doxycycline 100 mg twice daily and rifampicin 600 mg once daily for 45 days
2. The ofloxacin plus rifampicin group had 15 patients who received ofloxacin 400 mg once daily and rifampicin 600 mg once daily for 30 days

Patients were hospitalised for at least 10 days at the beginning of treatment in order to monitor clinical response and potential side effects. The patients were assessed and laboratory tests were also performed during the therapy period in the 2nd, 4th, and 6th week of therapy. At the end of therapy, laboratory tests were reassessed at months 1, 2 and 3, as well as whenever clinical symptoms reappeared.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ofloxacin, rifampicin, doxycycline</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15214959 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2f2e5e11-7980-4249-b8b0-5a2609021312" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-06-23T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15214959"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11244-0</funderId>
      <contactId>Contact41685_11244</contactId>
      <sponsorId>Sponsor39430</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41685_11244">
    <title>Dr</title>
    <forename>Oguz</forename>
    <surname>Karabay</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Izzet Baysal Faculty of Medicine
Infectious Diseases and Clinical Microbiology</address>
      <city>Bolu</city>
      <country>Türkiye</country>
      <zip>14280</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor39430">
    <organisation>Izzet Baysal Faculty of Medicine (Turkey)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Dr Oguz Karabay
Infectious Diseases and Clinical Microbiolgy</address>
      <city>Bolu</city>
      <country>Türkiye</country>
      <zip>14280</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+90 374 253 4656 / 4140</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">drkarabay@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411082.e</gridId>
    <rorId>https://ror.org/01x1kqx83</rorId>
  </sponsor>
  <funder id="Funder11244-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-10T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-05-21T00:00:00.000Z">32823119</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of prize draw incentive on the response rate to a postal survey of obstetricians and gynaecologists: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32823119</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6f6da5e8-695a-4d36-8a2e-1e15e39fcb42">
	  <name>Birmingham Women's Hospital</name>
	  <address/>
	  <city>Birmingham</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>B15 2TG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Gynaecologists</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>1410</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1410</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Epidemiology/Response rates</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Non-monetary incentive versus no incentive.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15222889 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2c2fd244-2583-4756-a32a-e4af84daab1a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-06-28T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15222889"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11229-0</funderId>
      <contactId>Contact41666_11229</contactId>
      <sponsorId>Sponsor39411</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41666_11229">
    <title>Dr</title>
    <forename>Thomas Justin</forename>
    <surname>Clark</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Birmingham Women's Hospital</address>
      <city>Birmingham</city>
      <country>United Kingdom</country>
      <zip>B15 2TG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)121 4721377</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">justin.clark@bwhct.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39411">
    <organisation>Birmingham Women's Hospital (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Edgbaston</address>
      <city>Birmingham</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>B15 2TG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)121 4721377</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">justin.clark@bwhct.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.423077.5</gridId>
    <rorId>https://ror.org/00xe5zs60</rorId>
  </sponsor>
  <funder id="Funder11229-0">
    <name>Royal College of Obstetrics and Gynaecology (UK) - Endometriosis Millennium Fund</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-10T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2004-04-21T00:00:00.000Z">14429643</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised trial to assess the impact of an anti-thrombotic decision aid in patients with non-valvular atrial fibrillation</title>
      <scientificTitle/>
      <acronym>DAAFI</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14429643</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>I-10</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="837d1e58-bef0-4e1d-9fbb-f473097714c7">
	  <name>2E3.24 Walter Mackenzie Centre</name>
	  <address/>
	  <city>Edmonton</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T6G 2R7</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Family physicians and their adult patients with non-valvular atrial fibrillation.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>1100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1100</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Non-valvular atrial fibrillation</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Other forms of heart disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A prospective, multi-centre, two-arm cluster randomised controlled trial to evaluate whether an evidence-based patient decision aid for patients with non-valvular atrial fibrillation can improve the appropriate use of antithrombotic therapy (as defined by the 2001 American College of Chest Physicians [ACCP] Recommendations) by patients and their family physicians compared to usual care.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Protocol article in https://pubmed.ncbi.nlm.nih.gov/15128463 Protocol
2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16129870 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="bbcc8be3-8144-47c6-b809-4401fdada367" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2004-05-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15128463"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
      <output id="01205c8a-bb3f-449e-aafc-c33d598029b4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-08-30T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16129870"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11214-0</funderId>
      <funderId>Funder11214-1</funderId>
      <contactId>Contact41645_11214</contactId>
      <sponsorId>Sponsor39389</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41645_11214">
    <title>Dr</title>
    <forename>Finlay</forename>
    <surname>McAlister</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>2E3.24 Walter Mackenzie Centre
8440 112 Street</address>
      <city>Edmonton</city>
      <country>Canada</country>
      <zip>T6G 2R7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor39389">
    <organisation>Canadian Stroke Network (Canada)</organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>451 Smyth Road</address>
      <city>Ottawa</city>
      <country>Canada</country>
      <zip>K1H 8M5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder11214-0">
    <name>Canadian Stroke Network (I-10) (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder11214-1">
    <name>Alberta Heritage Foundation for Medical Research (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003179</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-10T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-04-19T00:00:00.000Z">46889446</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled clinical trial of General Packet Radio Service (GPRS) mobile telephone technology for monitoring type 1 diabetes</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46889446</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="abc2198b-7abc-490b-9390-96fc7fd9f21a">
	  <name>Institute of Health Sciences</name>
	  <address/>
	  <city>Oxford</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>OX3 7LF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 17 to 30 years
2. With type 1 diabetes
3. HbA1c (haemoglobin A1c) between 8% and 11%</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Type 1 diabetes</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Control arm: Collecting blood glucose data with a mobile phone.
Intervention arm: Collecting data and receiving regular feedback and interpretation of results.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16249542 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="7233f395-bccd-4195-88b4-edfd2e081ff0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16249542"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5748-0</funderId>
      <contactId>Contact7181_5748</contactId>
      <sponsorId>Sponsor5345</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7181_5748">
    <title>Dr</title>
    <forename>Andrew</forename>
    <surname>Neil</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute of Health Sciences
Roosevelt Drive
Headington</address>
      <city>Oxford</city>
      <country>United Kingdom</country>
      <zip>OX3 7LF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 266 777</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">andrew.neil@wolfson.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5345">
    <organisation>University of Oxford (UK)</organisation>
    <website>http://www.ox.ac.uk/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Institute of Health Sciences
Roosevelt Drive
Headington</address>
      <city>Oxford</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>OX3 7LF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1865 266 777</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">andrew.neil@wolfson.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4991.5</gridId>
    <rorId>https://ror.org/052gg0110</rorId>
  </sponsor>
  <funder id="Funder5748-0">
    <name>The Vodafone Foundation (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-24T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-03-09T00:00:00.000Z">85109383</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised, placebo controlled trial of prednisone in early Henoch Schonlein Purpura</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85109383</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>95/25S(E)</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e1a20502-18c2-4945-9185-e78306987ed1">
	  <name>IWK Health Centre</name>
	  <address/>
	  <city>Halifax</city>
	  <state/>
	  <country>Canada</country>
	  <zip>B3J 3G9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Eligible participants were children between the ages of 2 and 15, presenting to the emergency room within 7 days of onset of Henoch Schonlein Purpura.

Children were excluded if:
1. Another explanation for purpura was present
 2. They had a known underlying systemic vasculitis
3. They had been treated with any form of corticosteroids in the preceding month
4. They had a known chronic illness affecting the renal, gastrointestinal or immune systems
5. They had an active infection
6. They were experiencing a life-threatening complication of Henoch Schonlein Purpura</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Henoch Schonlein Purpura</description>
	<diseaseClass1>Haematological Disorders</diseaseClass1>
	<diseaseClass2>Coagulation defects, purpura and other haemorrhagic conditions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention:
Prednisone 2 mg/kg for 7 days, 75% on days 8 and 9, 50% on days 10 and 11 and 25% on days 12, 13, 14, then stopped.

Control:
Comparison group was an identical appearing placebo.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Prednisone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15059282 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="810c47c0-3ace-4b5e-bc00-b007a8ffb5a7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-04-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15059282"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder8211-0</funderId>
      <contactId>Contact20642_8211</contactId>
      <sponsorId>Sponsor17386</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact20642_8211">
    <title>Dr</title>
    <forename>Adam</forename>
    <surname>Huber</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>IWK Health Centre
5850 University Avenue</address>
      <city>Halifax</city>
      <country>Canada</country>
      <zip>B3J 3G9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 902 470 8827</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">adamtheresa@hfx.eastlink.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor17386">
    <organisation>Children's Hospital of Eastern Ontario Research Institute (CHEORI) (Canada) </organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>401 Smyth Road
Room 139</address>
      <city>Ottawa</city>
      <country>Canada</country>
      <zip>K1H 8L1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 737 7600 ext. 2686</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">brazeau@cheo.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.414148.c</gridId>
    <rorId>https://ror.org/05nsbhw27</rorId>
  </sponsor>
  <funder id="Funder8211-0">
    <name>Children's Hospital of Eastern Ontario Research Institute (CHEORI) (Canada) (ref: 95/25S[E])</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-24T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-03-09T00:00:00.000Z">05982584</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Continuous Negative Extrathoracic Pressure in neonatal respiratory failure</title>
      <scientificTitle/>
      <acronym>CNEP</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN05982584</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1989-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1993-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b9c37377-9386-4d51-8e78-8897f500da81">
	  <name>Academic Department of Paediatrics</name>
	  <address/>
	  <city>Stoke on Trent</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>ST4 6QG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>The trial was undertaken in two neonatal intensive care units, Queen Charlotte's and Chelsea Hospital (QCCH) and North Staffordshire Maternity
Hospital (NSMH), between October 1989 and November 1993.
There were 244 patients: birth weight 1.53 ± 0.69 kg (mean ± SD), gestational age 30.4 ± 3.5 weeks, with respiratory failure.
Patients were considered for entry at 2 hours of age if they required
additional inspired oxygen or ventilation to maintain an arterial partial pressure of oxygen (PO2) of ≥8 kPa (60 mm Hg: conversion factor 7.5) or
an arterial partial pressure of carbon dioxide (PCO2) of &lt;6.5 kPa at Queen Charlotte's and Chelsea Hospital (QCCH) or 8 kPa at North Staffordshire Maternity Hospital (NSMH). This latter difference was because the two participating units had different practices at the time the trial commenced.
Patients were randomised if, after a second assessment at 4 hours of age, they required ≥40% inspired oxygen or ventilation to maintain these blood gas measurements.</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>244</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>244</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1989-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1993-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Neonatal respiratory failure (respiratory distress syndrome)</description>
	<diseaseClass1>Neonatal Diseases</diseaseClass1>
	<diseaseClass2>Respiratory failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised at four hours of age to receive either standard neonatal intensive care, or standard care plus continuous negative extrathoracic pressure (CNEP, -4 to -6 cm H2O) applied within a purpose-designed neonatal incubator.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1996 Results article in https://pubmed.ncbi.nlm.nih.gov/8951269 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d1d8356f-eb01-4ceb-a6d5-796cf1668092" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1996-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/8951269"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder8212-0</funderId>
      <funderId>Funder8212-1</funderId>
      <funderId>Funder8212-2</funderId>
      <funderId>Funder8212-3</funderId>
      <funderId>Funder8212-4</funderId>
      <funderId>Funder8212-5</funderId>
      <funderId>Funder8212-6</funderId>
      <contactId>Contact21642_8212</contactId>
      <sponsorId>Sponsor18386</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact21642_8212">
    <title>Prof</title>
    <forename>David</forename>
    <surname>Southall</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Department of Paediatrics
University Hospital of North Staffordshire</address>
      <city>Stoke on Trent</city>
      <country>United Kingdom</country>
      <zip>ST4 6QG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1782 552575</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">davids@doctors.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor18386">
    <organisation>University Hospital of North Staffordshire (UK)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Newcastle Road</address>
      <city>Stoke on Trent</city>
      <country>United Kingdom</country>
      <zip>ST4 6QG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1782 715444</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@uhns.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.100995.4</gridId>
  </sponsor>
  <funder id="Funder8212-0">
    <name>Horner &amp; Wells (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder8212-1">
    <name>Priory Foundation (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder8212-2">
    <name>Dunhill Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder8212-3">
    <name>Moorgate Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder8212-4">
    <name>Little Ones (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder8212-5">
    <name>Queen Charlotte's and Chelsea Hospital (QCCH) (UK) - use of their premises</name>
    <fundRef/>
  </funder>
  <funder id="Funder8212-6">
    <name>North Staffordshire Maternity Hospital (NSMH) (UK)  - use of their premises</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-24T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-02-23T00:00:00.000Z">64132371</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Zinc sulfate as an adjunct to methylphenidate for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children: a double blind and randomised trial</title>
      <scientificTitle/>
      <acronym>Zinc ADHD Trial</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN64132371</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Roozbeh Trial</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="66299fe5-0d06-4578-b6a9-c790dd1f1615">
	  <name>Roozbeh Psychiatric Hospital</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>13337</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Subjects were 44 outpatient children (26 boys and 18 girls) between the ages of 5 - 11 (mean ± SD was 7.88 ± 1.67) who clearly met the Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM IV) diagnostic criteria for attention-deficit hyperactivity disorder.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>44</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>44</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Attention Deficit Hyperactivity Disorder (ADHD)</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Behavioural disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised to methylphenidate 1 mg/kg/day + zinc sulfate 55 mg/day (with approximately 15 mg zinc element) (group 1) and methylphenidate 1 mg/kg/day + placebo (sucrose 55 mg) (group 2) for a 6 week double blind clinical trial. The principal measure of the outcome was the Teacher and Parent ADHD Rating Scale. Patients were assessed by a child psychiatrist at baseline, 14, 28 and 42 days after the medication started.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Methylphenidate, zinc sulphate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15070418 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1b727396-1b82-43ff-a5f6-a5fa539d64f3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-04-08T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15070418"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder7207-0</funderId>
      <contactId>Contact9642_7207</contactId>
      <sponsorId>Sponsor6386</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact9642_7207">
    <title>Dr</title>
    <forename>Shahin</forename>
    <surname>Akhondzadeh</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Roozbeh Psychiatric Hospital
Tehran University of Medical Sciences
South Kargar Street</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>13337</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.akhond@sina.tums.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor6386">
    <organisation>Tehran University of Medical Sciences (Iran)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>South Kargar Street</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>13337</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.akhond@sina.tums.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411705.6</gridId>
    <rorId>https://ror.org/01c4pz451</rorId>
  </sponsor>
  <funder id="Funder7207-0">
    <name>Tehran University of Medical Sciences (Iran)</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>